var title_f38_9_39056="Hydrocortisone: Patient drug information";
var content_f38_9_39056=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hydrocortisone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/36/35398?source=see_link\">",
"       Hydrocortisone (systemic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/25/19861?source=see_link\">",
"       Hydrocortisone (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11760 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-C9F66847B9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_9_39056=[""].join("\n");
var outline_f38_9_39056=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/36/35398?source=related_link\">",
"      Hydrocortisone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/25/19861?source=related_link\">",
"      Hydrocortisone (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_9_39057="Robot-assisted rad hyst 1";
var content_f38_9_39057=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/62730/Dis_right_uter_art_conv.mp4?title=Robot-assisted+rad+hyst+1\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dissection of the right uterine artery during robot-assisted radical hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Colleen M Feltmate, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_9_39057=[""].join("\n");
var outline_f38_9_39057=null;
var title_f38_9_39058="AML FAB M7";
var content_f38_9_39058=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute megakaryoblastic leukemia (M7)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow smear from a patient with acute megakaryoblastic leukemia (FAB classification M7). Panel A shows large blasts and promegakaryocytes; the latter cells are larger than the blasts and have coarse nuclear chromatin and irregularly shaped nuclei (Wright-Giemsa stain). Panel B shows staining of these cells with a monoclonal antibody to platelet glycoprotein IIIa (CD61).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_9_39058=[""].join("\n");
var outline_f38_9_39058=null;
var title_f38_9_39059="Left ventricular aneurysm four chamber echocardiogram 2";
var content_f38_9_39059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/70859/4chlvanr_conv.mp4?title=Left+ventricular+aneurysm+four+chamber+echocardiogram+2\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left ventricular aneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 235px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apical long axis view from a 2-D echocardiogram shows a very large dyskinetic left ventricular aneurysm of the apex. The right ventricle appears to be small, perhaps as a result of compression from the aneurysm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_9_39059=[""].join("\n");
var outline_f38_9_39059=null;
var title_f38_9_39060="Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Pediatric drug information";
var content_f38_9_39060=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?4/56/4998?source=see_link\">",
"    see \"Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6215528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kinrix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14790063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adacel&reg;-Polio",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F7726087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F7726097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/56/4998?source=see_link\">",
"      see \"Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M.: Children 4-6 years: 0.5 mL;",
"     <b>",
"      Note:",
"     </b>",
"     For use as the 5th dose in the DTaP series and the 4th dose in the IPV series",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6215828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Kinrix&reg;: Diphtheria toxoid 25 Lf, tetanus toxoid 10 Lf, acellular pertussis antigens [inactivated pertussis toxin 25 mcg, filamentous hemagglutinin 25 mcg, pertactin 8 mcg], type 1 poliovirus 40 D-antigen units, type 2 poliovirus 8 D-antigen units, and type 3 poliovirus 32 D-antigen units per 0.5 mL (0.5 mL) [contains aluminum, neomycin sulfate, polymyxin B, polysorbate 80; may contain natural rubber/natural latex in prefilled syringe]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6215686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7726098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake well; do not use unless a homogeneous, turbid, white suspension forms; administer I.M. the deltoid muscle of the upper arm;",
"     <b>",
"      not for I.V. or SubQ administration",
"     </b>",
"     . U.S. law requires that the date of administration, name of the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F6215817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not mix with other vaccines or injections.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F7726094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store under refrigeration of 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Discard if frozen.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7726088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active immunization in children 4-6 years of age against diphtheria, tetanus, pertussis, and poliomyelitis; used as the 5th dose in the DTaP series and the 4th dose in the IPV series (FDA approved in ages 4-6 years)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends this as routine vaccination for use as the fifth dose in the DTaP series and the fourth dose in the IPV series in children who received DTaP (Infanrix&reg;) and/or DTaP-Hepatitis B-IPV (Pediarix&reg;) as the first 3 doses and DTaP (Infanrix&reg;) as the fourth dose. Whenever feasible, the same manufacturer should be used to provide the pertussis component; however, vaccination should not be deferred if a specific brand is not known or is not available.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14790062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Adacel&reg; (trade name for Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine) should not be confused with Adacel&reg;-Polio (trade name for Diphtheria and Tetanus Toxoids, Acellular Pertussis, and Poliovirus Vaccine in Canada)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F6215809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adverse events reported within 4 days of vaccination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Drowsiness, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Loss of appetite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Injection site: Arm circumference increase, pain, redness, swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Cellulitis, cerebrovascular accident, constipation, dehydration, gastroenteritis, hypernatremia, injection site vesicles, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Additional postmarketing events associated with Infanrix&reg;: Allergic reactions, anaphylactoid reactions, anaphylaxis, angioedema, apnea, hypotonic-hyporesponsive episode, lymphadenopathy, seizures, thrombocytopenia, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7726090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component including neomycin and polymyxin B; encephalopathy occurring within 7 days of administration of a previous dose of a pertussis-containing vaccine that is not attributable to another cause; progressive neurological disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy (pertussis vaccine should be withheld until the clinical condition has stabilized)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F7726103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute severe febrile illness; may administer to patients with mild acute illness (with or without fever). Use with caution in severely immunocompromised patients (eg, patients receiving chemo-/radiation therapy or other immunosuppressive therapy including high-dose corticosteroids); may have a reduced response to vaccination and vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (CDC, 2011). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with history of seizure disorder, progressive neurologic disease, or conditions predisposing to seizures; ACIP and AAP guidelines recommend deferring immunization until health status can be assessed and condition stabilized. Antipyretics may be considered at the time of and for 24 hours following vaccination to patients at high risk for seizures to reduce the possibility of postvaccination fever. A family history of seizures is not a contraindication to use of DTaP. Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever due to vaccines has been shown to decrease the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009). Administer with caution to patients with thrombocytopenia or any coagulation disorder that would be compromised by I.M. injection; if the patient receives antihemophilia or other similar therapy, I.M. injection can be scheduled shortly after such therapy is administered.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7726091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate treatment for anaphylactoid or acute hypersensitivity reactions should be available during vaccine use. Subsequent vaccination with a pertussis-containing vaccine should be carefully considered if the following reactions occur with a temporal relationship to a previous dose of DTaP: Temperature &ge;40.5&deg;C (105&deg;F) within 48 hours, not attributable to another identifiable cause; collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours; persistent crying lasting &ge;3 hours within 48 hours; or convulsions with or without fever, occurring within 3 days. Guillain Barr&eacute; syndrome occurring within 6 weeks of vaccines containing tetanus toxoid has been reported. Tetanus toxoid containing vaccine (including emergency doses) should not be given more frequently than every 10 years in patients who have experienced a serious Arthus-type hypersensitivity reaction following a prior use of tetanus toxoid; these patients generally have high serum antitoxin levels. Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs. Patients with latex allergy should not handle the needle cover or plunger of the prefilled syringes since they contain latex. Product may contain aluminum, neomycin, polymyxin B, and polysorbate 80 (Tween 80) which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6215812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6215691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6215692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted; Kinrix&reg; is not indicated for women of childbearing age. Adacel&reg;-Polio is not recommended for use in pregnant women unless a definite risk of pertussis exists.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7726095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes active immunity to diphtheria, tetanus, pertussis, and poliovirus (types 1, 2, and 3) by inducing production of specific antibodies and antitoxins",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F7726099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause increased sleeping, restlessness, fussiness, decreased appetite, or fever (use antipyretic if directed by healthcare provider). May cause some redness, pain, or swelling at injection site; consult healthcare provider if excessive or persistent. Notify healthcare provider immediately of any excessive or persistent reactions (eg, fever &gt;105&deg;F within 48 hours, inconsolable crying that occurs within 48 hours and lasts 3 hours, seizures that occur within 3 days).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F7726100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contains the following three pertussis antigens: Inactivated pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin. Contains the same diphtheria, tetanus toxoids, and pertussis antigens found in Infanrix&reg; and Pediarix&reg;. Contains the same poliovirus antigens found in Infanrix&reg;.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-15):1-48. Available at:",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm",
"      </a>",
"      .",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/9/39060/abstract-text/17136024/pubmed\" id=\"17136024\" target=\"_blank\">",
"        17136024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Recommended Immunization Schedules for Persons Aged 0 Through 18 years &minus; United States, 2009,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2009, 57(51):Q1-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine and Guidance for Use as a Booster Dose,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(39):1078-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/9/39060/abstract-text/18830212 /pubmed\" id=\"18830212 \" target=\"_blank\">",
"        18830212",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/9/39060/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13042 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_9_39060=[""].join("\n");
var outline_f38_9_39060=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215528\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14790063\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726087\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726097\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215828\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215686\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726098\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215817\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726094\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726088\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14790062\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215809\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726090\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726103\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726091\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299216\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215812\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215691\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215692\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726095\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726099\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726100\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13042\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13042|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/56/4998?source=related_link\">",
"      Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_9_39061="Meralgia paresthetica (lateral femoral cutaneous nerve entrapment)";
var content_f38_9_39061=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Meralgia paresthetica (lateral femoral cutaneous nerve entrapment)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/9/39061/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/9/39061/contributors\">",
"     Bruce C Anderson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/9/39061/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/9/39061/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/9/39061/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/9/39061/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/9/39061/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lateral femoral cutaneous nerve, a pure sensory nerve, is susceptible to compression as it courses from the lumbosacral plexus, through the abdominal cavity, under the inguinal ligament, and into the subcutaneous tissue of the thigh. Meralgia paresthetica is the term used to describe the clinical syndrome of pain, dysesthesia, or both in the anterolateral thigh associated with compression of the nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/36/22088?source=see_link\">",
"     \"Evaluation of the adult with hip pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of meralgia paresthetica cases result from entrapment of the lateral femoral cutaneous nerve as it passes under the inguinal ligament. The most frequent associated conditions are obesity, diabetes mellitus, and older age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/2\">",
"     2",
"    </a>",
"    ]. Additional associations include large abdomens with overlying panniculus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/3\">",
"     3",
"    </a>",
"    ], tight belts or garments around the waist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/4-6\">",
"     4-6",
"    </a>",
"    ], scar tissue near the lateral aspect of the inguinal ligament, and pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injury during local or regional surgery (eg, spine procedures, iliac crest bone harvesting, hip prosthesis, aorto-bifemoral bypass) is another important cause of meralgia paresthetica [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/10\">",
"     10",
"    </a>",
"    ], accounting for 17 percent of cases in one series of 120 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/5\">",
"     5",
"    </a>",
"    ]. Seat belt injury following motor vehicle accident is a less frequent cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/11\">",
"     11",
"    </a>",
"    ]. Meralgia has also been reported after long-distance walking and cycling, possibly as a consequence of local ischemia during repetitive muscle stretching [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective population-based study from Minnesota, 262 patients with meralgia paresthetica were compared with 262 normal controls and 262 body mass index-matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/2\">",
"     2",
"    </a>",
"    ]. The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The adjusted incidence of meralgia paresthetica in people with diabetes mellitus was seven-fold greater than that of the general population (247 versus 33 per 100,000 population)",
"     </li>",
"     <li>",
"      Among subjects with both meralgia paresthetica and diabetes, most developed diabetes after the diagnosis of meralgia",
"     </li>",
"     <li>",
"      Patients with meralgia were significantly more likely to have diabetes than controls matched for body mass index (odds ratio 2, 95% CI 1.3-3.0)",
"     </li>",
"     <li>",
"      The mean body mass index of patients with meralgia was significantly greater than that of matched controls (30.1 versus 27.3",
"      <span class=\"nowrap\">",
"       kg/m2)",
"      </span>",
"     </li>",
"     <li>",
"      The mean age at meralgia paresthetica diagnosis was 50 years",
"     </li>",
"     <li>",
"      The incidence rates of meralgia paresthetica were similar for men and women",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The course of the lateral femoral cutaneous nerve is under the inguinal ligament in the majority of patients. However, in a small percentage of cases the nerve enters the thigh lateral to the anterior superior iliac spine or in an extremely medial position near the insertion of the inguinal ligament on the pubis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/13\">",
"     13",
"    </a>",
"    ]. This is important from the standpoint of local injection. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Nerve blockade'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burning pain, paresthesia (numbness and tingling), and hypesthesia (diminished sensation) over the upper outer thigh is the classic presentation of meralgia paresthetica. The onset of pain is typically subacute. Sensory loss is quite discrete, and it is often possible to clearly demarcate the area of numbness. The patient often rubs the outer thigh when describing the symptoms. Neurologic symptoms are restricted to sensory changes since the lateral femoral cutaneous nerve does not contain motor fibers.",
"   </p>",
"   <p>",
"    A retrospective population-based study found that the pain tends to be unchanged with positions including walking or standing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/2\">",
"     2",
"    </a>",
"    ]. However, other reports have observed that pain can be aggravated by thigh extension or prolonged standing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/14\">",
"     14",
"    </a>",
"    ]. In some cases, discomfort can be exacerbated by Valsalva maneuvers or other activity that increases intra-abdominal pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of meralgia paresthetica is based primarily upon:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The unique description of pain and characteristic location",
"     </li>",
"     <li>",
"      Sensory abnormalities on examination",
"     </li>",
"     <li>",
"      Absence of neurologic abnormalities of the lower leg",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sensory function of the upper outer thigh is examined, and a lower extremity neurologic examination should be performed in patients with suspected meralgia paresthetica:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pinprick and light touch tend to be abnormal in a 10 x 6\" oval-shaped area on the anterolateral thigh (",
"      <a class=\"graphic graphic_picture graphicRef62268 \" href=\"mobipreview.htm?31/44/32463\">",
"       picture 1",
"      </a>",
"      ). However, the distribution of the lateral femoral cutaneous nerve is not strictly lateral; thus, abnormalities are occasionally also seen on the anterior thigh.",
"     </li>",
"     <li>",
"      The lower extremity neurologic examination is otherwise normal (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38377?source=see_link\">",
"       \"The detailed neurologic examination in adults\"",
"      </a>",
"      ). In particular, the straight leg raise is negative, and deep tendon reflexes and distal motor strength are preserved.",
"     </li>",
"     <li>",
"      There is no evidence of hip, back, or sacroiliac joint abnormality. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/36/22088?source=see_link&amp;anchor=H18#H18\">",
"       \"Evaluation of the adult with hip pain\", section on 'Examination'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain x-rays of the hip and pelvis are not necessary in patients with characteristic findings on the history and physical examination; no specific changes are evident on plain radiography with this disorder.",
"   </p>",
"   <p>",
"    Radiographic studies of the lumbar spine should be obtained when the clinical findings are equivocal to exclude spondylolisthesis, spinal stenosis, or disk disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Electrodiagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensory nerve conduction studies have been described for the lateral femoral cutaneous nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/5,15-18\">",
"     5,15-18",
"    </a>",
"    ]. However, responses are extremely variable, and it is often difficult to perform this study in overweight individuals. Therefore, if this nerve conduction study is to be performed, it is essential that the contralateral side be studied as well. Electromyography has no role in the diagnosis, as there are no motor manifestations. However, electromyography and nerve conduction studies are occasionally useful to rule out radiculopathy or plexopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42233?source=see_link\">",
"     \"Overview of lower extremity peripheral nerve syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nerve blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection and blockade of the lateral femoral cutaneous nerve as it enters the thigh next to the anterior superior iliac spine is uncommonly performed to distinguish meralgia paresthetica from referred pain from the lumbosacral roots (",
"    <a class=\"graphic graphic_picture graphicRef55118 \" href=\"mobipreview.htm?23/24/23939\">",
"     picture 2",
"    </a>",
"    ). Relief of pain with local injection confirms the diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The conventional technique employs a fanned-out injection just inferior to and within one inch of the anterior superior iliac spine along the inguinal ligament.",
"     </li>",
"     <li>",
"      Alternatively, ultrasound can be used to identify the variable position of the lateral cutaneous femoral nerve in relation to the anterior superior iliac spine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/19\">",
"       19",
"      </a>",
"      ]. The injection needle is then advanced under ultrasound guidance to the lateral femoral cutaneous nerve via a lateral to medial approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conventional injection is effective in most cases. It has the disadvantage of using more anesthetic than an ultrasound-guided injection, which is time consuming to obtain, requires a trained technician, and is more costly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of meralgia paresthetica is limited. Lumbar radiculopathy can cause leg numbness, but it is rare that the symptoms or signs are as localized, and back pain is usually present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/20/20810?source=see_link\">",
"     \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meralgia paresthetica is a self-limited, benign disease in most patients. Spontaneous remission is frequent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/2\">",
"     2",
"    </a>",
"    ]. The goals of treatment are to reassure the patient that this is not a serious condition and to recommend ways to reduce pressure over the nerve in the groin area. Local glucocorticoid injection is used infrequently in patients with refractory symptoms. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Nerve blockade'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Better than 90 percent of patients respond to conservative measures alone, although recurrent symptoms are common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/13,20\">",
"     13,20",
"    </a>",
"    ]. Rarely surgery is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acute therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute therapy of meralgia paresthetica includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Educate the patient that the disorder does not represent a serious back problem",
"     </li>",
"     <li>",
"      Advise the patient to avoid tight garments",
"     </li>",
"     <li>",
"      Discuss the need for weight loss if appropriate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical therapy does not play a significant role in the management of this disorder. Abdominal toning exercises may reduce pressure over the nerve, but are of unproven value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Persistent symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with persistent symptoms for more than one to two months, despite the above measures, reexamine the dysesthetic area to confirm the local nature of the problem. Anticonvulsants such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    can be helpful in reducing neuropathic pain symptoms.",
"   </p>",
"   <p>",
"    Consultation with an anesthesiologist for a local nerve block can also be considered. Injection of a local anesthetic agent, glucocorticoid, or both can be useful to temporarily treat this neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/19,21,22\">",
"     19,21,22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Nerve blockade'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Rarely, surgery is necessary in patients with severe chronic symptoms that are refractory more conservative measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decompression of the nerve (sectioning the inferior slip of the attachment of the inguinal ligament to the anterior superior iliac spine) may provide long lasting relief in some. This procedure has the advantage of preserving sensory function. However, it is not uniformly successful.",
"     </li>",
"     <li>",
"      Sectioning of the lateral femoral cutaneous nerve as it exits the pelvis is the most definitive procedure, but has the disadvantage of permanent anesthesia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/13\">",
"       13",
"      </a>",
"      ]. From a practical point of view, only patients with intractable dysesthetic pain are willing to undergo a procedure that results in permanent anesthesia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One retrospective series reported 167 patients with meralgia paresthetica who had surgical release (n = 153) or transection (n = 14) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/24\">",
"     24",
"    </a>",
"    ]. At a mean follow-up of 98 months, symptomatic improvement and patient satisfaction were observed in 130 (78 percent).",
"   </p>",
"   <p>",
"    In a few case reports, patients with refractory symptoms noted improvement after pulsed radiofrequency nerve ablation of the lateral femoral cutaneous nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39061/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Further data are needed to determine the benefit of this procedure for treating meralgia paresthetica.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meralgia paresthetica is the term used to describe the clinical syndrome of pain, dysesthesia, or both in the anterolateral thigh associated with compression of the lateral femoral cutaneous nerve. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of meralgia paresthetica cases result from entrapment of the lateral femoral cutaneous nerve as it passes under the inguinal ligament. The most frequent associated conditions are obesity, diabetes mellitus, and older age. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of meralgia paresthetica is based primarily upon the unique description of pain and characteristic locations, sensory abnormalities on examination (",
"      <a class=\"graphic graphic_picture graphicRef62268 \" href=\"mobipreview.htm?31/44/32463\">",
"       picture 1",
"      </a>",
"      ), and absence of neurologic abnormalities of the lower leg. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Injection and blockade of the lateral femoral cutaneous nerve as it enters the thigh next to the anterior superior iliac spine is uncommonly performed to distinguish meralgia paresthetica from referred pain from the lumbosacral roots (",
"      <a class=\"graphic graphic_picture graphicRef55118 \" href=\"mobipreview.htm?23/24/23939\">",
"       picture 2",
"      </a>",
"      ). Relief of pain with local injection confirms the diagnosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Nerve blockade'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Meralgia paresthetica is a self-limited, benign disease in most patients. More than 90 percent of patients respond to conservative measures alone, although recurrent symptoms are common. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with symptoms that persist for more than one to two months despite conservative measures, anticonvulsants such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      , can be helpful in reducing neuropathic pain. A local nerve block can also be considered. Rarely, surgical nerve decompression or sectioning is necessary. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Persistent symptoms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Anderson BC. Office Orthopedics for Primary Care: Diagnosis and Treatment, 3rd Edition, Elsevier Company, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/2\">",
"      Parisi TJ, Mandrekar J, Dyck PJ, Klein CJ. Meralgia paresthetica: relation to obesity, advanced age, and diabetes mellitus. Neurology 2011; 77:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/3\">",
"      Deal CL, Canoso JJ. Meralgia paresthetica and large abdomens. Ann Intern Med 1982; 96:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/4\">",
"      Boyce JR. Meralgia paresthetica and tight trousers. JAMA 1984; 251:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/5\">",
"      Seror P, Seror R. Meralgia paresthetica: clinical and electrophysiological diagnosis in 120 cases. Muscle Nerve 2006; 33:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/6\">",
"      Park JW, Kim DH, Hwang M, Bun HR. Meralgia paresthetica caused by hip-huggers in a patient with aberrant course of the lateral femoral cutaneous nerve. Muscle Nerve 2007; 35:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/7\">",
"      Sax TW, Rosenbaum RB. Neuromuscular disorders in pregnancy. Muscle Nerve 2006; 34:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/8\">",
"      Van Diver T, Camann W. Meralgia paresthetica in the parturient. Int J Obstet Anesth 1995; 4:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/9\">",
"      van Slobbe AM, Bohnen AM, Bernsen RM, et al. Incidence rates and determinants in meralgia paresthetica in general practice. J Neurol 2004; 251:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/10\">",
"      Mirovsky Y, Neuwirth M. Injuries to the lateral femoral cutaneous nerve during spine surgery. Spine (Phila Pa 1976) 2000; 25:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/11\">",
"      Nahabedian MY, Dellon AL. Meralgia paresthetica: etiology, diagnosis, and outcome of surgical decompression. Ann Plast Surg 1995; 35:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/12\">",
"      Kho KH, Blijham PJ, Zwarts MJ. Meralgia paresthetica after strenuous exercise. Muscle Nerve 2005; 31:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/13\">",
"      Williams PH, Trzil KP. Management of meralgia paresthetica. J Neurosurg 1991; 74:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/14\">",
"      Harney D, Patijn J. Meralgia paresthetica: diagnosis and management strategies. Pain Med 2007; 8:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/15\">",
"      Sarala PK, Nishihara T, Oh SJ. Meralgia paresthetica: electrophysiologic study. Arch Phys Med Rehabil 1979; 60:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/16\">",
"      Russo MJ, Firestone LB, Mandler RN, Kelly JJ Jr. Nerve conduction studies of the lateral femoral cutaneous nerve. Implications in the diagnosis of meralgia paresthetica. Am J Electroneurodiagnostic Technol 2005; 45:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/17\">",
"      Shin YB, Park JH, Kwon DR, Park BK. Variability in conduction of the lateral femoral cutaneous nerve. Muscle Nerve 2006; 33:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/18\">",
"      Boon AJ, Bailey PW, Smith J, et al. Utility of ultrasound-guided surface electrode placement in lateral femoral cutaneous nerve conduction studies. Muscle Nerve 2011; 44:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/19\">",
"      Hurdle MF, Weingarten TN, Crisostomo RA, et al. Ultrasound-guided blockade of the lateral femoral cutaneous nerve: technical description and review of 10 cases. Arch Phys Med Rehabil 2007; 88:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/20\">",
"      Streiffer RH. Meralgia paresthetica. Am Fam Physician 1986; 33:141.",
"     </a>",
"    </li>",
"    <li>",
"     Lee CC. Entrapment syndrome of peripheral nerve injuries. In: Youman's Neurological Surgery, 5th, Winn HR.  (Ed), Elsevier, Philadelphia 2004. p.3923.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/22\">",
"      Khalil N, Nicotra A, Rakowicz W. Treatment for meralgia paraesthetica. Cochrane Database Syst Rev 2012; 12:CD004159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/23\">",
"      de Ruiter GC, Wurzer JA, Kloet A. Decision making in the surgical treatment of meralgia paresthetica: neurolysis versus neurectomy. Acta Neurochir (Wien) 2012; 154:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/24\">",
"      Benezis I, Boutaud B, Leclerc J, et al. Lateral femoral cutaneous neuropathy and its surgical treatment: a report of 167 cases. Muscle Nerve 2007; 36:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/25\">",
"      Philip CN, Candido KD, Joseph NJ, Crystal GJ. Successful treatment of meralgia paresthetica with pulsed radiofrequency of the lateral femoral cutaneous nerve. Pain Physician 2009; 12:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/26\">",
"      Choi HJ, Choi SK, Kim TS, Lim YJ. Pulsed radiofrequency neuromodulation treatment on the lateral femoral cutaneous nerve for the treatment of meralgia paresthetica. J Korean Neurosurg Soc 2011; 50:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39061/abstract/27\">",
"      Fowler IM, Tucker AA, Mendez RJ. Treatment of meralgia paresthetica with ultrasound-guided pulsed radiofrequency ablation of the lateral femoral cutaneous nerve. Pain Pract 2012; 12:394.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5270 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-0C172D990F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_9_39061=[""].join("\n");
var outline_f38_9_39061=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Electrodiagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nerve blockade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acute therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Persistent symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5270\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5270|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/44/32463\" title=\"picture 1\">",
"      Sensation anterolateral thigh",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/24/23939\" title=\"picture 2\">",
"      Local anesthetic block of the lateral femoral cutaneous nerve",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/36/22088?source=related_link\">",
"      Evaluation of the adult with hip pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/20/20810?source=related_link\">",
"      Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42233?source=related_link\">",
"      Overview of lower extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_9_39062="Traumatic brain injury: Epidemiology, classification, and pathophysiology";
var content_f38_9_39062=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Traumatic brain injury: Epidemiology, classification, and pathophysiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/9/39062/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/9/39062/contributors\">",
"     J Claude Hemphill, III, MD, MAS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/9/39062/contributors\">",
"     Nicholas Phan, MD, FRCSC, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/9/39062/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/9/39062/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/9/39062/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/9/39062/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/9/39062/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic brain injury (TBI) is the leading cause of death in North America for individuals between the ages of 1 and 45. Many survivors live with significant disabilities, resulting in major socioeconomic burden as well. In 2000, the economic impact of TBI in the United States was estimated to be $9.2 billion in lifetime medical costs and $51.2 billion in productivity losses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The focus of this topic is on the epidemiology, pathophysiology and classification of TBI. Other aspects of traumatic head injury are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35882?source=see_link\">",
"     \"Management of acute severe traumatic brain injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=see_link\">",
"     \"Concussion and mild traumatic brain injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/42/19112?source=see_link\">",
"     \"Intracranial epidural hematoma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4935?source=see_link\">",
"     \"Post-traumatic seizures and epilepsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6936?source=see_link\">",
"     \"Subdural hematoma in adults: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3481?source=see_link\">",
"     \"Skull fractures in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall incidence of TBI in the United States was estimated to be 538.2 per 100,000 population, or around 1.5 million new cases in 2003 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/1\">",
"     1",
"    </a>",
"    ]. Somewhat lower rates are reported in Europe (235 per 100,000) and Australia (322 per 100,000) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rates of TBI are highest in the very young (age group zero to four years) and in adolescents and young adults (15 to 24 years); there is another peak in incidence in the elderly (age &gt;65 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 78 percent of TBI are treated in the emergency department only; 19 percent of patients require hospitalization, and 3 percent are fatal. Most cases treated in emergency departments occur in the very young (ages zero to four years), while hospitalization rates are highest in patients older than 65 years.",
"   </p>",
"   <p>",
"    As with most traumatic injuries, the incidence of TBI is significantly higher in men compared to women, with ratios that vary between 2.0 to 1 and 2.8 to 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. For severe TBI, the gender ratio is more pronounced, 3.5 to 1. Lower socioeconomic status is also a risk factor for head injury.",
"   </p>",
"   <p>",
"    Falls are the leading cause of TBI (particularly in older patients), followed by motor vehicle accidents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The proportion of TBI secondary to violence has risen over the past decade and now accounts for 7 to 10 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/8\">",
"     8",
"    </a>",
"    ]. TBI related to military combat has received increased attention in the years from 2002 to 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/9\">",
"     9",
"    </a>",
"    ]. Mechanistic aspects of combat-related trauma may differ from TBI related to other causes, as the former usually involve blast explosives.",
"   </p>",
"   <p>",
"    Moderate and severe TBIs are associated with neurologic and functional impairments. The prevalence of long-term disability related to TBI in the United States is variably estimated to be between 3.2 to 5.3 million, or approximately 1 to 2 percent of the population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epidemiologic trends more specific to mild TBI are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=see_link&amp;anchor=H3#H3\">",
"     \"Concussion and mild traumatic brain injury\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;TBI is a heterogeneous disease. There are many different ways to categorize patients in terms of clinical severity, mechanism of injury, and pathophysiology, each of which may impact prognosis and treatment.",
"   </p>",
"   <p>",
"    The best prognostic models ideally include all of the factors described below, as well as age, medical comorbidity, and laboratory parameters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. However, treatment decisions are likely best informed by considering these variables individually rather than as a lump score. Further efforts at improved classification are ongoing as these may help to refine treatment approaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical severity scores",
"    </span>",
"    &nbsp;&mdash;&nbsp;TBI has traditionally been classified using injury severity scores; the most commonly used is the Glasgow Coma Scale (GCS) (",
"    <a class=\"graphic graphic_table graphicRef81854 \" href=\"mobipreview.htm?28/62/29676\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/16\">",
"     16",
"    </a>",
"    ]. A GCS score of 13 to 15 is considered mild injury, 9 to 12 is considered moderate injury, and 8 or less as severe traumatic brain injury.",
"   </p>",
"   <p>",
"    The GCS is universally accepted as a tool for TBI classification because of its simplicity, reproducibility, and predictive value for overall prognosis. However, it is limited by confounding factors such as medical sedation and paralysis, endotracheal intubation, and intoxication. These confounding issues are often particularly prominent in patients with a low GCS score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative scoring system, the Full Outline of Unresponsiveness (FOUR) Score, has been developed in order to attempt to obviate these issues, primarily by including a brainstem examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. However, this lacks the long track record of the GCS in predicting prognosis and is somewhat more complicated to perform, which may be a barrier for nonneurologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Neuroimaging scales",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic brain injury can lead to several pathologic injuries, most of which can be identified on neuroimaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Skull fracture",
"     </li>",
"     <li>",
"      Epidural hematoma",
"     </li>",
"     <li>",
"      Subdural hematoma",
"     </li>",
"     <li>",
"      Subarachnoid hemorrhage",
"     </li>",
"     <li>",
"      Intraparenchymal hemorrhage",
"     </li>",
"     <li>",
"      Cerebral contusion",
"     </li>",
"     <li>",
"      Intraventricular hemorrhage",
"     </li>",
"     <li>",
"      Focal and diffuse patterns of axonal injury with cerebral edema",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two currently used CT-based grading scales are the Marshall scale and the Rotterdam scale:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Marshall scale uses CT findings to classify injuries in six different categories (",
"      <a class=\"graphic graphic_table graphicRef67172 \" href=\"mobipreview.htm?29/11/29883\">",
"       table 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/22\">",
"       22",
"      </a>",
"      ]. It is widely used in neurotrauma centers and has been shown to predict the risk of increased intracranial pressure and outcome in adults accurately, but lacks reproducibility in patients with multiple types of brain injury.",
"     </li>",
"     <li>",
"      The Rotterdam scale is a more recent CT-based classification developed to overcome the limitations of the Marshall scale (",
"      <a class=\"graphic graphic_table graphicRef70406 \" href=\"mobipreview.htm?40/30/41451\">",
"       table 3",
"      </a>",
"      ). It has shown promising early results but requires broader validation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are other important considerations for prognosis and treatment in individuals with severe traumatic brain injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Different disease mechanisms (eg, closed versus penetrating injuries, blast versus blunt trauma) may affect the type of pathologic brain injury.",
"     </li>",
"     <li>",
"      Extracranial injuries are present in about 35 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/24\">",
"       24",
"      </a>",
"      ]. Multiple systemic traumatic injuries can further exacerbate brain injury because of associated blood loss, hypoxia, and other related complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of TBI-related brain injury is divided into two separate but related categories: primary brain injury and secondary brain injury.",
"   </p>",
"   <p>",
"    Current clinical approaches to the management of TBI center around these concepts of primary and secondary brain injury. Surgical treatment of primary brain injury lesions is central to the initial management of severe head injury. Likewise, the identification, prevention, and treatment of secondary brain injury is the principle focus of neurointensive care management for patients with severe TBI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35882?source=see_link\">",
"     \"Management of acute severe traumatic brain injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Primary brain Injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary brain injury occurs at the time of trauma. Common mechanisms include direct impact, rapid",
"    <span class=\"nowrap\">",
"     acceleration/deceleration,",
"    </span>",
"    penetrating injury, and blast waves. Although these mechanisms are heterogeneous, they all result from external mechanical forces transferred to intracranial contents. The damage that results includes a combination of focal contusions and hematomas, as well as shearing of white matter tracts (diffuse axonal injury) along with cerebral edema and swelling.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shearing mechanisms lead to diffuse axonal injury (DAI), which is visualized pathologically and on neuroimaging studies as multiple small lesions seen within white matter tracts (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67573 \" href=\"mobipreview.htm?29/9/29843\">",
"       image 1",
"      </a>",
"      ). Patients with severe DAI typically present with profound coma without elevated intracranial pressure (ICP), and often have poor outcome. This typically involves the gray-white junction in the hemispheres, with more severe injuries affecting the corpus callosum",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      midbrain.",
"     </li>",
"     <li>",
"      Focal cerebral contusions are the most frequently encountered lesions. Contusions are commonly seen in the basal frontal and temporal areas, which are particularly susceptible due to direct impact on basal skull surfaces in the setting of",
"      <span class=\"nowrap\">",
"       acceleration/deceleration",
"      </span>",
"      injuries (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53951 \" href=\"mobipreview.htm?12/4/12354\">",
"       image 2",
"      </a>",
"      ). Coalescence of cerebral contusions or a more severe head injury disrupting intraparenchymal blood vessels may result in an intraparenchymal hematoma.",
"     </li>",
"     <li>",
"      Extra-axial (defined as outside the substance of the brain) hematomas are generally encountered when forces are distributed to the cranial vault and the most superficial cerebral layers. These include epidural, subdural, and subarachnoid hemorrhage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In adults, epidural hematomas (EDH) are typically associated with torn dural vessels such as the middle meningeal artery, and are almost always associated with a skull fracture. EDHs are lenticular-shaped and tend not to be associated with underlying brain damage. For this reason, patients who are found to have EDHs only on CT scan may have a better prognosis than individuals with other traumatic hemorrhage types (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56200 \" href=\"mobipreview.htm?40/10/41123\">",
"       image 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Subdural hematomas (SDH) result from damage to bridging veins, which drain the cerebral cortical surfaces to dural venous sinuses, or from the blossoming of superficial cortical contusions. They tend to be crescent-shaped and are often associated with underlying cerebral injury (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68102 \" href=\"mobipreview.htm?22/0/22530\">",
"       image 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Subarachnoid hemorrhage (SAH) can occur with disruption of small pial vessels and commonly occurs in the sylvian fissures and interpeduncular cisterns. Intraventricular hemorrhage or superficial intracerebral hemorrhage may also extend into the subarachnoid space.",
"     </li>",
"     <li>",
"      Intraventricular hemorrhage is believed to result from tearing of subependymal veins, or by extension from adjacent intraparenchymal or subarachnoid hemorrhage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately one-third of patients with severe TBI develop a coagulopathy, which is associated with an increased risk of hemorrhage enlargement, poor neurologic outcomes and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/25-29\">",
"     25-29",
"    </a>",
"    ]. While the coagulopathy may result from existing patient medications such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or antiplatelet agents, acute TBI is also thought to produce a coagulopathy through the systemic release of tissue factor and brain phospholipids into the circulation leading to inappropriate intravascular coagulation and a consumptive coagulopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Secondary brain Injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary brain injury in TBI is usually considered as a cascade of molecular injury mechanisms that are initiated at the time of initial trauma and continue for hours or days. These mechanisms include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39062/abstract/25,31-39\">",
"     25,31-39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neurotransmitter-mediated excitotoxicity causing glutamate, free-radical injury to cell membranes",
"     </li>",
"     <li>",
"      Electrolyte imbalances",
"     </li>",
"     <li>",
"      Mitochondrial dysfunction",
"     </li>",
"     <li>",
"      Inflammatory responses",
"     </li>",
"     <li>",
"      Apoptosis",
"     </li>",
"     <li>",
"      Secondary ischemia from vasospasm, focal microvascular occlusion, vascular injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These lead in turn to neuronal cell death as well as to cerebral edema and increased intracranial pressure that can further exacerbate the brain injury. This injury cascade shares many features of the ischemic cascade in acute stroke. These various pathways of cellular injury have been the focus of extensive preclinical work into the development of neuroprotective treatments to prevent secondary brain injury in TBI. No clinical trials of these strategies have demonstrated clear benefit in patients.",
"   </p>",
"   <p>",
"    However, a critical aspect of ameliorating secondary brain injury after TBI is the avoidance of secondary brain insults, which would otherwise be well-tolerated but can exacerbate neuronal injury in cells made vulnerable by the initial TBI. Examples include hypotension and hypoxia (which decrease substrate delivery of oxygen and glucose to injured brain), fever and seizures (which may further increase metabolic demand), and hyperglycemia (which may exacerbate ongoing injury mechanisms). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35882?source=see_link\">",
"     \"Management of acute severe traumatic brain injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/47/8947?source=see_link\">",
"       \"Patient information: Closed head injury (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic brain injury (TBI) encompasses a broad range of pathologic injuries to the brain of varying clinical severity that result from head trauma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among adults, TBI is most common in the young (&lt;25 years), although there is another, smaller peak that occurs in elder adults (&gt;65 years). Motor vehicle accidents are a leading cause in younger adults, while falls are the most likely cause of TBI in the older age group. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TBI is classically categorized as mild, moderate, and severe according to clinical severity using the Glasgow coma scale (GCS) (",
"      <a class=\"graphic graphic_table graphicRef81854 \" href=\"mobipreview.htm?28/62/29676\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical severity scores'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TBI can also be classified according to the type and severity of neuroimaging findings, the mechanism of brain injury, and other variables. These factors individually, and in the aggregate, influence prognosis and treatment. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathophysiology of TBI includes primary and secondary brain injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The pathoanatomical sequelae of primary TBI include intra- and extraparenchymal hemorrhages and diffuse axonal injury. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Primary brain Injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secondary TBI results from a cascade of molecular injury mechanisms, that are initiated at the time of initial trauma and continue for hours or days. It is likely that secondary brain injury can be exacerbated by modifiable systemic events such as hypotension, hypoxia, fever, and seizures. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Secondary brain Injury'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/1\">",
"      Rutland-Brown W, Langlois JA, Thomas KE, Xi YL. Incidence of traumatic brain injury in the United States, 2003. J Head Trauma Rehabil 2006; 21:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/2\">",
"      Tagliaferri F, Compagnone C, Korsic M, et al. A systematic review of brain injury epidemiology in Europe. Acta Neurochir (Wien) 2006; 148:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/3\">",
"      Hillier SL, Hiller JE, Metzer J. Epidemiology of traumatic brain injury in South Australia. Brain Inj 1997; 11:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/4\">",
"      Langlois JA, Keyl PM, Guralnik JM, et al. Characteristics of older pedestrians who have difficulty crossing the street. Am J Public Health 1997; 87:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/5\">",
"      Kraus JF, McArthur DL. Epidemiologic aspects of brain injury. Neurol Clin 1996; 14:435.",
"     </a>",
"    </li>",
"    <li>",
"     Langlois JA, Rutland-Brown W, Thomas KE. Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths. Centers for Disease Control and Prevention, Atlanta, 2006.",
"    </li>",
"    <li>",
"     Jennett B, Frankovyski RF. The epidemiology of head injury. In: Handbook of Clinical Neurology, Braakman R (Ed), Elsevier, New York 1990. Vol 13, p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/8\">",
"      Butcher I, McHugh GS, Lu J, et al. Prognostic value of cause of injury in traumatic brain injury: results from the IMPACT study. J Neurotrauma 2007; 24:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/9\">",
"      Summers CR, Ivins B, Schwab KA. Traumatic brain injury in the United States: an epidemiologic overview. Mt Sinai J Med 2009; 76:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/10\">",
"      Thurman DJ, Alverson C, Dunn KA, et al. Traumatic brain injury in the United States: A public health perspective. J Head Trauma Rehabil 1999; 14:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/11\">",
"      Zaloshnja E, Miller T, Langlois JA, Selassie AW. Prevalence of long-term disability from traumatic brain injury in the civilian population of the United States, 2005. J Head Trauma Rehabil 2008; 23:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/12\">",
"      Steyerberg EW, Mushkudiani N, Perel P, et al. Predicting outcome after traumatic brain injury: development and international validation of prognostic scores based on admission characteristics. PLoS Med 2008; 5:e165; discussion e165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/13\">",
"      Menon D, Harrison D. Prognostic modelling in traumatic brain injury. BMJ 2008; 336:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/14\">",
"      MRC CRASH Trial Collaborators, Perel P, Arango M, et al. Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients. BMJ 2008; 336:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/15\">",
"      Saatman KE, Duhaime AC, Bullock R, et al. Classification of traumatic brain injury for targeted therapies. J Neurotrauma 2008; 25:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/16\">",
"      Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974; 2:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/17\">",
"      Balestreri M, Czosnyka M, Chatfield DA, et al. Predictive value of Glasgow Coma Scale after brain trauma: change in trend over the past ten years. J Neurol Neurosurg Psychiatry 2004; 75:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/18\">",
"      Stocchetti N, Pagan F, Calappi E, et al. Inaccurate early assessment of neurological severity in head injury. J Neurotrauma 2004; 21:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/19\">",
"      Stead LG, Wijdicks EF, Bhagra A, et al. Validation of a new coma scale, the FOUR score, in the emergency department. Neurocrit Care 2009; 10:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/20\">",
"      Wijdicks EF, Bamlet WR, Maramattom BV, et al. Validation of a new coma scale: The FOUR score. Ann Neurol 2005; 58:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/21\">",
"      Eken C, Kartal M, Bacanli A, Eray O. Comparison of the Full Outline of Unresponsiveness Score Coma Scale and the Glasgow Coma Scale in an emergency setting population. Eur J Emerg Med 2009; 16:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/22\">",
"      Marshall LF, Marshall SB, Klauber MR, et al. The diagnosis of head injury requires a classification based on computed axial tomography. J Neurotrauma 1992; 9 Suppl 1:S287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/23\">",
"      Maas AI, Hukkelhoven CW, Marshall LF, Steyerberg EW. Prediction of outcome in traumatic brain injury with computed tomographic characteristics: a comparison between the computed tomographic classification and combinations of computed tomographic predictors. Neurosurgery 2005; 57:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/24\">",
"      Maas AI, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol 2008; 7:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/25\">",
"      Harhangi BS, Kompanje EJ, Leebeek FW, Maas AI. Coagulation disorders after traumatic brain injury. Acta Neurochir (Wien) 2008; 150:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/26\">",
"      Allard CB, Scarpelini S, Rhind SG, et al. Abnormal coagulation tests are associated with progression of traumatic intracranial hemorrhage. J Trauma 2009; 67:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/27\">",
"      Wafaisade A, Lefering R, Tjardes T, et al. Acute coagulopathy in isolated blunt traumatic brain injury. Neurocrit Care 2010; 12:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/28\">",
"      Stein SC, Young GS, Talucci RC, et al. Delayed brain injury after head trauma: significance of coagulopathy. Neurosurgery 1992; 30:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/29\">",
"      Murray GD, Butcher I, McHugh GS, et al. Multivariable prognostic analysis in traumatic brain injury: results from the IMPACT study. J Neurotrauma 2007; 24:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/30\">",
"      Zehtabchi S, Soghoian S, Liu Y, et al. The association of coagulopathy and traumatic brain injury in patients with isolated head injury. Resuscitation 2008; 76:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/31\">",
"      B&uuml;ki A, Koizumi H, Povlishock JT. Moderate posttraumatic hypothermia decreases early calpain-mediated proteolysis and concomitant cytoskeletal compromise in traumatic axonal injury. Exp Neurol 1999; 159:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/32\">",
"      Coles JP, Minhas PS, Fryer TD, et al. Effect of hyperventilation on cerebral blood flow in traumatic head injury: clinical relevance and monitoring correlates. Crit Care Med 2002; 30:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/33\">",
"      Diringer MN, Videen TO, Yundt K, et al. Regional cerebrovascular and metabolic effects of hyperventilation after severe traumatic brain injury. J Neurosurg 2002; 96:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/34\">",
"      Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/35\">",
"      Morganti-Kossmann MC, Rancan M, Stahel PF, Kossmann T. Inflammatory response in acute traumatic brain injury: a double-edged sword. Curr Opin Crit Care 2002; 8:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/36\">",
"      Oertel M, Boscardin WJ, Obrist WD, et al. Posttraumatic vasospasm: the epidemiology, severity, and time course of an underestimated phenomenon: a prospective study performed in 299 patients. J Neurosurg 2005; 103:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/37\">",
"      Vespa P, Bergsneider M, Hattori N, et al. Metabolic crisis without brain ischemia is common after traumatic brain injury: a combined microdialysis and positron emission tomography study. J Cereb Blood Flow Metab 2005; 25:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/38\">",
"      Yi JH, Hazell AS. Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury. Neurochem Int 2006; 48:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39062/abstract/39\">",
"      Stein SC, Chen XH, Sinson GP, Smith DH. Intravascular coagulation: a major secondary insult in nonfatal traumatic brain injury. J Neurosurg 2002; 97:1373.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4825 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_9_39062=[""].join("\n");
var outline_f38_9_39062=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical severity scores",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Neuroimaging scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Primary brain Injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Secondary brain Injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4825\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4825|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/9/29843\" title=\"diagnostic image 1\">",
"      CT Diffuse axonal injury after TBI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/4/12354\" title=\"diagnostic image 2\">",
"      CT bifrontal cerebral contusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?40/10/41123\" title=\"diagnostic image 3\">",
"      CT traumatic EDH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?22/0/22530\" title=\"diagnostic image 4\">",
"      CT traumatic SDH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4825|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/62/29676\" title=\"table 1\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/11/29883\" title=\"table 2\">",
"      Marshall scale for TBI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/30/41451\" title=\"table 3\">",
"      Rotterdam scale for TBI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=related_link\">",
"      Concussion and mild traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/42/19112?source=related_link\">",
"      Intracranial epidural hematoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35882?source=related_link\">",
"      Management of acute severe traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/47/8947?source=related_link\">",
"      Patient information: Closed head injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4935?source=related_link\">",
"      Post-traumatic seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3481?source=related_link\">",
"      Skull fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6936?source=related_link\">",
"      Subdural hematoma in adults: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_9_39063="Subarachnoid spaces and cisterns";
var content_f38_9_39063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Subarachnoid spaces and cisterns as seen in a median section of the brain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 437px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAG1Ah4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACisrSvEeiaveT2mk6xpt9dQDMsNtdJK8Yzj5lUkjn1rVoAKKKKACiiigAoqnq+p2Wj6dNf6rdQ2llCAZJ5mCogJwMk9OSKWx1Kyv5ruKyuoZ5bSXyLhY3BMUmAdrehwQce9AFuiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiio7kbreUBDIShGwNtLcdM9vrQBm2fiXQr7VZdMsta0y41KLPmWkV3G8yY65QHIx9K1q+cPBPhTxjo1+tj4Ysr+10mCxvTD/b9naiSwunjYReTPGxaTLt8xIC7c9zxiXcPjXw54Pv7rUr7xTaSyGwiuI2Z0Bn+0oHaOY3crMzqWB2hEIxwOlAH1NPcQwGPz5Y4jI4jTewXcx6KM9TweKkr5v1nwj4k1DSra8ksPFB0m08UxXtpYPqDtfQ2XlFZHBMud2/lfm3KGYjGTna1dfHsOsapptrYeI5IJ/ENne219HdgxRWP7sSRE+ZuA4bKAEdSfcA92or55t/CPjG916yk1C88Upb3eoavFe7dSlVUtQrNahQG+UFwAMckcdOK6XW7rxFpP7Mc8+qXN9aeI7bSh5sxlKzpICBkuDndjHOc0Aew1Q1HWNO025tre/vbe3nuRIYUkcKZBGu98DvtUEn0FeDT6R49utE8RT+HE8QWum3M9g8drf3jSXUqqCbpoiZgyhsrwJE3YIUrSWPhbxTNL4Ze5h1q9itLjWCGv4fLe3ilsdsaANPM5TzCyqXfd+GCQD6B069ttSsYL2wnjuLSdBJFNG25XU8gg9xVivneGx8eaB4e0+1sdK16aKbwT/ZscNlcKos9RG8+Yyl12sFK/MuW4AGa2fD+meJo/FNlN4rsvFV6xTTf7Pns9QKW9ttjQXH2hPMGSX3F9ytuHAoA9fs9b0y90QaxaX9tNpZjaX7Wjgx7Fzubd0wMH8qs2N3b39lb3llMk9rcRrLFLGcq6MMqwPcEEGvnK40Lxzd+DPD1t4js/E2pRnRL2GW3tr1lmGoNI3lPcHzFLp5ZwMkjtjnBmuLL4g6L4Wm0zTtM8QytdeFdOtbI2dyFWxuoowJsguCje6gk4H4AH0dRXgGseGvGl94nnu/tfiWOL+3tPhjEN/IkaWLwqtyyqGwOc5OMg8jvXo/wfstY03wtc2WvG9aSDUbpLY3khkkNv5h8oliSWG3oSaAO4rD8dabeaz4L13TNLm8i+u7KaCCTONrshA57cnr2rcooA8E07TtfX4bTaP4a8DXfhzxPZaQtqdSH2eIysJIvMjhlVixMiq7BzjDAHOcGgaL4ylsmh0oeJtN0SfxJYG1gnvma9t7LZi5LvvZhGWyQrMfpXvdFAHzf4ntfEdx428W+H/Dd14ovdQsF0kaXcDUpPJs2KkyST5kAYMoOcq2ee9bt2vj2LxFNpi2XiB7dvGUGoLqEd0DANMJQGH7+7YMMSm3b1z7+3R28Mc8s0cUazS4EkiqAz46ZPfGaloA8S+C2m+L7HxhfSeILfWJbFrZ997qdxIkjymQEKYfPkibABAeNUAGR3xVprDxFD431241LTfEuoXz3jSaPPZ6l5Nglr5Q2xyL5gCncGDZQkkgj1r2Oua8Y3M9vf+FlgmliWbVljlCMVDp5Ex2tjqMgHB9BQB88S+GfHt/4V8V2M2m66Yb/RYCLO5kkdPtouVLCPzZ5WOEB+bK7sZ2jiu11Pw74ohuPEsttZap/Zt14rS7u4bCbybi7sfIVW8tgynG8DIDAkA17vRQB84+ING+IJ8H6Cnl+ILm4hlvHSx8923Rs/+jpcyxXEcgdVxhtzD15HNu/j+I9rHq2mjTvELTXV1pdxb3VvqHmxW0SrELiPeZA/3g4OB83JPByfoOigDwS48K+Lr/xVJdXN34mjtpvFNzAyx6jKkaaW0IwVUNhVL8AjBHbHWvR/g3b61afDjSbfxP8Aa/7ViM6Sfa23S7BNII9x7/u9nPpiu0ooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqO4t4bmPy7mKOWPIbbIoYZByDg+9SUUAFFFFABUdxBFcwvDcRJLC4wyOoZWHuD1qSigBAAoAAAA4AFLRRQAUUUUAczqepXml+N9LjuJd2jarC1qilQBDdpmReeuJE3jnvGoH3jXTVh+NdFfXvDl1Z28iw3y7Z7OYj/U3EbB4n/B1XPqMjvU3hPWU8QeHbHU1jMLzJiWFjzDKpKyRn3Vwyn3FAGtRVK71WxtH2T3KCT/nmvzN/wB8jmqb69Gf9RaXMnoSAg/U5/Ssp16cPiki405y2Rs0Vzt1r08YGIraHPAMkpb9MD+dVV1q9lmeIXdsHXkqkB9M9Sx9awlj6K63NFhps6yiuKTWbme3eVbu8GxdxQRICR7DbUI1N2MbyXd0EbhmecIF4B6A89azeY0+iZf1SXVnd0VxaTSvM6mW/RR91zO+1+OxzVVdQMtuswfUtrNtx9obgevDUv7Sh/Kw+qvud9XK+OP+Qj4Q/wCw0v8A6Tz1UiuZDcNCk97hQDvM7EfTk1zvi++kA8PXEs16iprKAbz8w/cTjIqoZhCTtZieGa6nq9Fcd9vuEljiTVJxJINyqyI2R+K/1qa31W/Zm8u8tpghwweHkH8GFCzGk97g8LNHV0Vzy61eKwV7e1c+glKn8sGpU1/DYnsLhB/eQq4/nn9K1jjKMvtEOhNdDcorNj1vTmYK10sTHoJgY/8A0ICtFGV1DIQynoQc5rojOMvhdzJxcd0LRRRVCCiiigArlfiF4wTwhptjIljLqOo6jeR2FjZROEM0z5wCx4VcA5Y9K6S9uoLGznu7uRYraCNpZZG6IijJJ9gAa4S78OS/ETwPpU+vSz6ZqYuRqtjNaALLZHczQg5yCwjZQwPBOenFAFseOn0nTYn8Z6TNpGpz3Dw21hZu2oyXKqgcyRiJNxUAnOVGNvPUZlg+JfhK4vdLtLfVvOuNTgiubRI7aZvMikkMasSEwo3gg7sbcc4FYWvfCdPEVlp7eIfEF3qurWNxLPDd3tnbSxgSIiNEYDH5ezCKRxkNk5rW8L/Dyz0HXIdSS6MzJpP9kmFbaKCMp57zFgkaqq8uRgADHvzQBla/8Y/D9r4f1e90WSS+urS0e8t45YJYIryNHCM0UrJtdQTjK5rTh+KnhT7Bc3N7fT2RtJIIbiO4s543Rph+7O0puKtg4bGOOtcrb/AXR7TStQ0y01AxWVxbyW0bDTrUXEauc/NOIxI+OcZPpnOBWsfhLb3DT3Op65e3upTXdlcPcvFGmEtTmOIIoAA5OT1OaANnUfib4Z077E95PfxWt2EKXTadcCBN7bVDuUwhJHRse+BVzwT4qPiNvEvnW6WqaPq8+mbvM3CRY1Rt5yBjO/p7da5jx98ILLxhr95qlxq1zA13FbxvGbeKby/JfcPLd1LRg/xBCNx656V1vhXwrD4eHiDyLqWX+2NSm1JyQAYmkVFKr7DYOT60AZVt8VPClxplzqYu72PTIArfbJNOuFhlDSrEDG5TDje6j5c9c9ATVfxt8TtN8O6jbWNsj310mr2umX8KRSl7cTwvKrKAh8xtqDCrnrjrxXO2/wAB9JWy12GbV7zfqtvHAzWsENqibJVlWQxxqFZ9yLzjpkDGatz/AAgee8n1CbxVqMury6laaob2S2h3CW3heJPkChcYfOMdh15NAHRTfE3w3HoMWsJJqE1k0ksb+Tp08jwNEcSCVAmY9pIB3Y696sW/xF8LXOp6dp9tqhmvNQghubZI7aVt8UpIRshcKDg5yRjviuS1D4J6fe6fZwvrV61zHPd3VzPPBDMtzNc48yQxupRXGPlIHy/rW94R+G9p4auVmg1G6lI0aHRugQhIyxEgI6Md34YoAmsfih4Vun1BJL25snsbQ30y39lNbN9nBA81RIgLLkgcc8j1rF1b4xaTZ6xoEEVnqLWeoPOszzWFxFNGEh8xGSIx7pA/AyBjvWXpHwE0azivobzU7q6t7vS30plW3hgfYZUlEhZFBeQMg+Zs57+ldTaeArs+JNB1rWvEt9qt1o8kzQCWCKNSskJiIIQDnktnufagBtx8W/BsGmWN9/ac00N9bSXcAgsp5WaJG2uxCodu1gQc4xg1Yuvij4Rt5LQNqjPFcQw3HnxW0rxQxzHETTOF2xBjwN5Hvisrw98JrHRVsRFqdzL9l06905dyKNy3MxlZj7gtgVQHwT00acunprOoR6fcWdpZanAiR4vktj+7JJUlD2O08j86AOgl+I2k2EuqrqtxFutdTGmQQWUU888spQME8vywS+DnCblx/FnirHgTxvB4j8Dz+Jb+JdNtIJLkS72OI44XZS7ZAI4XJBHFZN98LLebU7rVLPWLyz1R9XOsQXEcaN5LtEImTawIZSo785/XZ8LeCYvD/ga68Nx6jcTrcfaS13JHH5mZmZi23BQkFjwVx7Y4oArW/wAUPC8unJfvPqMFrLNDBA82l3See027yvLBjy4ba2CM++MjL2+Jfhz+wjqsTalNbrPJbSxw6bO8sEkf31ljCbo9uRncB1FcBe/BOfSrKzXw3qTm8k1ywv7hxFFBFBHAWy8cKrs3/NnpzgDpW5ffBexvLK0SXW72S8S/udRuZ5reGZLqadVV2aFlMYICrsOPl59aAOjl+J3hVfsP2e+uLwXdqt6n2Oynn8u3Y4EsmxD5a54+bFWLD4g+HL/xGmiWt7K15JLLBE5tpRBNLEMyIkpXYzKAcgE1zuhfCceHUsj4e8Salp08dlHp91JHFE/2mKNmKnDKdjjcw3Dt2qTw78JNK8P+LTrOnXCCP7VJdiGTT7Z5Vdw2VFwY/NCZY4G7PbOM0AelUUUUAFFFFABRRRQAUUUUAFZ+vaomi6TPfy2t9dpDtzDY27TzNlgvyovJxnJx0AJ7VoUUAeZWXxp8N3lnZ3sVnraWF1fQ6el3PZGGESSOUyZHIXCkHdgkjHSuuj8W6TcXWkx6ddQahb6i0yx3VrcwvEhiTc2TvyemPkDY74HNeead8KL+H4f+G/Dt3dafO2neIE1a4yGaOWETO5jAI5JDYwRijSvhPfaf4rh1KG50+Kyi1nVNRWCJWXbHdWqwogG3AIZST2x0zQB6VL4p8Pw2Mt7LrulJZRbfMuGvIxGm77uWzgZ7etVfCXjDS/E/hp9es3e301JJkaS5KIAInZWckMRt+UkHPT0rz20+Edzpvg/wba6aNF/tnQrlbm482Ei3vWCuuXIG4sN+VYg4OfWuu+G/g2bw94Dk8P661pdmeW6acQA+UyTSMxXB5xhsUAdNJrekxJI8uqWKJHALl2a4QBYT0kPPCH+90qp/wlvhz+z4r7/hINI+wy7vLuPtsflvtGWw27Bx39K8j074H6gngjWNLv8AXIptVnmtFtLnaxRba1x5MLgYPPzZ2ng4I6VoeHvhFdW2v6Ff6nHo7W1pf3d7d2yyTXAnaa2WINmXOW3KCeAMAdTQB6FL458NR63pOlHWLNrvVYjPZ7JAyTJkKCHHHJOBzyQcZxUtz4u0hGsRZXUGofa7mK1BtLmFvLMgcq7ZcZX5G4XLHHAODjzjwr8J9T8Pz+BrhJdHuJdC+1w3KyRthoprgyqYjj76AnAOACam8P8Awjm0jwb4H0yJtLj1HRdXh1G/uYoyv2pY/OwN23LNiUY3e9AHZeKviL4a8OaVq95NqVvezaUgkurKynikuUG9U5j3DGCw64rdn17R7fV4tKuNV0+LVJRmOze5RZnHqEJ3H8q8fuPhHr//AAr7UPB8Nx4ee0MUqW2oyQSC7cvOsmZW5A4BBIzuIXpir+rfCW+uPiFd63Hc2V1Y3Wo2+pbbqa4SS3ki2j5VRtr4C/LnGM45FAHsdFFZ17rFrbFkQmeZescXJB9z0H4mplOMFeTsOMXJ2Ro1UvtRtLED7TMqsfuoOWb6KOTXNXmr3F1IYpLgW4K7xFbk7iOer/h2xWVbyvP9me1iktw5PmEJvJHHVv8AGvPq5jFaU1c6oYVvWTOgvdeufLd4IUtoVGTJP8zY9kH9T+FcNp9wdO8WXljNPO9nq4bUbZdxjTzxhZ0KjA5/dvj1Mh7E1Z1nVdJ0dmbVdRgsZ2YnZv8ANldfTbyfyFcD408fWl5Hby6DpN1cXNlcpdpNKfLDbQVdAvJIeNnTHH3qxp/WcQ+tn8kbOnCCvFHqMU8ojiECQo2wyGKNSd3pgjjsaJI7l1U3uwCNTIJCwVVbHANeQar4w8R35/c6pBZ2LqHh+yRhN8bAMjAnLDKkHr3rmp1Sdt1/f3F0c5/eOX/nW1PKJvWUkvxNPaLoe2XPifw9ZuHv9c09pQcuISJt3GOig4/Ksmf4heFsRj7bqNyUz/q4XG8++4DNeWwGyGEt7Iyv7jNaFuNQJ/0WxjT/AICK6o5VRj8Tf4EOrbc7ef4maa0pa20jWpQV2/MQgAxjj5jUEnxFuJVRYvCc8ypna09zgj/x01y8ltr7jlgo9AQKo3SazCMyNMV9VOa0jl+GXT8WT7VPqdnP8SdXzG3/AAi8Q2dN1xnH0+Xio5PilqTSI48Oxb0GATck4z/wGuYsNI1K+jWR5yit0GSTWkvhK6IyLiTP+7T+pYVfZ/F/5kuvFdTRg+Kd1BIzHwxHvYksyXJGc9f4Ki1T4ix3lppc02hyQQ2GpRSGNZA+8GKZcAED1zWdN4XvY1JFw+fdayNVsb2206NJCrM2oQBSD32TUfU8NvFfixOtGS3PRYPih4eIZpbXVY5CT8zxKxXPXBDHFXk+IHg67gWK4vpIxkEiaCQEn/aIXBrzE6PqeP8AlkR9f/rVVuNGvv44Ff6YrN5bh3s2vmWqy7nttrr3hm5aGSz1rTfNXao8y4G7A7AFgc1rrE5hhe0umkhjy3DBjJ7Z9K+abnS3jyZrZlHc7eKjtfOsm3WF1cWrZzmGQof0NYyyeL+CZop3Pp6Y3SW5Kxi4d24QgAKPfHX0qKGSCAXEkTNbCNsH7PIRk+6jjOeOleCaf428V6cQIdWe4T+5coJM/ief1rqtI+Lt0mE1zSEkHeW0bH/jjZz+dcs8sr09Ya+jHdM9hg1e6WRBHeRTll3CKZQGI+q4x+RrUh12PpdwSwH+8o8xfzHP5gV5rY+OvC2pbWg1CKxuyRg3UWwjt1Py9OOtdPGrG383TZ45vOcN5jPuQDnJXFZLEYig7T/EzlRhLodtb3ENzGJLeVJU/vI2RUtcJJIpkgJt3DudrSoTGVI9+Dj/AArSs9VvURXikS+gPQP8r/gwGD+I/GuunmMHpNWMJ4ZrWLK3j/8A4m93pPhSP5l1OQz3w64soSrSA+zsY4/pI2OldlXn3gXVrPVtZ1jxHdTLE19ILPTxJ8o+yQkhSpPB3yGV+OoKegr0Gu+MlLZnM4tbhRRRVCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4yG/u/C3iL7Dq9xLc6Hqk5NhezMWa2nck/ZpGP8LE/u2P+4f4c9nVTV9Ns9Y0y50/UrdLizuEMcsTjhh/Q9wRyCMigC3VS/v4LJR5pJkb7kacs30H9elcHpHiK90e7k8L6heC5uYgx0/U5eTdQKMsrcYaeMYDf3h8/ZgHrObmFpI2uIpJXUCZxvaTOfyH6CuHE4xUvdirv8DppUOfWRpalrZuFkE03lQqQrQwtzz/eb+gx+NZ1srzie2ZH+ysCoZUCIo7bfWuY8SeJ9H8N7otUlMt4zNILC35YggY3noB359eK8v8AE3jLW/EymCaUWWnHgWtucAjsGbq38vauSlhK+LfPLbu/0OxKMFaJ6brnjrQPD03lxXcupXEY2rbWhGxT33N0654yceled+IPH/iPXpHSK4Ol2RPEVsSHx7v1P4YHtXMQ28cQworW0ewF3N+8zsXt617FLA0aC5mrvzInUsrsqWFh5kpMMTSyk5Z29fc10VpoFzNjzZNo/up/jXVaRo64UKgAHQAV1VhpKrjK1tKq3sccq0nseaaJ4djjubjSp0zJajz7csPv27sTj3KPvB9FaMVvxeHFToAPoK6DxlaLpcFnr8Sn/iVsWuQoyWtXwJh/wEBZMesQq/dKEyVZWXqCpyD7g1ndmV2zz+40wW2pxIoAWQEHAxnFddo+lxbFJArMnT7RrUKj+BCx/Guv0yHaopCI5dMiCfdFc/qmnoVO1a7gx5jxWTeWe4njrQBynh63MalGHAcgfnXWQ2oxkjrVWzstk2cVupD8g4oAyrq1XZ0FcB45t1S1sSO+pQ/+i5q9Puoj5ZyK4DxtCZE0xAPvanEP/IU1AGpptsssKHArRbRkkj+6KXSotgRcdK6FEwgoA4i/0FcHA5rjb3RoLe9QvBGVY7Txxz3r1vUEG01xHiSLAVgOdw/nTTa2Gm1sZDeFYZkBECD/AHcj+VZ114PIyYy6/qK9FtIiYkGOcVfjsg45GTTU5LqUqkl1PD73w3cxg/Kknt0P61RsptS0Sctpt5dWMmclUcqG+q9D+Ne4X2lRn7yVy2uaFG6coGX3HSr9pdWkro1jXa3KOjfFbVLUKmsWUN5GBgywny5PqR0P4Yrc1PxlpWs+HGs9I1CePUb6eKzj+1/K9uz5zJk8fKiyMOSMqB3rzfVNJktZ8RKXjPT1FZd7YSN5X2mOQJFvKKVwuW25PTk/KB7c+prnlgKE3zQ0f9dDo51JaM+krO0/s+yjtI7dTYwW6xxWyKGCqgChQT149qtafqEtp5QtpWhVm2/ZbkErn0Xuv4ce1fPmg+LvEGgKsdjeme2XGLe5/eIB6DuPwIr0zw58TdH1R4otXT+zL0Hgy4aIn2fHH44+teXVwOIw754a+n+RppJWaPWbLWoJ5RBcK1tO3Cq5+V/91uh+nB9q1a4II6xv5zfabRg0rO2GBHZQP1zV7R9UnhhVoPMmtxwYZj86/wC639D+Yq6GYdKv3nPUw3WB19FVbC+gvYy0LHcvDo3DIfcVar001JXRyNNOzCiiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqC9u4bK2ee4bai8cDJJPQAdzSbSV2CTeiHzzR28TSzOscajLMxwAK5PWdba6ZokZre22kqDlWmx6n+Ff1NV9Wv5ry5jeaCR0B/d26Hd5Z7M/q3p2H61jaxqVrplgL7WdQMdkiujI67TO3PCqOvt9K8nEYuVV+zpbfmd9Ggo+9Lcr+I7BNY0plvTb2UNuizRagrlDbyKQRJG3QEfj3HQ4rzrVPHeo6jolzb6PPDHqED+XqNzbgoXQHak0KnlY26H+63y8AqWxvGPiy88VyJEENnpEZzHahuXP95z3Pt2/WsGFJ4bmG404hLyHPlkruVlIwyOP4kYcEf1ANd+EwHJG9XV72Lm+qGwWxaYsd807nJZiWZjXTaN4bmunBnBA/uj+pq5oFvZ3dv8AbLGNoiZPLuLeRtz2smM+WT3BHKt/EOeoIHo2kWiRwrgDNd0qvSJyzrt6RMKz8MQQxDEaKf8AdrOlsxaaqm4fK3GfevQ/IyvFc54ist8ZdR868j61je5z3uaukKvGK6KJcLXH+HLwSxrnhuhFdfayBkoAJ0WSNkkUMjAgqwyCPQ1weiSPZWF1os7M0ukSC3RmJJe3IzA2f9z5Ce7RMa9Al4FcB4yUWOt2GqLxFL/xL7s9trsPKc/7suBnssjmgCHRT5+qXMvbcFH0Fd3pyjyxXCeGPlVi33iSTn611tvd7AOaAN1l+WqpjBbmqn9pDoTUq3AegCwkSg5FWogKpxvmp1fFAD7hAyEVxfi21Hn6Fkfe1aMf+QZ67F5gBzXMeMJVE3h5vTVoyf8AvxPQBr29vsOcYq8WAWqiXKNwDUmQ44oAqXsgKmuP151Z4kz96RR+tdHqpZY2CH5u1cff2dwNt1M5LIwIXHAFAHXWOCoPtWvbdRWJpTb4lretlwMmgBbuMFa53UIwQRiukuiNhrBuyMnNAHBa9EDdRxgclsVq2+lrJCPkzUFxH9q1pAv8PNdhZWoAVRQBwup+FkmBIiw3qvBrkNU8O3Nvn935qew5/KvefsalelZOoaYrkgqKuNRxNI1JRPHvDHirWfC8gWymM9iD81pMSU/4D3U/T8Qa9h8NeLdK8VREW7GLUVG42c7AEHHJX+8PcfpXF+IPC0cqtIg2S/3gOv19a8/vrGeyuxuLRTodySISCD2INY18HSxOq0kddOspH0irSplppNs6Scyo2wxKeep6j25FdFpesFisOoFFc8JMvCSf4H279vSvD/CXxNCRx6d4sTehwq3oGeO3mD+o/LvXpjIsaqYSJLDyiVhQbxIOuc/j614/77BTtJafgzScI1FZnf0Vy2j6o1lHGt0ztZPjZJJ96H2Y919+3fjkdSCCMjkGvVo1o1o80TgqU3B2YUUU2R0ijaSRlRFBZmY4AA6kmtjMVmCqWYgKBkk9AKi+123mQp9oh3zgmJd4zIB12jvj2ryj40E+I/DfhbUbC2u9a8J/2lHcanb2CO73Ftg4bYMF0DYJA68HpzXOT+H7LWPF/gZfBGn654W0nfq3mXENkbdo2aGD51WVWCK+3aMqMkNjnmgD6Aor5o/4ST4jT+GdIuL6TxFb37aLvshZ6cX+06iJ3XZcjyztHlhDhtqkEnOa7d5/H114g8dz215eRNpdpC2macLeP7Pc3D2WWAdlywWU5ADY3YB44oA9cuLiG2j8y5ljijyF3SMFGScAZPvRPcQwGPz5Y4jI4jTewXcx6KM9TweK+dH1PxjdeH9QWD+3dSsFbSmD6tpmJlujMPtKIjRjKKOc4IU9D3qXxA/iHVviFpyauNeeey8ZxNb2i2T/AGGLT1RhHOJAm0sd3JL55PHFAH0VUYuITcNbiWMzqodoww3BT0JHXFeSfGTxFqGmeMNC02DVdZsbC7069lkXSbXz5pJU2eXgCNyOWxngc8kVxc7/ABDt31TV4dPvP+Eok8L6ckskdvlt/wBobzdo2lTKEJO0A4PQdBQB9J0V8/Wmu+OIfCEsuk3+qaprA1WJdMgnsJgJ42UeZDO8sUR8tRubzMDBwN3arkfizxTpsHhy6nHiO/trzRLpbkjSy0iakCCodFTMYHzAZ+UgZyeTQB7rRXzdZ+IfH8ms+FGu5fEF0JrawE1nb2j2zK7AGaR3MDROv94M6FcEAD71fSNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAyaVIIXllYJGgLMx6AVxepajLdyJNK0cZyWt4JeMKOrEDq2Pyzj1qxrmoLeXgiLYs432oOolkHc4/hU/r+Fc3qeoadoOitrOp3TTxx/cA58yQ5G1QfX+npmvIxeIdWXsqf/AA530KSguaW5W8Ua/ZeGtJTUNSkeeaVibe3iHltK3UZ9hxknOPfIFeH67q1/4n1Q6hq0mT0ihX7kS+ij+venarqV94j1OTU9VbljiOPPyxL2VR/nNWtI01r2YFgRCD/31Xq4PBxw0eaXxFzmlqx2h6PJqEgOCsAPJ9fYV21n4cSGMCNMf1rd8P6WkUKnaBgcACukitF29K1lNyOGdRzPJdWsbvQtTTVNOjEj7RHPbs21LmPOdhPYjqrfwt7FgfQfDd9b6jp0N1ZO0lvJnaWXaysDhkdf4XU5BHr6jBLtd05Z7aRGXORxXEaTPcaFdS39tHJNCWC6jaRjLSBeBNGP+eir2/jXjqFIgzPV4gCtZ2pQBgQRwaksL6G5t4p7WaOe3lQSRSxtlZFPIYH0NSXJDigDiUY6dqnPEUh/I12umT7sc8GuX8RW3mQtt+9jINaHhi4861ibPIGDQB08rHFcl4vht7vSb23vV3W8sTI6+oIxXVscpXNa1avdKYwPlJGaAOJ8M3OqXVgkwaN7lGMF2rDBEy43Nx/fBWTHYSAV0UJ1Jzgoi/nToLX+xvE9pMVxZ6uotJfRLhAzQt/wJfMQ+p8sV1ckIjFAGNZ20g+adyzflWrDx3qje3SW/LHAp0Mu4BgeKANRXK1ILg1UDbhxS4IoAtGQkZJrkvG8p2aMQcY1SP8A9EzV0TSYGM1yPjiQC20ts8DU4/8A0TNQBr6LO06bie5rorcnGDXIeFWIt1Zuh5rsLVhwaAIbu2MnOKz5bPeNrLkV0JwRSeWp9KAMaytvLPTitVflUU5kCjgVA74oAZdyYQ81z+pTbI25xWpdycVyfiCcsPLU8txQA7w/B5s0lyeS7cfQV2dmnSsPQbcR20SgcAV0tsu3FAFpYxtrPvFG41pFsLWdfA7SRQBl3UaspBGRXG+JdKgnjYSLx1BHUfSulub5Y2Ik4xWHrl4jQEqc/wBaFoNO2qPMb+weEssyFos4DgcGtvwf4wvvCjJaX5e88PyZDR9WiB7ofT2/Lmuns9Jeay+Zc5HINcvq+jvYliYy1sfvp/d9xWklCvHkqI6qde7sz3CxuLe9ggv9Llins7hFzKz5UIPT3+vcVqaTqbac0Uc2f7NfhGI5gOeh/wBn+X0r5/8ABevz+Db398DceH7tgJkxu8o/3wP5juPwr2TUdV07TdJGqSTR/wBmeWBCI33Ccv0RVAO9jngDJPTFeFVoVcHVXJrfbz8jolyzj7x3+pX9ppen3F9qNxFbWcCGSWaVtqoo7k1xkdjeePZFuNbt5bLwqrB4NLmUrLf4PElypGVj6FYu/V/7oy/Dlnca1q1ldeL4XjsoWD6Vpkrh0gcElXn7NNgjaMlUxgZb5q9Qr1adSNRXiedODi7MRVCqFUAKBgAdAKWiitCQooooAKKKKAKk2mWU2p2+oy2sL31sjxwzsgLxq2NwB7A4GfpVuiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsfxDemOIWcDFZ5wcsOqJ3P17D3+lalzPHbW8k0x2xxqWY+wrhLh57+7ZmmaK6bEkka5BCfwoD047+pNceNr+zhyrdnRh6fPK72RBbPBJFIWmmt4dgdYzx5ca9Tntn868O8XeIJfGmveau6PSLXK28Z4yO7kep/QV3Pxh8Rz2WmW+hwsv9oaipa4ZOqQ5+7+PT6A+tefWdngJZQ8cZkYdqeWYZRj7aXy/zOucrFcQvcybIUPlJ1IHAFdvocMKpH5eNoAAqbRtJC24REwn8/rT5dEurSQyWR+UnJQ9PwrunPmOCpU5zs9MdQoFbkW1k4rhtKvJwdk0Tow9eldJb3mxRk4zUGZavow6EVwN3aTx6vIbc4YgHBHDV3+8SLnNZ8tohm345oA4mwu7jw1dyNdRGPQJ3LysCStjKx5kA7RMfvj+Enf0LZ74Bhw4ww6imi2SRGWRAysMEEZBHpXPaezeGL2DSLpidGuGEem3DH/j2btauf7p/wCWbH/c/uZALmrqPKY1n+DJB++TsHIFXtafEZU9a5/w1N5IlfdjMjH9aAPRF+6OabIEAzxmudbXEiT5nA+pqjJ4kEhIjJc/7IzQBs+IrNNW0S6sfMMMrgNDMOsUqkNHIPdXCt+FM0rWxq+iWl9JGIJ5FKzw/wDPKZSUkT6K6sPcAHvWA2p3crfu4H/HisqzW+ttaurPCxpqWby3z085FCyr9WQI4H/TOQ96ANjxLdotu2G5yBV3TLyJrZfnGQKyj4fuLlg11OT7AcUf8Iu6f6q6kH40AdGL5EH3h+dK2pIR98Vzn9gXg4F05x7U8aDdEYad6ANiXUolHLiuS8bX6T6dZCI5ZdRi/WKYVqjw85/1kjn/AIFVfWdGgt4dJRVH73U4g3v+5moA1NDlQWyAEdK37a52YHauQm0q5sHL2bMUP8J5FOi1a4gO25iZR64yKAO9jugRUomHrXI2usRSAYYVoR3ysOHFAG5LcDGBVGaf3qmbgt/EKrz3CqpJYUAJfXG1SSawbWJr+8MpH7tflX39TSahcvcyiCM4LdcdhXQ6RaiKBAAAAKANTToQiL7VrwJ3qnbgBQKstOI06jNAEkrqpxmoJirrisq8v9rZLYFGn3X2pgyHKetAFPVdNWbccda4rUdNmtp1ZdzIrZ2k/wAq9Xe3VxWTqGmh0ORmgDJ0mVJbZNvpUmp6etxCflzRaWLW8m1RgU/W9XTTfJtLeBr3VrlSbeyjYAsB1d2/gjHdj9ACcAgHmusQ22hFzfDdp85KiBcGR3/uxqSMnn2A6kgc0eC9QTR/FFhb+KLeP7E6BNM2Ss8VgzHJwTwWY8NJgegAXgdLe+GnQS3mqzLe6nMpV5ApWONf+ecSEnYg/NjyxJrlJLSK+gm0W+OGXLWsp6g+lXKCrQcJHTRnd6ntksBErwu0UcLuXfLHLAkYYHsQf1rq9Av3uYXt7k5urfAZv+eino/4459wa8j+GPiaTW7GfQNdw2q2SjBc4M8Y6N9Rxn8D6129jcSwTxXIMfnRD/UxZ+aHgEH1PGR7j3rwacpYStyT+f8AmdNWHtI+Z3dFMhlSeJJYmDxuAysOhBp9e2eaFFcb8T/Gc3gqw0Wa102LUbjVNVg0uOOW6+zojShyHZ9jcArzx3z2rA8M/FiDWn0g3FtDp32iTUYriFneclrRVLGGRV2uvzdTtz2BoA9Rorz2w+MHhC8S4ka8vLWCKw/tITXdlLCktuCAXjLL8+CQOM5J4zVmz+J+g3mmajeW8WqtJp8kcdzafYZBcR+YCyMUx90gE56cHNAHc0V53p3xNstb8ReD7XQUE+n64L8SyzK0csD2yoSm098sQc+nFafi34j+HvC2ozWWpyXbzW9t9ruTbWrzLbRE4DSFQduT0oA7GivPrP4jx/a/Ff22xnaz0a7gt4jZxPNJKskKybmUdMZ69ABTf+FweFG06xu7eTUbk3iTvFb29hLJN+5IEoZFU7Suec8Y5zigD0OivMvFvxg0TTPDRv8ARBPqt5LpbarBFFbyMqw8hXmIH7tSwK89wa9B0a7a/wBIsbx1CNcQRzFR0BZQcfrQBcooooAKKKKACiiigAooooAKKKKACiikdgilmOFAyT6CgDnPFl8qtHanJjjH2ifAz8o+6v4kZ/4DXPwTRW8U2o3Ms6WsKNK7zPgLwcjb7DmpJbqeeWe7iD+dOfNClMjacKgJ9hziuC+NOryx6Rp/h+ABLnUGDzBMYCKen4t/6Ca8N3xeI5V1/I9SEfZwSPPWvJNd1rUPEN6pAlc+Sh/hUcKv4DFdN4a08llDDMjHc5/pWS1skF1aaZGBttlDSe7da9B8MWqqgc9TX0M7RShHY46876GzZ2QjjUYAqw9txU/RRQJOME1kc5nyQ7ecVlarI8Sbo+oreulMkZ2da57ULK9dW2S4HoVzQBo6TfrNAhz1rYjZW5NeZxz3mkSlZULxZzlR0rpdM1qK4UbXH50AdU0iLWNrwtL6wntL6NJbaZSro3Qj/Peop78KvrXOzXU+p3LRWwO0HDP2H0oAoQ6pcsz6Ndytc6hEpNtcOfmu4QOSx/56oPvf3h8w/ixY07Qbgrnz5F3ctjgZrUm8M293YiF2eKZWWWKeI4khlU5WRT2YHn/61X/Dd5LdSTadqaJDrNooaZEXak8ecCeIf3DwCP4G+XptJAKEHh1M5lO4+p5NbFrpMMSgKg/GthIVUc4p+5F7igCjHZgDhQPwrM8T6VcXOl+bpyKdSs5Fu7QE4DSJzsJ7BxuQ+zmt2S6iTqwqpNq0KdxTsOzE06e21PTrW/smLWt1Es0RPXawyAfQjoR2IIqfyq5DQ9WTTb/VtLB/cBzqFoPSORv3qj2WVt3/AG3Udq0zrykcUcrHys6BIRin+QPaucXXR708a7g0+UOVnQ/Zwaw/FNuBJoA9dWjH/kCemjXgKyvEWtrINGk/55apE3/kGYUrMOVnXtaiq0+no/VQfwqnH4gjfGSKuQapFL3FFmKzMm60CFzlV2t6rxWe+kXkBzDLvHo1dikkcnpStCrDikI4Z2voeGhY/wC6c1Wur2aOFmaGTI9RxXczWoPaqF1Zq8Toyghhg0Ac/oFv5gE8vLvzXW24AWuOs3k0q6FtPkxE/u3P8q6aCcMuVPWgDSEm0VWu7rCnnioHlOM5rF1m+2QsseS54UDuaAI3lbUrwxqT5MZ+bH8R9K6TTQIsKoAArl9H8+3iCrb4z1Jbn610umM7t8y4oA3omPGasbA681Tiz3rD1DWLzU7+bRvDDqLiI7LzUWXdHZdDtUEYkmx0XovVuysAJ4h1SRL/APsjQoY7rWWUO4fPlWiHpJMR+iA7m9hlhPoGgx6Sk0jSSXWoXJD3V5L9+Zh09lUdFQcKOnetXQtFs9EsPs1kjfMxkllkbfJPIfvSSMeWY9yf5YFXZEAGRQBh6rADHg15b4ssGV2li4kiO9SPTvXrV+cqa4LX9vmsGGeOaadnccXyu5xl/fTxJY+JdLIXULFx5yj+IdDn2IyD9a9o0rW4dc0ey1jT50iglX51ZAxDZwUJHIwc14nYxyaddtb3i5trgGNvQ10Pwi1T+wfEl74dvD/ot3maFmPyq6gk5zwAVHX/AGRWGY4ZVaftI7r8j0YSR7l4bvtk32RxthmBlt88Y7sn9R9T6VT1fxDe6rqM+h+DjE95Edl5qci77ew9Vx/y0mx0jBwOCxHAPETXl74l8yDQbyS10YuwGpn5XuTj/V2ndU7GYf8AAP71ep+GbXTrLQbKDRbaK109Yx5UMYwF7n8c5yTyTknmscHN8vs5PVHLXjrzrZnOeIPhvpWvaDomk6pc3l3baZqUeqMbllma7kUuWWXcCCjeY2VAAxwABxVjV/h/pF/faLPbr/Z8Ok215a29tZxpHEFuUCP8oHGAuRjHJrr6K7DnPNrj4P6Deabp1hfXF7Pa2ejNoqruVS0ZZGDkgffBRSO3tVV/gzpsmivYS6xesftVvdRSraWce1oN+wMiQhZQfMbPmBskA9ufU6KAPPfC/wAK9M8Pahol5b399PLpU99PH5ojAka6C79wVQONoxgCuc+L3w31/wAT65fyeGZorODV7CKy1CaS8Cq4R2IzEYHJwCMFZEJzg4HX2WigDzbV/hJpepRaiH1G+ilvNQttS3KsTqksEYjUbHUq6kclWBGfpTvDPwm0rw/e2Vzb6hfzSWovQvmiMbvtJUuSFUDjbxgAe1ej0UAeUS/BTS/7IhsLLXNXso/7K/sa5aHySbq3DMwDhkOCCx5XBxxXp+m2iWGnWtnGzMlvEkSs3UhQACfyqxRQAUUUUAFFFFABRRRQAUUUUAFFFFABWP4qnMWlGFG2yXLCEfQ/e/8AHQ1bFcrr9wr62okbEVrGB/20f/7ED865sXU9nSbNqEeaaMyF0nu4y0rgoDIibSoCnjn8q8O/tJNf8a6x4gmO+ztiUt89Nq8Lj69fxr0z4h6rJo3gLVJobjzZZQLaGQkZy52nHuBk/hXkIiGm+GbS2XiS4Pmv9O1Z5TR0lVfp/md030NHQma5ubi6k5eR+v616doQAjWvM/DuBZqR13nNd9pN6qgDOK9Cp8TPPqu8mdTKQI6wbvUTbXao/CscA1fFyJE4NZes2y3Nq4P3gMg+hqDM3LeZZEBHINOePca5rw1emWMIx+YcH611MPNAGdfWEc0ZDKCfpXEappMllO01pkHqR2Nelyp8prmPEDiNDQByVpeXWpEQRAoOjtnp9K7fSdPjtLZI415HU1z3gy1BQylfvMWru7ePABxQA2KEDk1leJ9PF5FBcWUwtdWs2Mlpdbc7GIwVYfxRsOGXuPQgEa11II044rnNUvdqnDc00rlJXH2HiVdQsXlaI211A/k3VqW3G3lxnbnupHKt0Ye4IGfeaxIc7Sa5u7S9n1dLrRYGudQVfLlgBwtxDnJRj0UgnKsfut6gsD1fhPwsniK0W+kv5BZszKYETy5Y2BwUlzyrg8Ff1IwarRFXSMK61eUcM+CfU06EX18o+yWd3cZ/iSI4/OvXdI8MaVpqAW1nEGH8bjex/E1uJEijAHFHMLn7HgOp+Hdfs1j1qTTJVh07dLOpYF3typEyhc8nYSwH95Vro7DwJrFzCkqXth5Eih45ELOGUjII9iK9bbbgrtBB4rk/ALnS31LwtJwdJcNaA/xWcmTDj2TDxf8AbMetLmYuZmFD8OdQ/wCWurxD/dg/xNWB8OXJ+bWJT9IVr0Ik0mT60rsXMzgR8NwR/wAhW4/79rWD4r8CSWg0W3j1Fna71SNAzRgbMQzHPv0r10ORWH4ptbm9vPDj20ZkW21NZ5SCPkQQzLn82UfjRdhzM4K7+H2twKTbXdvPjsQUJrFnsNd0pi15YzCMdWQbh+Yr3gNxyKayI45Ap8zHzs8NtNdbja3Tt3rd0/X1chXIruNY8KaTqisbi1j8w/8ALRPkYfiK8+1vwNqemlpdMY30A58s8SL/AENO6Y7pnUW9zHOuQQadLAGFed6fqkttK0cm9JEOGjcEMv4V1mmazHOArNzUtCcbDdU02O6iZJEyPWucZ7vSX8uTdJB/C46j613xCypkYOazL60DoykdaRJykmtPL8kEbu35Vc0vTpJ5BLdcv2HZaoNF/Z+pHen7tzkGuw0spJgrjGKAJbWwAX5Vq5FB5R6Va3xW8DyzSJFDGpd3dgqqAMkkngAetcjIbnxsTs8608LH+LlJdSHt3SAg+zP7L94Abd6ldeJZpLPQbh7XSUYpc6rGcNIRwY7Y4weRgy9B0XJ5Xe0eG00qzgstOgjt7WEbUjjGAP8AEnqT1JOTRJHHb2qwW8aRQxqFSNFCqoHQADoKybe6KX5jY5GMigDslkDRg0E7hVS2bdEKlDheKAKGqAohI54ri5LGS8vGllGEHQV30wEgwelYeu3ljo1skt3vZ5m8u3toV3zXEmM7I17n1JwFHLEDmgDhPEGmRm2nknljtraIb5LiU7UiGcAk/XAwOSTgAk4rhvEV7c6hp7fY0NtYgeXL5iYnvADn94D92PgYj79XJ4VfRr/Rr3UCl9ryxq8Z8y20+Jt0Vqf7xP8Ay0lweXPA5CgDryesWwjneNh8s6n/AL6H+RWtN3dmbUXrZnr3h7UY9Z8NafraJGhNuMgIT5bg4cADsMMPyrrvCtygkntUJ8p/9IhyMcE/MPwPP/Aq8Z+CGohrbVdAmOXhf7VApOODgMM9gGCn/gVenWN+q3Ed3vhKQTD/AFYxtjb5Tkfjn8K8Fr6riXHpf8GdtSPPBo7uiiivZPMCiq95fWll5f2y6gt/MO1PNkCbj6DPWrAORkdKACiiigAooooAKKKguby2tZIEubiGF538uJZHCmRsZ2rnqcA8D0oAnoopk0scEMks0iRxRqWd3OFUDkkk9BQA+io7eeK5t4p7aVJoJVDxyRsGV1IyCCOCCO9SUAFFQfbLb7cLL7RD9sMfnCDePMKZxu29duTjPTNT0AFFFFABRRRQAVxFxKsslxOeY5ZnZmLADA+QfoBXX6jcfZbC5uP+eUbP+QzXBmKBLOIXLScQLu2sM9Qc465zXmZjLSMTswsd2ec/GeQyN4b0YKqs8jXMip93jgf+hNXIasjXmrrbRfdiURg+gHU10XxElWb4mxrklLKyRcE9D8zf1FY2gRm4uZZ25aRsCvTwa9nhov5/eXVly6mra6Z5VqotsqR3PO761PFPPbMPPiYL/eXkV1Wm2AMSlhWgdMTH3RQ3c4W76s5yx1eBesi/QnFSX2uQCJtrA8dBzWrNoUEp5iX8qRPDsCc7PyFAjmfC10Fu5Fkyrli20jHBr0CzkB61z97oqMweMFJV6MOtaOjR3Ea7ZyGx3HFAG3IPkJrhPFchJKA8sdo/Gu4uZNkJx6V55rshk1W3XqNxNAHQ+HLUQ2qgV0Q+WOs7SVxboAO1W7uXZGaAMnVbvYCM1zIiuNW1KOytP9Y/zM56Io6k1Y1q6+8c11Pwy0krp73864muyGGeyDoP61b0Ro9EdB4b0C20uzSKFPm6s56ufU1R1/Trnw/qUniTQ4HnjcKNV0+IDNzGvAmjH/PZB2/jUbeoXHXxps4FSdqgzKenX1rqWn297p88dxaXCCSKWM5V1I4IqyAa4jUA3gXUpdShBPha8kMl9EMn+z5mOTcKO0TEkyD+E/P3arniXxjb6YxtrNRdXhGdqn5Fz0yf6CgDqZWSNSWI4rz7xnr2m6R4g0XW472EPBJ9ivVVs5tZiAWOP7kgjf2UP61i3k+r61k39ywiP/LJPlUfh/jUTaBaTWstvcIJIpUMbqe6kYI/KgDrb3x3bwzPFHY3cjoSp3YTBHbvVCTx3esP3GloD6vIT/IVz/hnM2l+Te/vNQsJDZXLnrIyAFJD7vGyMT/eLDtWwI0HRRQBJ/wm+q99Nt/++mqaPx9cJ/r9JB/3JSP5iq2xfQUx4I36qKANy0+IOnSMFuoLm1PqQHH6V0Wn6vZ6gm6yuI5gOuw8j6jrXm8+mwyA/Lis2TTJbaQS2kjxuvRkbBoA9mEpo35615hpvjDU7B1TUVF3AOCcYkA+vf8AGu/0jUrXVLcT2UyyJ3HQqfQjtQBR8SeGbHXE3Tx7Z1HyTJw6/j3/ABrzDWNLvvDtyq3XzwE4S4UYB9m9DXuKKCKq6jYQXtvJDcRrJG4wysMg00xp2PMdF1kkhJDXR70mXINcb4o8P3HhyYTW5eTTicBicmI+jeo96n0XVycI55p27DtfY1NWsEuI2Vhz2NY2n6pFoyztqc6QW8C7nlc4UL0z+eBj14rd1jVbPTdN+130hClgiIi7nlc/dRFHLMewH8smuNutLvry4j1bWkETxMJLXT1bcsH+05HDye/Rei92aSTo7K2ufFssd1rkMltoiMHt9Mk4acggiS4GcYyMrF0HVsnAXsJHAXArm9F1DzoVOfathpRs60AV7luDXNREtrQ+n9a3p24Nc7pziXVZmHOCAKAO6tWxEKjnfDUW4/dgVzOta5NcXk2meHBHLeQtsur113QWR7j0kl/2BwP4yOFYAv6zrv2GaOxsIPt2szpvhtA20KmcebK3OyPOecEsRhQTnC6LoX2W5k1LVLj7frUy7XuSu1Y0/wCeUKc+XGPTJJ6sWPNQeHdNt9KikEBeSeZvMuLmZt8s7/3nbuf0AwAAABW6GyOtAGZqUe6Ns15l40j2wo6/ejfOfY8f4V6dqjhY2rznxDF9qLwjlnBNVF2dyoO0kzm/BWpjRvHul3THENw32aX6PwPybB/CvfJ0ZZTDPMZEnYgqEHCkEAHvjkflXzFqQZYg65EkZ3D2Ir6IvPENjbaXpeqXDrHNqMEbW8catJPOThtkcS8t15PQdyBXn5rRcpxlFb6fcekpJLU9E8P3Ju9It5H/ANYo8uT/AHlO0/qKxrrxfHPqzaX4bs31m9ikCXLxPstrTnkSzYI3D+4oZvUAc1zuh6Zqvil7uHWJJ9F0ZXEh0y2m/f3Ab/nvMv3QcHMcZHfLsOK9C0zT7PS7GGy021htLOFdscMCBEQegA4FdVGXNBNnnVFaTseCfE3TNYsPiB4q1ebwsviQ3ljbR6IbjS5NRt4QikTQMiEGNnYhg54xn1Nbmg2njW41HxE0Eup6Wum6NYtpOmrGqWUl01o4aPMiklUkCggPwcbs8V7RRWhB83aFf+P7fwzrsl0viy+uXsYd9rJbTxTRXHmqJHilZORtLEpEDwPlI4rLbT/GGo2GkXOunxfPbaV4mYxyw2UwuVtXtxiVUdWkIVsgE5xuYH2+pa4vXviToOh67Ppl59tY2rQJe3UVuWgs2mOIhK/bdkdAcZGcUAUfi1Jrcb+Hhp51hNDa6cas+jRl7tU8s+XtCgttL43FRnFeaeKLnx8NYhOl3Xi230xLSB9Llexknkdwx8wXUca/fPAxJgbeeDmvTPAvjbUvFHjnxRpx08Wuj6PKbVHkicSySjbyWPygYLHbjONpzWNp/wAUb7VdUaW0i8O2WinUn022Gp6p9nur4xuqSPCm3BwWGFJyeOmRQBj3kHxBfwv461SwvtebVY9WurXTrB40VRZ/aEIlhDIGZvLDBW3EYJwM81zF1beJbuw0GXVD4svbO08QLcCVNMuftdrAbdwwG9PMYBjw23jdgE8Y9X1f4qaPYeIbrQHgvIdWWOc2/nxARTPFGz4GG3AEKcEgA9j0rKt/jTolj4a0K88QLMuoX2mRancxWUJdLaN+N5yc4yDwMtgE4oA5/wALW/j3VL7wpY6rqHiXTtNlj1B5rgRqJxEsqm2W4ZkZVkK564bHvmsDULrx3feLtUh+xeJ00y8j1e3ubKeCaaFV8iUwFZNojwzBQoT2BLE8+q6h8W/Ddlq0li6anKkNzDazXkVmzW0LzKpjLSdMHcOmT7V6DQB5vbaZro/Z/wBMsdHe607xFb6DbeSoXZKk8cKHyypHBJXYQR3NcLqF98SNR8Gw620OtWQ1LWGe4sIYnF1ZWSqURQijzAC67m2jdgjHGa+gqKAPnW1m8fR2t5LnXLu5i8JXot7x9Nkile5F2PKGGXd5mzopAJAzjvXc/Da38S6d42v7XVr3XL/Sp9ItbsS6kuVS6YsJERgqgYGCUHSvUaKACiiigAooooAyPFj7dBuU7y7Yh/wJgP61yUzRf2pG62khl8zyd+SBgDOcf56V03ixgY9Ph7vchvwVS38wKwIJj/aLKlwx8xs+W6ngKCDt+pxXi5hK9W3ZHoYZWhc8J8VXJl8eeJJyckSeSP8AgKhf6Vq+EIx5cBYep/WuZ1uXzPFfiFvW+mH5ORXR+FpcWkTj+ElTXvJWoxXkvyMsRsem2mBGuPSrqcisO0vFMancAcVp20+/ociszkLiA56VbRAV5qsjjFMuZykRYHpQBbNspOeKidFj6daoWWqedkA8ikvrzy13GgAv5gsZya8/1GcNrdtz2atHVdVnuXMVrEzHpk9BXPXum3tv/pkkhaVDuxjjHpQB6RpEgNupz2pNUlKoayfDF8JoAM9s1qagpeM00OO5weqtJJu38FyEVR2ycV7xotutvZRRoAAiBR+Arw7W4jGvmYP7tg/5HNe4aLcpdafBNGcq6BgfqKcipmiaM8UnamMTipIOU+IWtGy04WNtg3V2CpyM7U6E49+leX6HD/wj9za6ff8AOnTkRWFw3/LF+1u59D/Ax/3P7lb+qXB1TxffyOSVhkMKD0CnFW76ytr+xms7yFZraZSjxsOGFAFjGOKWsLRry4s70aJq8rzXIUtZ3bnJvI1GSGP/AD1Ufe/vD5h/FjbkdY0LOQFHc0ANWGJJZJUjRZZMb3CgFsdMnvjJpzuqDLMAPeo7GK/1diNOg2w5wZ5eF/D1/Cug0/wlaxkSajI17N6Nwg/Dv+NAHNNqEG7bGxkf+6gyaeo1CUZh027YdiYyP516Fb20Fsmy3hjiT0RQo/SpcZ9aAPPBZ6y3TTZfxKj+tP8AsWqqP3mnTfhg/wAjXoGKMfWgDzS7tpAp+02c8fu0Zx+dZkDS6fdLd6VPsmU9AeGHoR3Feu59QaqXWlWF5k3FpE7H+LbhvzHNADfCmvw65aFgvlXcQHnQnt7j1FbUnIrjx4XFjqEN9o9y9vNGeUk+ZHHdT3x+ddUJCQCeCeo64oAiubaO6heOZFdGGCrDIIrxHxzZJ4O1OPaWliuifskCHMjsMZQD0GR8x4APJ6Z9T8SeI2sLmLS9HtxqGv3K7obXcVSJM4MszAHZGPXqx4UE9KVn4Nt1tLyfWJf7T1m9QLdXsiBTgciONf8AlnGp6KO/JJJJLTsNOxwPhK3aW9XVNZdJ9T2lIlHMdoh6pH7n+Jzy3sMKOl1ZQ8BIrmbiCXRtUks5SS0fKtj769j/AENbSXYntyCe1NrqU11RS8PMY55Y+waumb7lcxpakak5HTiumYnHFSQYl5qSRrKrMAwB4PBqDwlFvVpmxliXJPYepqv4uhhFm9zcSxwRQjdJNIcKg9+/0AySeACeKraDpz+IolW/jkg0L5WWykGJLsjkNOB0ToRFz6vk/KoBti7u/FWYNGmks9B5WbU4ztluvVLc/wAKesvU/wAGPv1pvY2umadFZafAlvawrtSNBgD/AOv3z3rZiASMKoAAGAB2qjqSFlJoAx9NuS5IJ5BxWyJgsea5SOcWmoOjnAb5hWjPdqYvlPWgCHW75Qjc1gaTavefabqQAIqkl3IVUQdWZjwB7nio9auokvVspFlutQOG/s+2I80A9DKx+WFfdvmP8KtT5dInuGtR4geKWLO6PT4ARaxEchiDzK4/vPnH8IWgDhdVv7C3urj+xYo9SmZiwvLmM/ZY88/u4zgzH/aOE9nFeo/DSztr3whbatNEbrVLksl5dyHMzBHbaqnoqjAwigKB0ArzfxlGI9ZlwMBkB/p/Su9+Dcu7wNMxhaVra/k8tc4Gdqnr2+8a58yX+zqXmj0KKvZ9T1rw25+3TbozH5kCHa3UYLf/ABVdFXIeFE8jUIUCuqvbyNhmz/EmP5119RgXeijmxCtMKKKK6zAK4fxD8MtF13XbvUrq41GNL57eS/soZlFvetAQYjKpUtxgD5WXOBnOK7iigDD8O+GrPQL7W7uzkuHk1e8N7OJWUhXKKuFwBhcKOuT71yl58H9AuNY+2Jeatb2v9pLqx06KZPs32oHJkAKFlyeoVgD6dK9HooA8z/4U1oA119TXUNYUtdXN4LcSxeWsk6MkhyY95GGJGWOPpkU6f4O6A0Wk/Zb3VLS406wTTVuImhZ5oEJKiQPGykgk/Mqg89a9KooA4O6+F2i3Nrq8El1qW3U7u1vZiJEyr24QIF+TofLGc5PXBFd5RRQAUUUUAFFFFABRRRQAUUUUAc54j/eavYL/AM84pJPxJUD+tY225E8DyIkjmQgkH7ic46fjWjqkrS6zfNGu9oY0iUE4BOCxH/jwrMhAGo+Zbwly5ZZpGY/LjsP89q+exUuatJnp0laCR826u23xpr6H/n+n/wDRjV0fhSCaWCUJLsUuMDGc8c/0rn/GsRt/iLriDjN0z/8AfXzf1rqfCbAQQY7sc/nX0170YvyRjiPhOltdJujjfdMV9FGK6nTLYQxheSfU0yyUFF+lasMORxWRxFOaUI4GcU2Zw0RHqKq65ZSSLlCysOQR2rDbU7u0Hl3MDtj+NBkH8KAF0ecxarPATxnI/GunlhWePDDIrz631HZrhuJY3jikwoLjHNehadOk0YKnINAFSOwjjPyIKh1CzWeFkYdRW+Ixmie2DJx1oA800520nUjbuSIycof6V2tu63EY75rJ8R6SLhdwGGHcVm6HqEltN9mucq46E/xCgDT1ywHlMcZBq58PfES2Lro+oSBYycW0jcD/AHCf5Vdyl3DtyCSK5jV9M2scoCp9qtalr3ke0xncOKXuK8j0TxbqWjxrA6/bLVeArnEij2bv+Ndlp3jfSLvaJJ/ssp/guBs/U8H86lpolxaOCiU2viXUoJeHW4fr7kkfoa3ateNdEbUZk1bRyslyFxIikfvQOhB9awtN1ATZimBjmThkYYIPuKQh+uadBqentDcFkKsJYpozh4ZFOVdT2YH/AA6E0zwNt8Q3T2niFtl/aoH+zqvlpdpuK+enqhI5UfdY4PG0teuVMkDqP4hiuL8aeMo9M0yxs4IMeIdMbfZXUbgeV6q4xyjDhk7j0IBDSb0Q4xcnZHubGCztiWMcFvEvJJCqoH6AV5z4n+L2j6WHXS4J9UcHb5sfyQg/756/gCPevIvE3jLUPF0Jnu4JJY3OwW+8hLV+uwr3PcN/EOeOVFeHTNV1eCOCQHyV6KFwKyca03aKsu7Pew+Ey+jBVMRNzf8ALG6Xo3/wx3OofEnxRNE1xDcaVZQeWXAjjMjD2JY4/Sub0nxx4i1x3j1DxHcW5OceUFi/9BAp9l4DJUfaplRfQmtA+DdGhAD3se6peDnJe9UdzthmmCpP93ho289X8m0cwmq3q6vNb3fiPVJoyp2P9skwD271fg1rULTVLOFfEWqCORfmAvXIU/nWjJ4V0YnC3seaydR8JwoSbWeOQexpLL3/ADv+vmdP+sFGTadBW+X+Ro3PjrxlosQuIdYNxbM+FS4jSTj64z+tddpnxiu7DyB4p0kCKQA/abI9PqjH/wBm/CvH7/TbqNQjs7IvQE5FW59VjuNL+x3UDGfhVcngVjUo4igk0+ZHRTeU5i3CdNQffRflp9+59S+GvEuk+JbM3Gi3sdyi/fUcOn+8p5H41na5r91PqL6F4WWKfVwAbi4kBaDT1PRpMfec/wAMYOT1OF5r5y1VdQ0lbK80dWsroJgXcUuNo6cAHJb2Py+ueh9r+CniK0m0kaHNbJaapbr50hBJ+17j80xJ5Lkn5iSSSc9+LoYpVNHozw81yCpg06tG8qa6vdf5pd/+Cdt4Z0C10C3lWEyXF5cN5l1ezkNNcv8A3nbHboAMBRwABWu5xTyKjbNdR88cd490U39k1zbL/pdsC6Y/iHdfxFcFplzuA2nKsMivZ3XnpXj+s2P9j+JLq2AxCW86L/cbt+BzVx7FwfQ1dFt3M7SEYya1Nb1K10a0jkuvMkmnYx29tCu6a4fGdqL3PcngAckgVmtrAtDDY6bbfbtZnUNHbBtqxof+WszfwR/mWPCg8kauiaCLGeTUdRn+361MmyW7ZdoVM58uJf4Iwf4RyTyxJ5qCGcpe6Ld6ift/iLZ9oTLWtjE26G0465/5aS88ufooUddfwtNmNB3Awa1tWj3Rk1y+kTfZNSlhPAJ3D8aAO+U8VDcruQjFJaSeaAF5OKwbjxFJqbPb+E4Ir8glX1GYn7FCR1wQQZ2HohC+rg8UAZviuC2gs/tl5dRWUaMFWWTJ3Mf4VUAs7H+6oJ9q5G41XVboi206O50q3PHnuALub/d6iBfoS/8AtL0rr/7Ihsrg6lqVzJqGqBCv2y4Ayinqsaj5Y1/2VAz3yeayytxPei5it2eNeFzxn3oA1PBPhu30y2/dxqpYl2x1Zj1JPUk9yeTV/wAUQGOBJ0HMR3fh3qnY661vKsdzE0JPZuh/GtTUbqO6sX2kHIoA8i8aOJNTDDvEP5mu6+C4j/4Qm7R5GjMupMFZc8HZGe30rzvxQcajIv8AcQL+mf616L8Hlx4FYCdoXl1ByjKuecKMfpWOZf7svVHo0PhR6X4caN9ZglhmlkWRJjlyfVeme1djXIeHW8zV7PI5+zSt9zbzuQHj860v+Eu0J9Zj0m31CO71Fm2tBaK05iP/AE02AiMe74FYYD+F8zmxPxm7RXg9/wDE3xPH4a1nxxBJp40LTNXOnnRjbkzTQiVYi/m7uJSXyF24AHeu3f4nWa+b/wAS+4/d+J08MH515lbb+9/3fm6deK7TnPQaK8is/jdpx1TULfUNMkitLezub2O7trhbhJlg++oIAXdj+6zDPBIrLb4u6vp2qa1qGu6PJb6XbaRY3sOmxyxySk3Fx5QbeAOcMvynpg0Ae40V5VrHxOfQNZ1KXxDYajp8NloP9pyaa3kSkE3Twp86E/M2F43FQG9QaZe/GFdKi1iHXPD1zZarp8tjB9kW5SQSS3QcxrvAwAAhJOPpmgD1iivJYvjE9xZ6YLTwtfzapfXN3apaGdI13W8QlLCR8BkKkENjsRgniqkfxmGqaHqcyaPf6UR4ffXbO4MkMrSRq2xsLyAQ543dRyQOlAHstFeRaj8YjpjXwPh++vLHSvsC6jfieJBGLqONkYJnLHMgBAGPcVa1P4tw2njRvD39mlke4kso76C5WUJOqFgHUDCng/LuLDuBQB6nRXnnhDxu8fwTsfGXiaRppE083dy0MYBcjPCqMDJ4A6Cqz+OdY/tvwtb6pot3oyapcMqRpNDcidPIeTDEDKkbRkDuRyRmgD0yivB9W+O91N4S8Q6joehwQ32mRLKIL66UyxgyrGfOgBV1+92JGSOfXoPEXxjTQtYbTLnw3fSXdpFBLqMUUqu9v5p+VUCg+aQo3HBAx3JoA9Yory3Vfi2LCy8TXw8NahNp2g3x06e5WeELJN5kSBVUtuyfOB5GMDrk8dJ4G8Yy+JNS17TL/R59I1PRpo454JJkmBWRN6MGTjleo7etAHXUUVT1m4NrpN5Ov3o4mZfrjj9aUnZXY0ruxxk7xy2N3PNP5KXE7PvHUDfgfoBRcAR6jbs8XnFpNqMpx5S4HX1yfWlnMFnpuy9jb7Jb2/mSP247e5NU4dSt57KG+sIpWjv+JCeGUD5ccd6+aalJOZ66Wmmx4n8XLQ2nxJu5CMLdRRzL/wB8hT+qmp/CsgEX+6/866j486Mf7P0zWIQT9lb7PMScna33SfoQf++q4Lw9diOdVJ+SXA/HtX0uEn7XDRt00+45q0bxPZ9MmDRIfat60euB0S9KqFY8Cuns74ZADUzgNu4jV+tZN7bRnkgGtEuWQEVh6rdPCjFVLN2AoAx9fsYpLKTgDiq3hXUPLt/Llf5kO059qrXEWq3+Qf3aHsBk1S/4R29g3PFM4YnJB6E0AekWt2JFHOa0Ym3LXllnq15psoS8Qhf73au10nWYrhQQ457UAat3AGBzXMaxpCy5ZRgg5BHUGusWdZAM4qvcBCOMUAcdYXk9lII7jJHQOK30kjvI8N1qK4tY5Cdy0kUIhHyUAVrzRgclKwb3TJUB4yPTFdrDL8vzUk6RSKcgVakaKZ5/aTX2lyFrG4ltz1IQ/Kfqp4NdDaahbeIpIbfUFW11bG2G7jGFlP8AdYf0/L0pmqWqc7RXJ3e6Gb5SVIOQR2I6Gm1cppSOp8RX9/4e0K5ur6yZWQbI3BDKzE4GcdB35rxW3R7ud7idjJLIxZmPUk19CeL7+zvfhldT6m8a/abLcoJ6y4yuB678V414SskllDzD5EGTWlLRM0oaRbJrPRJ7SH+1IFj8xVw0Eh2rcp12E9j3Vux9QSDqXXiiI2sT6UhW3lXKswww7FWHZgeCOxHfg1R8RaoZ5TBCcRLxgVzRc2cjyhWktZSDcRKMsCBgSoP74GMj+JRjqFIu3U0a6mvc6rdzk5lbH1qmZZG5LsfxprKF2lWV43UOjqcq6kZDA+hFJVFodvb+8acJ5F6OfzqOimBP9pZlxIciql3BHKDgc1JRQBnLLIlxBFeSubZWHBPQV0uiaqdP8e6RqFnP58EUipIwGP3bfIQfwNYlzCsyEEc0zQz5UtxEzhDtDDPfDA4FeVjMLGH7+GjVvzPp8qzOddfUq/vKSau35bemh9iRvkCnkDGarKcGpXmSOJnlZURAWZmOAoHJJPYVufDiMK8k+JWqpfanHHoEYnurR2tbm/ZQ1vauf4D/AM9JBg/J0Ukbv7p6h7y+8bZi0iafT/DP/LTUUJSe+HdYO6R+svVv4OPnp3jHSrPT/BDWem20Vta2flmKKJdqoAw6D8TTW41uc94EtYbGCQRl5Jpm3zzytukmfpudu5/QDgYGBXYsciuO8Pvscj3rpry+trGxkvL+4htrSIZkmmYKq/ie57Dqe1OQ5bi3ce+M1wfiee00u9ha4kka7I3JZWyiSeRfXbkBV/23Kr7k8VvG+1fXlI0lJNI0xv8Al/uIh9pmH/TKJuIx/tSAt/sDg1XXQ7LTIJVs4iXlO6aaRzJLM3953bLMfcmpJMqzguPEES/29IiafwV0q3cmJv8Aru/BmP8As4Cf7J611y3EcMCogVI0UKqqMAAdABXDSySabcfKcwMeP9k1LJqUlyBDAxZ249MUAa0sv9rX3lLzBEct/tH0rpbWzRIgAo6Vm6FYJaW6opDOTlm9TWlqmsaZovlx6rf29rNIMxwOd00n+5EuXb/gKmgDB8U20QsZGZeR0+tc/p1zMwEBDmQ8AY+99K0da1e41LZHp+iXJjZwFn1N/sqH3Ea7pGHs3lmqupafftCBqOrz7CMG204fY4T7HaTIw9mkYe1AHD+JLRINRu31m/tNNYtxDKxe4I7YgQNJ+JUDnrXffD2TVk8JWNp4Z0+P7DO8jDUtUJQnJOWW3iYnGQRlpFPHTmvIb22t7EXMdrDHEgduEUDPPU+tfQXheJLLwZoVkszQzC0jnzg4PAZgcfU1z5lNwpxXmehTg2rNlnQvDI16+YeJdU1DV7fySxtJD9mts7gAPJjwHHB4kL16Np1hZ6ZZx2mm2lvZ2sfCQ28axov0UAAVi+GgDqF0wJKpBCqk59XP+FdHSwjcqSbOWukp2R5p4u+E2n6t4lsdd0aeHS76K7N5dRSW7XFtdyYwJHh3qokU8hxzk854rZufhl4QufER1yXRx/aZu478yrcSqvnxkFZNgbbnI54575rsq8ovZpG+JXjvUZXiGpaFokP9kCeNpEhWRJXklCKCzZdAp2gthcdwK6TE6HTfhZ4N024MtpowUmGa3Eb3MzxLFN/rEWNnKqp9AABnjFRwfCfwZDZ3dqukytDdQwwSiS+uHLRxSCSNQWkJAVlBGMcDHTivJ/D/AMTPFsehtqGo3d9dW9pq2nR314LSKW3Fq5fzzG0cStj7uQVLLxySauz/ABQ1me4jeTWn0vSbnxNe6et21gA8dmlskkZCOmc7mJyVPvkcUAeu+KfBWla+dUuZbaH+077TTpbXEytKgh3Fwpj3AHDEnIw3uOK5fwf8HdK0mw1y316ca3/a7W5mDLJGsYgDeXsLSPIGG4/NvJ6YwOK871L4g/EJfD3hp57oaUl3aXMv9qz2YjW4kWUrD5imJxGGjCvtAUtngjpW2/iLxdrumeP5L2+tf7P0vQ4pxYDTgyXUk2mGRl3OA2wSnO1lyfunHIoA9PsvAHhyzmsZorKd57KSaaCWe9nmdXmjEUhLO5LZQBec4xxioU+G3hOOzFqmk4gGmPowX7TL/wAejPvaPO/PLDO773vXlGreNvF2mRWUOnSPZyw6VpcmlaXDpyvHq0kgAnQttJQIOMKVwOelei/DnUvEWt+IvFU+qakn9l6drFzp1tZfY1ViiiNlcyZyQNxGMc85J4wAbFz8PvDFza6rbTaZuh1T7N9sX7RKPN+zhRDyGyNoRemM45zzUD/DPwk+uNq50phfNdNekrdTBPPYENIIw+wMQTkgc9TzXC+I/FWsf8Jb4l0/U9am0mO3dYtN0oaWJ49RhMWWdpChJydw+VgEx8wNcjceOvFOj6T4Kg06Z4LWbSLR20/TLKMTtK7YO2OSIq6Y42RspGDnHFAH0DYeGtHsPDCeHbexj/sVIDbC1kJkUxnOVJYkkcnqaxtO+GnhTTrm1uLbTZTNaPvgaW9nl8v5GQAb3PyhWYBfujPArx//AISXxd4dtPHy2eq3t3qEPiIqYprUubSycpm6T5G+XHAUBlGC2081peHfFnjjWr/w1pMPiKzH2+51OKTUYrET5jiiheLdlI1LgyOCVAU+hIIAB6XD8L/B8drf27aQZ4763FpObm6mnbyQ24RqzuSi7gDhSOQD2FPvPhp4Vu3gkn0+486GAW3mpf3CSSRg5CyOsgMo5/jLV53b+LPGn/CRW97JqxfTG8aT+Hjp32CMKbbL7ZDJjdkBRg8A9812Pw8RLD4g/EDSdPwukwz2l0kSD5IbiaJmmVfTO2NyPVz60Ab9z4G8O3Ok6vpk2nbrHVr3+0L2Pz5B5s+5G35DZXmNDhSBx05Naen6Fp2n6xquq2dv5d/qjRNeS72PmmNNicE4GFGOAM960qKACsjxTltJMa/8tJY1P03gn9Aa16yfE+V01ZOyTRk+w3Af1rHEfwpW7M0pfGjz74hXSf8ACLagIpHLNLFAynoPmzx+VUvAFxMljPZRyCMxSpMNwzlGGCPzA/OtD4hxNL4Uu8RBTHLHMxHQjdt/PBFc5pd0NMvbK9cZtnTyLgf7Dd/wOD+FeTThzUrHvUYc9GSR1Gp6VaaroV5pM03mxX4cI6fMsbdVOfUHB/CvnWK3uNPu7iwvUMdzbSGN1PYivp94J4ZJVhkghgKr5ZCj5WyB+OR3ryb4vaMskkPiSwG9cCC9KqVweivg9u2f92unK8R7Op7KWz/M4pa6mbol9cz267It7r8pbcBmus0e2vJJleYqq+inNed+HL8W8+xjhJMYPoa9L0K/VsKx5r1qkbM86rHlkdjZrhArc1LPZRPyQKqW0wZQQafNckDg1BmSLaxjgAUj2KkcYrCfXQl6IJAVJ6E1oR6qgOCwoAr6jpMcyMskYII9K5G80S6sGMlg5KjnZ2r0WO5jnQdDUc1sjdMUAcHYa9PbkR3iMje9bsGrwyqPnq7daRDMDuRT+FZ//CPQh9yDbj0oAtfaEYEg5rKvdUZXKRI7N6KuTWxDpwiXb1BqxbafEGJKjNAHIHV75OfscpH1FEfiB5plgELrIeSH+XArs7mxjC8KPyrlvEFmsaLOgw6Hg0AWJ/mjUt1xXIa/PDDew2xLNcyL5nloM+XHg4dz/CCRgdzzgYBI09W1eWFhp+mrHLqm0NI0nzR2akcPIO7HqsffqcLjdmaFoi3eqxWFuZJHuJTLdXErbnk7vI7dyfy6AYGK0iax0KnxRysHhSwP34rLzWHpvI/+JNZsb/YdJG04eSo/GWsJr3jO9u4sG1jYQQY6bF4BH1OT+NV9SmDiJF6KK3irJI6YK0UmUiSSSepooq1YabfagxWws7m5I6+TEz4/IVRZRhjWGMpHkR7mcLnIUnk49ATk4Hck9zUlXL/StR09d19Y3VsvTMsTKPzIqlQvIFboLRSxo0kipGpZ2ICqBkkntXvvgb4c6fpFjHc6tBHeai6hmEg3JF7AdCfc1MpqO5E5qC1PAaK988YePvD3hjVY9IvrGWVzGHYQQoVQHpnJHpS2umeDvGtg8+nw2snZngXypIz/ALQGCPxGKn2nVoj2rtdrQ8Q0nR9Q1dpV0y0luTENziMZ2jtVzU9IszYTmKKITwmMjaJRMuAfMEu4hfvdAo7dfX2Hwh4fHg7V7m2EjTWWo7fJmI5R1DHY2PUE4PsfauT+KdvDoXiNdTnbNrqCFPJjwZZZAACqLkZP3Tk4A5JI6104V0as3TrbNGNXE1aTVSi7NNM9U1DV7HTNJbU9SuY7eyRA7SN05xgAdSSSAAMkkgDmsGLTb7xfKlz4ggks9BVg8Gkvw9zjo917dxF0/v5PC5vgHTG1W3stY16QXF7ZfubSz3borAKMAjgb5SuCZCB97ChR19GPK5rz5xcJOMt0Yppq6GDaqhVAAHAA6CsTxqjN4Y1BUUu7RgBQMkncOlO13xBYaEIvt0jvcz5FvZ26eZPcEdkjHJ9zwo7kVw3jp9f1LTU/te4OkWdy4SPTLOX986/xGeYdsZ+SPA9WcVI0Y0GreTdtZ6XENS1FDskVX2wW7eksozyP7ihm7Hb1rpNK0ISXMOo69cHUtSi5hLJsgtj/ANMYskL/ALxy57saxtEhgtUSG1hjhgjGEjjUKqj0AHSt281OOysmubqaK2tV4M08ixxg+m5iB+tUypGtcXCqCM1i396iI2WHT8q5u98WwyKG021vNS3dGVTbwn/tpIMn6ojilsbLXNWIe8u4tLtj0hsY8yt9ZnyR9UCGpJILwQkpd6rcw2Onk4jkuZBGJT6Jnlj7Lk1qWsvnAJoeg3N0h6XN4PsUB9xvUyt/37A9+9bWi+HdK0mVrmC2Q3j/AH7qZjLO/wDvSOSx/E1teag7igDAttB1W7j26rrD28JPNtpCm1XHoZctMf8AgLqD6Vp6bo+laKsg0yyt7d5P9ZIi/PIfV3PzMfck1PPfxxISzAAe9c1f+IgZSlujSN/sigDV1GFZ3U56HNYevyhIizHAUEmoxrF0mTNbSBfXrWF4t1IPYER8GU7B/WnFXdhxXM7HnepFpvkX78rYH1Jr6enhMEEFvbyeW4jESN5eQMYHXHHHavnfwxZf2l400az27lNyruPVV+Y/opr6JSRJNRkKvcRSBhGQR8rDk8fkea8/OJ+9CPqepBG/4YT95qEvUmVY/wAFQH+bGt2snwwuNKEveaWST8NxA/QCtaujDR5aUV5HnVnebCsDUU0CHxhpNzeGKPxDNDLb2hVmEksQwzqQv3lHB+bIB54Nb9ecysLX47Sm9YRyahoCw6XK4+XdHM7TIvq3zRMR1IHtxuZnd6tqVnpFhJe6lOtvaxlQ0jA4BZgo6epIH41Bquk6be3dhqGpQRvNpjtPbzOxXyWKlWbrj7pPWvBx4X8YR+CNRtE0fxEnjIxRi61Y6uHhvG+2wufLHm/88g5ztTaoZed1Wp/Bvi2++I+utLZalPpV618rXN9eGIRRvGyRLC0VwdyHIwrRLt7nIzQB73a3EF3bx3FrNHPbyqHSWNgyuD0II4IqWvmX/hB/F8fgzwnYQ6XrttY2dvLBqNlFeCSYXJVAtxGv2lFKcEKN4C8nZzXY6F4S8UT6tqFxrVxr2LfQ7RLLfflBLdrE6v5iRyFWfJXJJIyc5PWgD2mivGfhf4S8RaB4n8OXl7/avlXGgFNYN1fvOv2wOm3IZ2wQNwG3jH1OYfFvhvxjdfEW8u7GHUXaS+sZdN1KK+CWtnaoB9ojki3gksd3Gxt27qMYoA9W03xHpGp6tfaZp+oQXN9YnbcwxNuMR9GPTPt1FLc+ItHt1tWl1K123V2LCErIGD3Bz+6yP4vlbj2rjfgx4Sn8Lr4ta7trm3e9126lh865aUPbbyYnALEAkMcn7x43ZwK80sPhlqsdpb6Q+i6tEkXjJL6e5/tElJLH/SAskbCUsrAONzAK5LDkkcAH0lRXznqXgvxxFosOnwR6rPoVnruoZs1uzJNJZNt+ysCZoy6qdx2mQHLA4OK9o+HFnqGn+CNItNZkvZb6GLY73xQzkBjt3lGYbtuOjH65oA6Ss/RtF0/RY7lNMtxCLmd7mdtzM0srfedmYkknA6noAK0KKACiiigAqG9t0u7Oa3l+5KhQ/iKmopNXVmCdtUeez276jpctpPMN88D22w95Vzz+Yrh9MT7RpqxSLkgbSD2NegXMyW1xqTNxsu2CsE3FSwHb8TXKeI7aTR9YkvUXNhdtuYgcRyHqD6Z6/j7V4uHajJ02fQ4SpvHvsW/CuoyBho18Qzhc2cjjPTnafp1HsMelbLwJNbTWmpJaNFKjG4TJ+ZSMZx6da4nVbpZmtWsTm7EqmLb13ZGMV32qSOtyI4YoiZEcB35C45A+lRiYqLUkTiYWkmup4B428NT+FdS+XdLpM5zbXHXHfax9R+o59cP0TXCjIsr4I6P6/WvbryCK6sJ7fU4lu1mUCSzGCB2yPT19q8d8YfDnVNDZ7vRVlv8ATPvbQMzRD0Ze/wBR+IFerhMfGsvZ1tJd+/8AwTiqU1JanY6ZrnygM1bCagki/eFeG6drcsHy7uB/C1b9t4jAX5kf/gLV2ulJbHHKjJbHW+J5zNLClqQJmcbT6Y6mrdhpTuoeWaVm9S2K5LStVinvmlkYrJ91Fb09q7jT9UhdAMgGoaa3MnFx0ZtabC0PBYkVdupmjTIrOhu4yBhhUslwjL94UhFf+3EWUxSHaw9akbV4FXJdfzqjdQWs/EoVq5a60+1GtwxoP3JBLLk4JoA7GLXreV9qupP1rTt7jeARXPbbSFQEjQY74o/tJY+FP0ppXGlc6iSdQvJrhvE+tvcXk2laK8ZvIm23V0670s++MdGl9FOQvVuynO13xLPcXE2naRcNDLG2y6vlAPkEdY4s8GXsW5Ce7fdx/Pt7CxWC3CwW0YwOfxJJPUk8knkmqUblxhctP9nsLb7LZKQCxd3ZtzyOfvO7HlmJ5JPJroJ7S/8AD3gue4sLK5utc1VfKjWGJnMMZHU4HHHP1I9K4vw/a3virXY7PS38iKP95LcMM7VB647/AEr3eW6i0LQzNqFzLOtunzSyY3yHPAwABknAFVL3bIuXu2R8u2cbwl45UaOVGKujDDKR1BHY1aJLHJrqvjBBHafEF2iUL9rto5nAGPmyy/8AsorB0fTbrV9QisrGMyTyHAHYDuT6AVundXOlSuuY6j4ZeE08Rak89+rf2bbY3gHHmP2XPp3P4ete9wRw20CQW0SRQoMKiKFAHsBWN4f0qHQ9GtbCAgiJfmfGN7HqfzrWQ1zTlzM46k+dj5kSeJklRXjYYZWGQR9K8T+K/guLRFXV9JjK2DvtniHSJj0I/wBk9PY17gvSodTsINU0y6sLpQ0NxG0bA+460oy5WKE3F3Pnr4Y2iXvjfS45BlFcyY91UkfqBXpnxb1jxToUdtf6A4OnIGW6URByh7Me+Ov0ryzwFNJoXj6xhvfkmtro20uexOUP4c19JTckgjINaVHaSZrVdppnyhdXM2s38+o30xuLufl5GAGeMAYHA4p+iale+G9UTUdJk2TJw8Z+7IvdWHcV3/xY8L2+i6ja6xp0axWl3L5VxCowqyEEhgOwIBz7j3rgb6Lyp2XtW0WpI3i1JeR9KeF9dtPEmjQajZH5HGHjJ+aNx1U+4/8Ar1kXHhK1GnavcahM+oapdwsJLycDcqjJVI1HCIpx8o6nliTk14Z4b1/U/DV61zpE6oJMebDIN0cmPUevuMGun1z4ka9rmlzafZ2cNqZUKyywbnfb3x/d+vNZezlGSlE55UHfyLHgvxNcWUH2yz2zRoga4ikkEatGP4yx4UrzyePX1rfu/irY6rObLQtQt9NtwB5uqX0RbGe0EeMOR/fYhe4DivH7K5sLQRxSPHfBGDCG3RbkZB7nPljBHQuCMZxW/HZSa9NJJbR6bpkx+6kubiU/7QziMfQq4969SvSWO/e0/i6r/g7HEuXDtwn8PRnpei6/4S0dby60q4n1XUSoa71CbLSOB0MkzgKqjsBhR2Arl9T8YJrlyziOXUnTIi+wIpiXOODM+FI46ozdTlTxjFn8LCysvM1Fn1C6X/VG4O9Yf9xPup/wECl0y9t7grFLcmCUfKYX+Q/QetYV8JLC0U5JNy+dvnsOnUjWm+S9kaYuNTdB5t1a6TF/ctVFxMfYySLt/KMH3qt5Fqt0LuK1kub0DAvbx2nmA9FZySo9hge1blpb2kXLIC3q3Naccluq8bcV5hszF02a2ikEl0sjS/3nHArptO1C3mb5GBqBXtXGNi4qvPp0THzLQ+XIPTvSEa2oLNOhEUhT0I7VjSW+pqcC5BHqRT7XVmtnEN0uG6c9DW7b3FrOuSQKAOdXS7m5P+k3LFf7oGK0LXSY7ZAET8a2N9snQ5qvJeoz7EIz6UAZ92ixRksBXnPicq2pKkf3UQuR7n/9Vdzrt2AmMgGvNdQuN8N5dn/lo21fpWtJXdzagryubnwXtvtXjq4uSMpa2zsD6MxCj9N1e0GdoZrwyzx5RC6wqBnaBwxP515z8DtPSHw1qmo3OEF7N5QYnGUUY6/7zMPwr0BVZ7WSCWCWNnMcK7wD8rELgMOteBmE/aYiSXTQ9BLQ7TRYfs+kWUR6pCgP1wM1door2UrKx5Td3cKa8aOys6KzIcqSM7T7U6imID04615fb/GjQ5LWSaWx1GH7NY3N9exsql7QQSmIo43ffZxhR+or1CuUtPh94YtbzxHcx6XE0niHjUQ5LLMOcjBPy53EnGMnnsKAOIj+Mdvq1gWtra7024i1Cxt2wIrpZEuHwMMr7exDc5XsDWvpnxZtr7xBZWH9g6nDY3epT6THqEjRGM3MW7K7Q5fB2nkgfzxrwfDTw7FaJbMup3EEc0E8SXWpXE4iMLbowm9ztUE9B175q3beAvD9v9j8q1kH2TUpNWh/fMdtzJu3N15HzHjpQBn+OfiJB4W1SWwj0m91Oe1059XvPs7RqLe0Vipf52G45DYUc8GsjQPGmteIvi5NpdhF5Xhi00+C8Mnlxs1wJkZkYsX3KOmAFJ+U5wCK6nxX4E0DxVdx3Os2szzrC1szwXMsBlgY5aGTYw3oSM7WyPzNX9O8N6Xput3erWVt5N5dQQ20hVjt8uLOxQvQY3HpQB5j4l+JWqxa/wCJhBqei6FomgTxWRm1Cxnumubh0L4by2Xy48AgNg/qBW3r/wAWbHQfFdjol5YtOLiW3ge5trmJ/LeYDaTFu3hcsOSAe4BrY8T/AAy8LeJdRur7VLGfz7xEivPs93NAt2iH5RKqMA+MDGeeB6Cm6j8MfC+oay2pz2t0tw08Fy6R3kyRPLDgRu0YbaWAUDJHSgDibT4z/wBl6W/9tWxvtTn1TULe3iheOBRBbyYyzOwGcEADqTWnqXxqsoLRrnT/AA7rF9DFpcWsXDKYo/s9u7MDuDOCWUqeFB/Lmulm+GfhmSCJFtrq3mhup72G5tryWGeKWY5lKyIwYBu65x7VK/w78OyRX8cltcSC+08aXcNJdSO0kALHBZmJzlm+bOeetAFe38S3cfxC07T5ZFm0bXdMa908+XteGSLZ5iHHVWWVGBPIIIrtq5Sx8JGLxpBrU9wj2un6eNP020VD+4UkGR2Yk7mbYgHTAXuTmuroAKKKKACiiq+o3Is7C4uW5EUZfHrgUm0ldjSu7I4qW4UT3P70xvc3knlsF3dDjp/wGkt7cu53RyCGUu0scqKVkyeAQf8ACpLRNgt4IoTcX4TO1f4c8kk9FGa3bbQBLGrapK0r9TFGxWMe3HJ/H8q8ClRqV5OUPvPSnUjTWpytra6Vp12stvb2NvPtO7aS7qT6f/WxUjebJAB9quGOSz7bVmVge3TgV31tbQWyBLaGOJB2RQo/Spa7f7PcvjkYyxjbvY88eS3gkMhJhlwNrOjgDjH3SMDiltmRZbiSyazLOCRiUkse2R0616EearT2FpcDFxawS/78YNS8t7S/AFi11R5f4h8KaVrkSNq2k77t87ri0wjj3Jzz+Oa4bUvhNLDdGPR9YjY43LDdoVYD/eXr+Qr3p/Dun5zCktuf+mMrKPyzj9Kil0GUKRb6hKPaZFcfpg1dOni6GkJXX9dyvb02fMupeEPEmmfNNpc00Y/5aWuJR9cLyPxFULXXJrSQxXCvuXgrICrD86+kxomo2W4QW9vIrDGbeQofrtbjP41m61YQ3qImqaajRqMH7ba+YPwYZArb6/VjpWp/cU1Cponc8ZtfFEW0ZkdfqM1cTxKjf8vAx7g12118P/Ct5KzW+nuqbSxktbk4J9NuTWdc/DLw7Gdo1HUbaTZv2PIhIGM5xtqlmGHe90ZvDI5p/EEA5a4z7KCazpvEIF2ksMLOFzyxxmulk+GOmlUZNfuUWQEqZIR0Hr0py/CJSnmL4jPlY3bvs4xj1zurVY3C9/wYLDxW5zq+JJriRY4rGZ5HICrG24k+gGKz9T164mZrTS/PU8rc3kL8oe8cLD+Ls0g6chcn5h0WjeA59bgu49K1aSPR3Bj/ALTMeGux0ZYVB+WI8gyZy/RcKSW2IvhPcQxolv4gKRoAFUWgAAHQD5ulOWNw0ZWcvzEqSeq2POUuLi3t0gtLNIIYxtVcZCj2qk8U9yztO7OI0aRsnCoqjLMewAAJJr0vUPhzqdnaTXEniS0SCJDJJJcQ+WiKBkknJwAO9cR4h0HV00OC9ubfy9AZlZmc7Jbts/KzofmWPOCqHk8M4Bwq708VRnbke5duXRLUt+CfEknhjUGuYIUuIZU2PGWxkdQQa6+z1XUPiF4ltIZIfs+kWbieSJTkcdNx7k9PpmuC0LSL3XLtLfToGkc9Wx8qD1Y9hXuuj6fp3gvw64klVY41MtxO/G5scn+gFbVGl6mVVqOq3OU8e+BdS8TeNIL2OWC206O1WNp5GyQQzEgL1798CtLRf7J8OWjQeHylxNIP3t9IQQ30x1HsOPrXmHjLxrqfi2SSCN3tNHDfLApw0g7Fz3+nQe/WsGyku7OExW17dRRHqkcpUfkKXJJxs2Hs5OKTZ6daeJ54PiLaWz3cs0FxF5cys3yq5JKnHY9PwIr1uB9yivlm0Y2txHPET5qOHDd8g5r6U8P6gmoadbXUZykqBh+IqKkOWxnVhy2NtDUyHnFQCnocHNZGJ4J8ZdLfTviBHd2ykDUYllXaOfMX5Tj34U/jXuGi3o1TSLS7X78kSNIndGI5BHY5rz39oHTY7zwtZXrxq5tbgIwYZBRxg/qFqv8ACjwz4X1rwijX/hvRLq4t5XiMk1hE7EfeHJXP8Vay1gmbS96CfY1PjhaXM/gsSwAlLW5jmlGOqcrn8CwNeO6iRIkMo/iUZr27X/BXhaz0LUJ4dEsbcwW0kivDH5Zj2qSCpXGMe1eARRk2qSC4vUlI+Zku5VJ+uGqqTdi6LdrIGMgX915W/wBZELAfgCOf09jUM1ublSt/NLdqSG8uTAiz6iJQEB99uaeltM4EMV7qxBPEa6hPjPXhd+P0q4NJ1P7RCJGv0eVhGrXC7hyf9sEVo/M1fmV1UKoVQAB0A7VNDO0WOMgdPUfQ131p4BgS223GqXjSNy5SKADPtmMkD8akfwHHhT/bF83oHtbPB+u2BT+tOninSlzQdmYTnTqLlkro5mx8QTIojeQPH/cm5/WrN0+lX6D7XatET/GvzCrFv4Pjm1e/tP7RyYQhVntxk5HONrKOD7U3UfBup2MUL6ff6c5MqofOtpVzk4G7EvT1wBXpU84i1y1o3X9dNjgnhIX5qUmn/XUpRaU6DOjauwA/5Zs2R+R4qWSfxFYr+9ghnT+9sIJ/I4qvq+jeJNNVp7m10eeJRy9rFMu33OZCapaf4g1W2jCq8W4f3pW2H2xtOPzpy+o1/hVn936tDX1qKu7SX3/lqaC+KpoRi5091Yf3H/oRWxpPi+xnO2SU20n92f5f16frWLPrt1OM3GgafcRnqU1Bl59ciE/yql9mXUNwj0y2gkPQDUiw/WFf5VlVyuyvC/3P9LlRxVN6TVvR/wCZ6WzWuowAvtORwwOf1rLkW5sGyCZIh0I7Vw8emaxpTrJZQ38SdWELRMv/AHyXAP44q/beLbu23x6rpOqSrj5ZIYoAT9QZsflXn1MHWgruLt6M0U6cnaEkzsY9Td0wquxPtTlnNvullI8wjAAPSuLk8W2mwNb2mpRSE8iSNcL9drNn8AazLrxI87MrTPCpHDLbTNn2yEJ/QVgoNmipyZr+I9VMrtBGxMjcMR2HpXN+IphDZwwDqBk/Wm21/p6ESTXMwI6p9huSfzEWPfrU2iGw1XxjY/bbqM2EcglnYK2Aq87SMZ5OB+NbXjTi32Oqmox0ue7+E9M/srwBpdpdQu8kcKyPEvB3M24g/Qtz9K6XTYw17ZKXdvMn8whzkrhS2PzArlbjxt4YW6WVNUtfP/1bCSbyiq+uGwfxFXPDnjHwiNStAvifQgFikba2qQsxYkdfm643GvmKcJzrKUlu7ms5xUHqen0ViweLPDtxkwa/pEoXrsvI2x+TVbvNY06y0a41a5vYE02CNppLkOCgQDJOR1/CvePNL9Fcn4X8faN4jW4ktU1G0hihFyJtQspLWOWE/wDLRHcAFffPet2HWdLmtYrmHUrKS3lyI5UnUo+Bk4OcHGDQBfoql/a+m/2hHY/2hZ/bpE8xLfzl8x1xncFzkj3rH8H+N9C8WaHDqemXsaRyQm4aGd0WWKMMRudcnaOOp4oA6Wisy78QaNZwrLeavp8ETNsV5blFUtgHAJPXBBx6EVXtPE1hdeK7nw/AZWvYLOO+ZwAYzG7FVw2eTlT2oA26KoDWdLOqHTBqVkdRHP2Xz183pn7mc9OelImtaU9zNbJqdi1xCWEsQnQshUZbcM5GByc9KANCiqwv7M4xd25zD9oH7wcxf3+v3ffpVaPXtIk0x9Sj1WwbTkO1rpbhDEpzjBfOByR3oA0qK5/wp4v0nxRaNcaZP8guZrVBIVDStE2HKAE7l75HY1fuNd0i2ht5rnVbCGK4O2F5LhFWU+iknk/SgDRorH0DxNo3iCfUYdHv4rqXT7hrW5RQQY5FxkYIGRyPmGQfXg1sUAFFFFABUdzBHcwPDOgeJxtZT0IqSihq+4Fezs7eyjKWsKxqeTjqfqeprP8AFPibR/Cumi/1++js7ZnESFlZmdz0VVUFmbg8AE8VsVwHxT8Mavq9/wCF9c8Opa3OoaDeNcCyu5DHHcI6bWG4A7XHBBIx1pJJKyG23qzf0HxfpPiD7K2jvd3MNx5gEws5USNoyAyyFlGxueFbBPar+oa3pmnJave3sES3NylnCS2Q8znCxjHcmvL/ABN4U8V+KtVstT1LTLGzcaXqNnJbWuokFfOVFjXztn3iFOWCkDjg1xlr8Gte/wCEbEN5o2gz/ZdWsru3smEMck1vEGEscsscSoxbcACVJxnJPApiPpLzEEojLr5hG4LnnHrinV4LF8LNcj+JUetz26y2/wDakGoW88F7DE1pEqqpgbdbtKyKoZQiyKjAjhTk03T/AINzx+AvDen3Om2TaqmuxXerMZsiW1S5mfbnofkkHAxyTQB71G6yIGjZXU9CpyDVTVNVsdL0y91C/uY4bOyjaW4kJz5aqMnIHPTt1rjPhp4Ou/C2j+LNMQR2NreavdXGmrA24QQOiBNo/hwwY7a8ytPg5rx8P6tYzadpNq7aA+mN5Fxv/tS780SR3MuVGCpXILZYE+goA978O6zba/pEGpWMd1HbTjKC5t3gcj12uAcHqDjkc1pVkeEdIi0Hwxpel29vFbJbW6IYohhQ2MtjHqxJ/GtegCnc6XY3JJntYWb+9tw35jms6bw7GMm0uZYz02y4lX9fm/Wt2q2pX1rpdhcX2oXEdtaW6GSWWRsKijqSaynRpz+JFxqTjszjtV097JhPqjeVaRBmadJP3IXqd+fujA78D1ri51XxcImlSS18HgFYgVYS6mc5yVPIgPJAxl8ZPynaewi0+68fut5rkM9n4YU7rXS5U2SXZH3ZrgHkLnlYvYM3OFUgMyQxedLGfs7PE6uMl3UkDB9eP1rzMRRWHacOv4HZSqOqve6FWWKKz84ItvbM+FjSWYBXXPPy8dOwzS3arb2aNfn7Naxq0skySCOKJVydzHPAxknntXm+nAaos1/fTo2Q0s1xK4Coo5JYngKB+VT6NNDqV3aW+ppOnhUOXghmJXzpeNs8iHogIysZ6cO3zYCwsKrXbPSq4dwVoO8u39f0xfF1/earbQXggmhs7ieOHTLa4Uhrl+ouZlPRVA3JGehwzDOAu74W8I2t3IJZk+1Sg/NcXR82Rj65bOPwqD4j2jQQWd3ZxySPo9z580W7JaJgA5Uewx+GTUvhzxKLSJZbUi5tG5DxnOPr6H2r0sG06V4/8MeRiLxtY7+HSotPt9sAVfUAYFeefFG1l1uzsNKiuVt/PvY43duV5VtoI9C2PxxXRTeMoJEwwYE9sVxfie7kuxA8YIluLuBIE7swkU8fgDXTdrVGFP40eeW+nzW17c6ddx+XdQEo6+4qpIpRyp6g16D8V7H7B4n03WU2mK8TypSnTevf8VIH/Aa43xC4sb7yrJx/aEyCRWHP2WM/8tD/ALZ52D/gR4A3bYev7amqnf8AM7ZPlM6ciO9e2GWeEYnPaOTP+r92A+9/dPHUED0/4Ra+qltHuWwSS8BPf1X+v515jpentI8Fjp8LOx+RI15J/wA9Sa9m8FeAotHljvtQk82+XlVX7sZ/qaubXLaRlUa5bSPQZDK1u4gdEmKkIzoWUNjgkAgkZ7ZH1FYSv4ygH/Ht4ev8dcTzWmf/AByXH+fw3YTVyMZUVzHIea/EW71m98F6rbal4Zuo4hGJWns7uCcRhGDE4do2PC9hnk/jzPwZ8UWOl22owXH9oujlJB5OnXE2zAIJby0YAdOenvXs+u2n23QdStf+e9tLH+aEV4T8CrwReJ/IJ4uLd0Az3GGH8jWkdYM2irwaOn+KHjvSbnw1Lpmmalai6vGETpPILd1Tq3yybSScbcY7mvLIbO6eDMVvLJGBnciFlx65HGK7v4/wsNV0KZxmJklj56Zyp/rXmI0vT5Z42ls7csGB3eWMj3B61rTTUdDWkmo3R7F4N0aPTdLjldB9rnUO7EcqD0Wtu6hS5tpYZRlHUqayYfDVhHs+zzapbLgcW+pXEa/98h9p/EVNNoGoQOotPEeprG3IWWK3mUj3LRbvyYVzt3d2crbbuyTQrm5ubQx3se27gPlyY/iOODj3HNbDr/oqk9Q1ck1vr9pqsbw3+lztOhQ+bZyITtyRysuM9f4a2WuvESWgkm0bTLiEHJaDUXV/++Ghx/4//jSEQWTB9e1I7SAqRKCRwxwSf51pXkAlVF/h3K/5c1z1rrVxFLdtc6BrCNJLuZ0WGRBwBj5ZSx/75rQk8U6UlrGLj+0LWQ/8/OnXES/99sm0/nQBoyyRxozzMqoBlixwMVh6boum3lgs1xYwFp2aQHYAdrHjke2KZc61omrItnb6vpc3mH94qXUbOi4z93OQT249TXS2duY44tqnyUUbWxxgU07DTa2OG8QeELO3tpruwuDZmMFirsShx2z1H61zFzp+pWdus1/YOYCAfNXGQD3JHT8a9UvrNL6MQzoHjJyQRkn6VPs2qEPOBjnmuqhja1B+5IU1GorVFf8AP7zyWy1CaPH2O6J/6Zyda04tZjkOy+tQG/vAUnjfw4tgxv7FcWzth4wP9WT3HtXNQXrphZR5ie/UfjXv4XN4VLe1VvNHJVy5uPNRd/JnZy3Og6Lo0uu63btcQ7/JtLJDtNzLjJyeyqCMn3/CuQHxE8QXczHTdN0TT7c/djj0+N8D3ZwSTVvxraSa94BsLvTUMo0a4lN1GvLLHKExJj0BQgn3FYPhdEkKKgyx6e5rrhCGJqNyd1+H9Pcw1oU9tTrhqGoa54R1p9es7DfZxJNBewWyQurmRV8s7QAQwJwMdRXe/CDw2/h/QpLzUk8m/v2DMr8FEH3V+p5OPcelS+H9Jim1EWDFW0/RGBmA5E96VyxPqIwQoHrzXTSyRXzxMF85sO8G37hIHG7I4Oa+Cz3GU51ZUKCtH+v+HPewcJqknU3HzSYn2vLFDcyMQjIucr6E49a3NCgiuLy/MyJIoWOPawBHGW6fiKxrZ5jdKrraGMjdmNhuzgZOPr/+uuj8MKDaXMoH+snbn/dwn/steXgY3rLyNMQ7QLE+iaVcEGfTLGUjgF7dGx+YrF8beDbPxF4C1fwxaCLTYL2JlVoIgqo+7cG2jGfmAJ9ea6qivcPPPIte8GeOvFngebQfEN54dtmhFu1u1iZmW4eJw377co2qQvRQcHnnGKzNJ+Dt39o0X+1rPRGsYNXm1G9s2uJLqOYPbiPIDxKpYsASNoGB1Jr3CigDxM/CLUIPiK+sQnTrnTG1eHVYme4khmttm0GNUVCHUKu1RvUYOCDWLoHwV8R2/h+DT71/D1rLY6JqOmwzWUkjNey3SFQZ2Ma4RMjGAx/lX0NRQB4r4n+E2oz+F/DukeH4dBtoLa0ePUoQptxcXDRIhmEqRl25TkHbvAGTxxt/DDwBq3hXWrW81K4spY4vD9ppJEDuzebEzFiMqPkwRg9fYV6fRQB4pq/ww8S6h8TLbX5brSXs7fXItRjkEjxSrbqm0xeWse1n/wBssSQB06Vzll8MNd0nxB4V0O5tbOS0Fprdu+sWUUjs/nx/JJdEqArndgDcc4OD2r6OooA+fn+D3i7VtN+xa1qOiWqweGU0C3ksmmcsY54ZEZwyj5WWIq2P73ANWYfhFrcdikqwaEL2PVrbU2s5byaa1u/KjdCHJiGw4YEYRuV5zXvFFAHh+i/DHxZolx4e1LT5/D41HTdR1O4eB2m8jyrvbwpCg5Xb0wB71U8OfCHxDoFjpJ8rwvrNxDpDaVPb6n5rQREzySeZEdhLAhwCpC5x96ve6KAOA+HPgy68J+IvFk8lvpJsdV1CS+t7i3BFwquF/cuNoAVSpIwxyWPArv6KKACiiigAr550X4yazpPw18PX9zbQa7qj6dLqN8HklSbylmdN+I4WRF+XG5yozxzzX0NXIXXw08GXVpZ2tx4c0+SCzha3gRo/uRsxYr7jcSeehORQBxviL4xXunanfx6f4aS6sLA6cZ53vhHIReD5AqbCMg8H5scU/SviPe6vr2h2V7YTadeLr93o11Da3ivCzRQeZklotzrhhwNhyM5I4rvH8I+GrpLpm0y0lW5+ziYjkP8AZ/8AVZ5/g7VJbeFvD4u0v7bTrXzxeSagsyc/v5FCPIDnqVAFAHnHhn4y3upjRLvVfDttpmlazYXl7a3B1LzNptRuk8z92u1cd+fp6bnww+JF14v1y/0vUNJSzlhtIr6CeF5jHPDISAQJYo27cHBBB46c9TB4L8OQW2nW8ej2gt9PimgtYymVijmGJVAPZhwQaTw14L8OeGJ5J9A0i1sJpIxC7wqQWQHIB9cUAean4q67o6+NrrWdIt7m00vV102yFvO24u+wIjBYySuG3Fhk5+UKeDV+D4ra20el20vgydNWv9RmsIoZ5pbVJAkXmCVDNCrFG5HKgjB69K7u58FeGrq81O6utEsJp9TQR3jSRBhOBjG4Hgn5VOevAqLTvBXhbRTaPZaRZWptrg3EDgYKysmwtknklfl57UAcLrHxb1ix8RT6dD4Vgljt9UtdHkkOpbWa4uIgyADy+FDHBbPTkDsIrD4o3Ooaj4de5sLi0uH/ALYiurWC7QwNJZqvUmIs4P8ACQUwSchuK9Jm8J6FPdyXU2mW73El5FqDuQctcRDEcn1UDio4/Bvh6OaKWPSbZZI2uHRgD8rXH+uPX+PAzQB5xp/xnvDbrda1oNlpdpdaG2tWUz6kZFKhlXZIRFlclxjaGPQYJOBQuPipreqtYWf2JtF1G18T6XYXYTeVnt7jLY2zRo65XqCoPQg816ifBnhe7soITpFjPaw2bafEpXcq25IzGPbKj8RTNP8Ah/4U05QtjoVnABcw3gCKR++iz5cnX7y5PPvQB5vL8Wb/AEjRnuYtKubyE6pfwT3t/O7w2iQyYAY29uzANztynGOWPWvSE0u08WLoOuX0zzWiwR3cNjHMHtTKwDLKTgeYV42k8D7wAOCGX3w78I38ax3mgWMyrLLMAyfxynMh9wxAJHQ11EEMdvDHDBGkUMahERFCqqgYAAHQCgB9cLrHl2WoajJcCFLeCUXbyzSBEijK5aQk8YBDV2WoXtrp1jPeX9xFbWkCl5ZpWCoijqST0rzbVra98XtBrmp2jQeGYXVoLCVCstyoyVuJx1Cg4ZYz0+83zYC8uLpKcLvpqbUJuMrLqeYB7e68SfZI7O4tfDsrG+tYbjhrsliUkdeyLj5Iz6Bm+bAXtLy3S6gBGCSKveLdIiu7O2b9yupQFjAI8gOp6rk/h+P1rm9NvmVjFNlWU4KtwQfSuSnV9oj6TBRXJeL16nQaLrKWZS31eMsiLsiuQCSq/wB1x3Hoe1V774daHqBS60x5rZ5m+aewn2J9dvI/AYqWHybhNrYNINOltZPOsJ3hf1RsZ+vrRySi+am7MmthoTd07P8AAzrPwLHE05PiTWVSLO7zAv5gsDWxo3hzT7C9hvreO81O+UELPdzb/KB/u4GBkegrR8P6vJfvLpmp7Dc7S0b7QBIB1BHTI6/55Nc1SHQbKbUNQiYFH8i2hib5rh2yERB3Yn8AMk4AJGFSriJPklLc8+pSVGTUlqcx8WrqztPDH2EWbz30Uv2i1t1yVYIMvIx6iNQ/zH1YKOWBry3ar6VDOztLdSsZJ5mxukc9ScdOAAAOAAAOAK9p8O6IhtL86zPDcaxqsJim2EssMWCBChI+4uTz/ESzHrx4bZborOe0m4lglKMPQg4P8q9TK5x5ZU10/UwabfMz2D4S6JDa6T/akqBrm5yFYj7iA4wPqRn8q9ABzWH4LRU8MaWEGB9mjP4lQTW2DzXVJ3dzgm7ybJYuGq+nQCqEXWryHAqSSfjbg9DXyj4VvjoHieG45/0O6IYHrtBIYflmvqzNfKOvw+T4x12DGNt7Nge284raj1R0UNbo9u+LmhDXvCEz2w33Fp/pUJH8QA5H4rmvAbaUSxKwr6I+GOrprHhGCJmDXVkPImU9So+6fy4/CvJfiP4Nn8M6rNfWURfRLhtwKjiBj/CfQZ6H8Kqm7PlZVKXK3BnX+H/EFpc6XbtdTLBNt2HzPlDEccE8V1On3UUqJuYPFnKsK5HwRLb33heGIqjomUdSAefWult7YIm2BFwOy1hLRnNJWbF1awZJIZFyUjfcrL6GryndpTqOzZpLWWaMeXLG7xHsR0q/DbIY5An3XHQjoaQjCVRzjqTn8at3a7beAe1V5Y2jlKMMEGrmpDEcB9qAMJ9Nt7iWZruCO48wgbJUDhQOg5pG8GeG4U80aTaW07clrVPIc/8AAkwa3tNhBDzSD5V6VUnkMszMfwFAGBc6Nb2yNLb6rrFlGB/FqUsqj6CZmUfQCstLm/bI03XNQvnXjZcafCwX2LIsefzNdZ9miZzK0au/ZmGSPpnpUkUBwdiELnJwO9AHFk+LNSt7uzvbPRZIGGzepktyf/HpOf0rhNXsbzSphHqOl3EOfumCdLhW+hYR17gUYfwkD6Vl+IbBNR0i5gkUE7SyH0YdDVwlys0hNxZ5FpGtPpl6t3p819ZSrkfvbYsSD1BEfmAg+hrQt/FGiWd59vi0rR0v1bertO9nEHHQmGTb9cDA9qoacN1yi46mqGvjy5ZF6c11xnOD912OiVJT+LU9n+FN4Lnwi6xalZSanc3UkzlJ0lJLMOflJzn+orrQn2YsgmMDpiS4XblGHTA4+nFct4R8KaTL4E0W21fRrS8eaPe5lt0dlDkvkkj0OKsp4M0YQGO2s59LncEQrZ3U1sDjBz+7ZcenpXyddwnVk79WdK5kjqbSO1WH7TCqeWoJU7SCoGcg+tdXoUJg0ezRxh/LDOP9o8n9Sa81i8JXMaWtpZeI9cglncK376O4G3qx/fI+eAfxP0rrf7H8W2+Psniy1nx21DSVkz+MUkX+QPfPXl9Ne9NPyOXEyeiZ1lFc5p7eLo72FNRi0G4sy2JJoJZoZFHqsZVwT04LD614/wCMdb8dL8VPGll4YuLq4sVtbOxEQJZdPa4iLfawOwTynz6lhXpnIfQdFfN3gjx9q9p4e8O6leJLq98vhXUdRaSW4mMkzxT4VSA+wjAHzFCwA4I6Hn/E/jDXL7T/ABVfv4ntLqb+xdJuA+ku8UFs8l6m5MeY3zANgnKkgjIFAH1jRXhZ+KHiYXD2FhL4f1WU+JLXRodTihkW1mSaB5GwFkb5kZQpIYj2zzTPE/xW17Q/HVno4uNJufIvLGw1C3Ft5WZJlXe0TNP5h5YkYiKgYyxOaAPd6K8G8N+NvEt1D4W0jw8uk2txrN1rKvNercXIj+zSDaV3S7ucnIJIHGAAMV6Z8KPE114w+Heia9fxRQ3d5CWlSHOwMrMpIzkgHbnGTjNAHW0UUUAFFFFABRRRQAUUUUAFFFFABXz7ptppC/EvxC3xD0nWLvxK+th9EuIre4kQWeV8kROnyKF5L5IHXOea+gqKAPm/wCfFOgx+Hvs95enS9S1TVYLnTJbNDHGoMrq+7buyWAPJwcgdOuPqvjHxjpfgfw4mj/2lpl9DoqXYS3sEjtppfNYGMQpbMNwABI3Rqo55zX1RRQB4ZB4r8WP8YLewln1K40ya5RBbWdv5cdtF5YLGYSQfMpb/AJaJN34GeK5bTvEHxKvPD0F5P4i1RLm58OXuqOg02BfLuLdyI41Hl8bwBkHk9u1fTlFAHzl4p8eeM49d0t7CTVbWVItMkmtmtt1vdCZUM2xRAxwpZgzNMpB4AyM1CsmuWF14ltLi7v766HjKB0tL3TY5oxbNJHi4RmiIBIyBtPy7cgA5J+k6KAPJvB2u6xefEC7tvEOraza3q6ldQwaOumj7G9mqMYpPO8vPOA2/zOThcc0a5rusx/FC9sdS1bWNI0yJrMaRDZaaJ4tQL487zH8tujHbgMm0fNXrNFAHy4fFPjHS/Bnhj7C13aho7x5NP0vTltppZftkqoVxayREBQCY8IW3biTnNa1xqXjLRNU+Jcuk3etXGrs1vc2dlPZBlEL+TvlQrGQWjVmQKpI4JKuQTX0bRQB8+aR4k8c3dtpFpa+IJJEvNcW2+2rYtM8Vs0DMVdpbaFWIYA7lQdQCe1WNf1nx7Zalr1zb67fywaLq2n2kNt/Z8Oy7ikWISsxCbiMsx+U8c+2Pe6KAOS1Lw1da/wCKFudflhk0GwZJLHToySs0wAPnT5HJU8KnIGNxycbesZQylWAKkYIPelooA43UtMGmOiyjzNP3funJ5hJ/hY+nYH8PSuU8RaEmovHPI8VjqcjELjJSUD+9jofevW5ESWNo5FDowwVYZBFc1qGhyW5V7GMXFupz5Dt8yf7hPUex/OvLr4SVN89H7j0MNi3Fq7szyGd73Rp/J1GB4m7N1Vvoehq2murs5bNd55ZkjnjX/SGeTMkNyv8Aqx6bTVaHS7OO8c/2JaKoJ2vsU5x3xjArnjibaNanrrHRa9+OpymgzbtSbXLxha6Rp6PLPdScKAFPA9evarFhBN4h1iHWNXiubeRcjT7ORP8Aj1ibjc4zxK/GcfdGF/vEtaf/AIS2eG7umI8MWU260SA4W9lRv9af+mSEDZ/eb5+gSusN2kEUUiTn7OVIjV1JZ2574zU16nRb9f8AL/M4qlV1589tFsFizGWECzI2oFMp69/Tj16+teD/ABFsG0fx7qUYGIbsi5T33df/AB7dXulpAVgKWxeFyAwbOVwc9D3Nee/HTTxNpml6xEyyG3c28rr0IbkfqD+da5ZV5K6T2ehnJHX/AA4uhc+EtPOclEMZ9tpI/litSz1eG91m/sLWOSRbHak9wMeWJTz5QPdgMFuw3AdcgeV+AdW1GLRm0nSvl1G/kLW0zruW3jAAlnK9wvAUHhnIHQNj1fRNNtdG0uCxslYQxA/M7bndics7HuzEkk9yTXtzVpM8yorSaNaPtVtelUozVlG4qSCYNxXzR47iEXxP1mMDAeUN+ag/1r6Tzwa+ePitEbb4pPIeBPHFIPy2/wDsta0tzeh8RV8LeIrnwxrourfLxH5Jos8Ov+NfQGm3dh4i0n7RZtFc2sow8bAHHqrCvmjVV8m7lwrNg5wMZP0zU+g+JrnQbvz9MfVLWQ8N5kEbRsPcJIxP5VdSCeppVgpa9T2qXwdFpc0sugD7H5py8J+aM/QHp+FJDaamhIuIoW/2oyRWDofxh0yRFj15jFL/AM9I7W4Cn65jwPzrqbfx94SulXyfEmkKzcBJruONifTDEGsHe+pzST3YqQXXZnH41o2CXUT5l+ZD69aLbUrW7UtZTQ3I65hcOP0+opx1Ag4PHtSJFvNPNzOrjAPf6VJc2ImjUMcbakW6JhL+nNU4dQNzMVxhRQBbS0UW5jU4XFUDp1vGC00nFVp9QlE2FbCg9Kl1JzLaRuvTvQArtbrE0kah1XgD0qnLfk/eCKv1xUEcnlk/3W4I9aZLaxTn5kSXHQMORQBFc6xaRg+bfwr/ALO/J/SsebWvtlreR2NpcySIjAuVwg465NbKW8UJ+SCJD7IBTLopFaXDkAAqzN7nHWgDx7QwDfIT2NU7m1bWPFFtp8Iy1zcLH9ATyfy5q9pRESTzH+FeK6/4M6CLvVLvxFeKPLtyYrYt03kfM34A4/E+lbYmsqFNzf8ATPSjuerXhSOWzt0laFQchUHUDsfQVWil2qgxvExKoIWLYB+8SSO3FSyO0PmyXs0AdNoDxLuKgnpt/rU2+5iEoAQ+a4jt41AHJ6fh3/A18ilfQ12Rq+GbQG5kuMHyrdfs0OfbG4/oB+BrpKr6farZ2UNupLbFwWP8R6k/icmrFfRUKXsqaieZVnzybColtoFmmlWGISzACRwoy4HA3HvjJ61LRWxmVoNPs7cxmC0t4jGhjTZEq7VJyVGBwCecVCujaWsbxrptkI3AVlECgMAdwBGOeefrzV+igCrHptjFDDDHZ2yRQv5kaLEoVH5+ZRjg8nketJPptjPci4nsraScY/ePEpbg5HJGeDzVuigCtFYWcTxNFaW6NEWMZWNQULfexxxnv61JbW8NrAkNtFHDCnCxxqFVfoBUtFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFedfH7XdZ8LfDPUde8O34s7yxeFsNCkolV5VjKncDj7+cj0oA9ForyLxb8TNZ8J3GtWEWjRa0PD1lbXd/fS3gt2mSQkErGIyN3B4zj+RqXfxW1jRtW+Id1qmlQXGhaCLQ26RT4mzOieWpGw5DFwxOfk6AP1oA9oorx+H4ta4q2dtc+DJ11G61JLCASSzWsM4eJpBIhngRsAoVIKjHUE8CpdQ+K+p2OpX0dz4ctks9M1Gz06+caiWlD3CoQY08oBgpfB+YZAyOvAB63RXkGlfGO4vtauseGL9vD0El3E9/FHOxiNurEtJmIRAMVIAEhIOMgVz4+LPiK31iTXNS063j0c+Em1u20uC83+Zm4jVGeQxjY+1yCBuH49AD3+ivKfE3xcfSNVvLC00NL2WH+zhGftvliRrskAfcONuBzznPaobf4r6pL/xK38O20fiZtbbRVt2vz9mDCLzfMMvl5xtPTbk9vQAHrlFeVaj8VrrSLfxUuraFbJf+H9PivZYoNQ3pMzuybVbyxgDaDkgn5sEAis1PiNqenX3jKWZ4LoxarZ2Wm2lwzgAy26v5aeVE7uxO4gBSfoBQB7PRXj3h/4v6nrk2i2Vh4UEmqXxvElhkv8Aylha2dVblo8kENnkAgjGO9dl438V3mi6z4f0TRtPgvdX1p5hB9quDBBGsSB3Z2Csc8gAAc59qAOvorxuX4k6vp9z4uf+w7u+v7CbToTZR3YnggM0Ad2Ty4fM2LyW4kJ6gKOBFpHxR13WvF3hODTrPSZtK1C3unu/Iu5CQYZArld8KuCqkMEZQWLYO3GSAe00V4npHxuvr7Rr/Wj4Ruxo6afPf21xmdUYxHiKSRoRGGYAkGNpAMY61o6h8UPEcM1raweD7X7bdaZNq0aS6sAogj29SIj8x3dPbr3AB6je2Ftej/SIgWHRxwy/QjmvMddtLzxLqN9oGlySXei2bhNVuUxG7nGTaRtkAtggyEYwpC9WOOiXW9X8W+B9CvfDUDWMmuQxvLdO6t/Z8TJuZgD99/4V4xkgnAGD0+haTZ6HpNvp2mxeXawLhQSWJJOSzE8liSSSeSSSaxqUITd2te5cako6dDjo7KJbaK308i2Ft8hhKAYH90rjj8qbcGVLuOFLSM2yDIY5znvt9K7HVtMW9AkibyrtBhJMdR/dYdxXMzCadJYQRb3sR2sCN236exHQ14uJw8qD7rud9KqqiKsPzXcmbkuAwTylHyocen1FYfjJrKbwPfw6lbOsUzrFBBbANJPKSCiRj++SPoACTwDWw9xGiSJJeJbiEFriXbtCqoJJLnjAHJ+hrE8NSyeJNZTxFerMLKFTHpMEiYxG3DXLDs744H8KEDqWqKXu/vH0/Mubfwo8j+GOsvB4tW5vAsUl1/o7xr92FOiRrn+FSAPUkknkk19CRPuAr55+I2mN4f8AH94IxshumF1ER23Hn8mBr27wlq0es6NbXaEb2XEij+Fx1FfS8yqQjUjszirw5bNHQRNVlDVUetTIeKk5yfPFeHfH2HyvFGi3YGPMgKE/7rZ/9mr2/qOK8n/aEsy+k6PfAf6mdomPpuAP/slXTfvGtF2mjzvWcNOkg/jQH9KqWkSz3CxvKIlOcuRkDAqedvNsbZ887cVPo+npqWpaVa2uoJbXVxKySl5FGyPuwBOTx+vFPFVnSh7u70R7WX4eFWo5VWlCOruavw88MXfiv7QPLFtpiSFZb4jLMB/BGD39T2/Sva0sbLTtO+y2tuiWqD5gwB3e7E9T7mrKRaf4d0URApaadZR87uAqjufUn9TXkOpeKb3x7rq6XpzvZ6GhLORw8qjqT6Z7D35rnoUOW8nq+rOXHY+eOfLH3acdl0X+bN27sPCWr3rQDS9HuJ15z9lQsMdwccGprbwppxkVLUXtqP8Ap0v57cD/AL9uMVc0rS7PTk8u0gCZ4yOSfxrYZhbxFEXEjDk9xWh5TMybw/LBYmWy8Qa5DzgbrhJ8/wDf1HzVK0sNdjkPkeIRIcdbqxjb8/L8sV0162zTLWLueTVLTyrzLj7rDigDAk/4SWOQ7m0S65/gjmts/m0tXLPVNeWB4Z/D9tKDxm21MOfwDxJj6Z9Oav3ZWF3LnCjqfSnRtsXIPJIoA5+81W6jylxoOtWzj+IxwTIfwSViR+AqlYeJ7e3eSPUI76CMHckj2FyqqO4LNGF/8eNd3NJG5Czr1HBFVJ4MqdgDRn05/OgDn7bxboFwxRdf0oODxHJeRoxHXhSQaqeLtR36NLBp4e5kmG0tAC6qvckjitjVLexe0kfULa3khjUs3mRg4Arwi4sNNadp3sLUHduU+UuV+hxWlOPM7mtKHM7mvIkz+Vp9sjNd3EgiVOhLE4Ar3rTNJi0jQ7HRIoZ5Io0G+SMDBbOWJz6nP4V5f8LvC66jb3Ws39xq0NhCPLto7W/nhyw6sNjjgdPTr6V6FbeG7pI0Np4j16PKb0driKQ5PYrNG/v/AJxXlZlXjUn7K+35ndHmWtjfiWRpogixtbnmTcATnnC8enFbXh+AXVy1+wzFHmOD3P8AE39B+NcRp+geIvMWxs/EMbPIpec3Ono4QYxn90Y+uBjGO/4dTDB43so0iil8MXkaAKoEE9pwP+By47VlgsNeXtG7pGNerZcp19Fc9pN/4me+ih1jQtOt7ds77iz1NpwvGR8rRRnk8e2a8s+IGr+Mrv4yy+H/AA3dax9hj0mK7aDTpLSNkYyspdjODkYxwOa9Y4j3SivJNJ+KWoXnjK2spLGwGl3Ws3WiRxJKxvInhUkyuvTadpyMDaCDk1jwfHCa48M6BqEFnp8l5f6VquoXNsk5Y272kZdEIHIDYOc+nFAHudFeK3XjbxxJr/w6ZxoWn2evmeVrcTPIkkQtlkXzHaMFWBLEBOM7QSRmqXwy8d+J47vw9aawtrfaVrOqahZR3LzyNdI0TyMuQRt2gLtABPABz2oA93orzH4p/Ei88C6xBaf2bFdR6hZMdNO47pr0SoghIHYiRWz14NZNx8VNeHj2fRbfRLWWzsL23sb472WQeYFLTKSQAoLfKpBLAdR0oA9korxDQvip4p1b+wJH0vRoLXxBFqUdkyTSGSKa1WQhpAVxtJjxgZPf2qHwZ8R/GV9oPgW28nQ9U1nxDDeSC4mnaFEEKRsDII4zhjvbKquOF5GSQAe60V4nYfEXVE1STRtOitlvb7xJqljHdardO8EKW2047HLbgFQEAYNZ9x8StX8P6l471G6e31H7PFo0dvDDcM9lDJOrh5Fb+4Tg9icAcdaAPfKK474Y+JtV8S6XfPrunxWV5a3RhHlH5Jo9qsrhSSVzu+6Semc812NABRRRQAUUUUAFFFFABWP4n8M6N4psks/EOnw39qj+YsUucBsYzx9a2KKAOd/4Qnw59lu7Y6RbGC7to7OdCCfMhjzsQ89Bk0+fwb4cuNRur+fRbGW7u7cWlw7xBvOiAACuDwwwAOewxW/RQBzGl+AfCulNA2n6HZ27QTrcxsinKyKpVWznsGYDsMmqFj8NdBh8Zap4lvbaK/1G7uku4mnjB+zMsYQbPyzk8g9K7aigDnE8D+GI9ebWk0OwXVGdpGnEQBLsCGYjpuIJBOMnJqvpvw68H6a10bHw7p0P2q3e0mCxcSQsQWjI6bSQOPaurooA5LT/AIceD9OjKWHh6wt0LxSERx7cvExaNj6kEk5q7feDPDl/Bew3ujWc8d7ci8nEke7fMAAJM9mwAMjBroKKAOOu/hj4JvEtkuvDGlyrbwm3i3QjKx5Jxn6knPXJPrV6/wDA/hrUILyG90a0mju5o7iYOud0ka7UfPUEKMZGOK6OigDn9G8GeHdFntZtJ0i0tJLXzfIMS48vzCC+B2zgflVvxF4d0fxJax2+u6dbX0Ub+ZGJkyY29VPVT7itWigDln+H3hN7Oe0Og2P2acwl4wmATCmyIj0KrwCO1TL4H8MIukrHodig0mQy2OyMKYHJDFlI7kgE+pGTXR0UAconw68IRzXksfh3To3vI3im2RbQyv8AfGBwN3fGM1qyeHdIkuobh7CFp4bRrGNyOVgbGYx7HA/Ktas/Vtb0rR/K/tfU7Gw83Pl/arhIt+MZxuIzjI/MUATaXp9rpWnW1hp0CW9nbRiKGJPuooGABVqmxSJLGkkTq8bgMrKchgehB9KdQAVla3ppulFxbAC8iHynoHXuh/p6GtWuS8Y6rd3N7B4Y8PzGLV7xPMuLpefsFrnDS/77cqgPVsnkKaicI1IuMtioycXdHFauj+MNQn06yVF0ixkX7c7ji7uFIIt+OqJwX7FgE7MK3pllFuIb5dySuF/dKASeuTz7VuHw1b6Lp1tFoFt5cNtGIzbqf9Yo/iyer9yTy3Oeayngt0M2oQOUkZTvYk4BAxyO2O49q8PFU5Upcr26HoUZKSv1PPvjboa6h4ch1W1y1xpjbJMHJMZIBz7g4P0Jrj/hr4mOj3YiuHxYzkb8/wADdm/x/wDrV7XBtmtEtroC6iu1ZZCkYCkEY+bp7ivnS80qXRfEV/o8uS1vIVQn+Jeqn8QQa9TK6vPB0ZdNh1IpqzPpa1uFmjDIwKkZBFWUNeBeG/F+o6Cwh/4+LUH/AFUh5X/dPavX/CXiO38Q2bT26ujIdro/8J+veu6UHE4J03E6dORXJ/FnTv7S8BaooGXgQXC+2w5P6ZrqYWHSnXMMd1bTQTDdHKhRx6gjBqU7O5Cdnc+UrGUvYop7V6P8JNH03WNT1SS4sknsreBEWC7jEi75CSzYYeiD8681EEmn3d3Zy8S20rRN9VJH9K9s+DMv2qw1i5IcM1wkR3rtPyoD09PmrPFK9an8z6GnLly+u11cV+JxHxjstP0TUNP0rw9G+mrMjTXENpK0cLAnCgxA+WRwTgr6VgeErrUbHV4Ftr20Bl/db7qzUgA9sRGPqQOTkitL4ryfaPiTf85EEccY9vkB/rXOAkHI4IrtjBOJ5MYLkSPX4r/X7Rx52j2l2P8AnpZ3mHP/AGzkUAf99mk/4Si1DH+0LXVLA55NxZu6j6vFvQfi2KxND12fxDHBpzP9mmQb5plPMijso7E55rtIx5caov3QAK5mmnZnJKLi7MhOsadrkKxaPqlndyhcYt51kKN/tBSSPxpfDtx5tvbs2FkUHzF/unnINP1vSNL1VI49U0+zuhtBUzwq+0+2RXIx6PBp2sy2VpqGq2S3Hz2/kXjsif3k8t9yDHUfL0NIR3l/hmBIyGFYaXi22oxae6uBJnyXYcEAZ2571CbXxFFFiHWLO9VT92+s8OR7PEyKP++D9Kz9VvtXSyc32h7jARMkthdpNtK87isgixxngE/jQB18p3wRt3HBqjb3oMs8ZzHLCRvB6YPQj2NcufiPoAs3czyxS/8APG4haHH/AANgE/JjXF+IdbvNYdrtV3WqptU2zeZHt/31yD9auMHJmkKbk7G1488TreFrGzfNup/eyA8OR2Ht/OsbwR4Yn8W6mQ2+HSoDm4nHH/AVPqf0HPpm/wCFPh7qeuOLvWFk07SlG8lxiSQdflU9B7n8M17Vp1rb2VtaWel23l6cEK7FTC+nzZ5J9e9ceMx8aMfZ0neX5f8ABO6FNRVkNtoYbUWdvpyQw6dDEURllxgY/hHfGOSaf9mWS9Qi3kkuw2yAu+S+B95vQCpoUkiYQ+VFPcN/qYYVxhfcnoPUmuo0bTPsKNJMRJeS/wCscdB/sr6Afr1rycPh5V5a7dWFWqqa8ybStPTT7cqrF5XO6WQ9Xb/D0FXaKK96MVFWWx5zbbuwqqum2K6m+pLZ2w1F4hA10IlErRg5CF8ZK55xnFWqKYjOi0PSItYk1aLS7BNVkXa94tugmYdMF8biPxqmvg7wysssq+HNGEkokEjixiy4kG2QE7edw4b1HXNbtFAGbe6Do99bWdte6Vp9xb2ZVraKa2R0gKjClARhSB0xjFEGgaPb/ZfI0nT4vssrz2+y2RfJkfO90wPlZsnJHJyc1pUUAU9Q0vT9RktZNQsbW6ktJRPbtPCrmGQdHQkfKw9RzVa+8N6Hf6pDqV9o2m3OowEGK6mtUeWPHI2uRkY9jWrRQBm2ugaPafYfsuk6fB9haRrTy7ZF+zmTPmGPA+Utk5xjOTmotO8MaBps0MunaHpdpLC8kkTwWkcZRpAA7KQOCwVQSOoUZ6Vr0UAZF14Y0G7s57S60TS57SedrqaGS0jZJJm+9IykYLnux5NPh8O6JDDcxQ6PpscVzEkE6JaoFljQYRGAHzKoJAB4A6VqUUAUNF0XS9CtWttE02y062Zt5is4EhQt64UAZ4HNX6KKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8i+M3hTWvE3jvwG+j21q9vbJqSXNxeW32i3gEkCKu9Ny5zggc9cHnGK9dooA+evEfgfxV4csrDRNBk8QalZ2WirbaVcWF39nWHUPNLNLOokHy7SAN25QoIxnk2fGPh3xxdX3jDUre81839pPpT6RHaXsiW8h2RLdFYt20r/AKwkEevqc++UUAeJeDNN8XwfGC5uL621i40d57p5Lq+uJIlhQgiKNEWdopUzjGI1I6nBGK9gsdLsrG8v7u1gCXN9IstzLks0jKoRck9AFUAAcDnjk1dooAKyNT0kzTG4tGSOVv8AWIw+ST6+h9616KipTjUjyyWhUZuDujipbC7S4G+3uUhCFDDGgZGz3BH/ANavJPjN4fvrDxPpuuCER2txFslLMAIvL6tI3RRtOck9FNe9+JNfsPDun/a9Rkb5mEcMMSl5biQ9I40HLMfQfU4AJrgPFfgnWPH2gXs/iSRrOfZ5mmaRFLmO2ccq07DiSU4x/dTJ25PzHLDYWNCfPFm/1mTsmeC3032qaOWzjMdiTvEsikSXBwRwp+4nORkbjgE7R8tes/BvA0a7I6mc5/75WvJbOV3smtrhSk8DFSrDBBHBBr1L4Nyj7BexZ5EobH1A/wAK9GorRKqq0D06JvmFWlPFVIhVpOlcxyHzl8TLM2HxF1MAAJOVnX33KM/rmvRfgtcST2urmVGRnljl5xhsqVyPb5K5/wCPdj5WsaRqSjiWNoGPupyP/Qj+VV/hR4ktNG1C+i1a6WCCeJDHJIcKChb5c++4/lTq03Nwmuh61KuvqdSk+treqf8Akc98QG8z4ga4/T96o/JFFYiDf5oQhjEAzgHJUEkAkdgSCM1d8RX0Wq+KNV1G2LfZ7iYmMkYyo4B/HFZksJaSOWKR4bmPPlzR/eXPUc8EHoVOQRwQa61eyMFdJFq3nltpkmt5GjlU5VlOCK7PS/HkkcYTUrfzSP8AlpEQCfqOn8q460U3U0UNyiWt3I21MZ8m4PohP3W/2Cef4S3QPuFtbdtrS7mHXFJpS3E1Ge56ZH430edQZJJoiBjDxkn9M1heIvFtnNJaS6bCzXVvL5iyyLhcYIK46nOfauEe7iJ2woSTwPWtzSPBviTVz+4057dMA77n90MHoQDyfwFZyjTprmm7IlUI3NQ+PtSC8QWgPrtb/wCKrndZ8SXmoki8uSU/55r8qj8P8a7rTfhSisG17WkA3BTFajnJ7bm/wrstE8H6DpXmNpelK94nAmvAX5zjgnp+AFcVTMsPT+DVmsaSWtjyLw14O1zxHtkt4PslmeftNwCqkf7I6t+HHvXfaN8OfDOjOst/Z/2pfvgC7ZABGx/uYOQffJNd7cLK7h5ZhBCqhJEcDY+euD+lS2kLzShtKt5pFxtBz5cI989/wzXmVsdXxL5Y6Lsv8zRqKWpzMPhaaCRorHW9esAFyWM/2mFuegW48zAx2AFWNO03xe8rtpl3pOoQkYM91bSWxOOwdWdT+EYH1ruLXQBIA2qS+e3XykysY/Dq34/lW6qhVCqAFAwAO1b0MJN61vu/4JyVK0VpA4fTdT1jQ1Kah4PvpC2DLdaddxXYY++8xyEfRPwrTsPHOhXd5FZyT3NjeSuI0g1GzmtGdycBV8xVDE9tpOe1dNRXoxioqyOZtt3ZwPiDx5qMXjC58N+FPDja5qFlbpc3rPepaxwh87FBZW3OQM44GO9ULP4u6VD4n1TRvEUMulyW15b2cT+XJKhaWNWAkdV2Rnc23k84z0zjT8RfD977xXN4i0HxDqOgaldW62t41rHFItwi/dJWRSA4BwGHQVUvvhZZ3dtrkMmq3jf2rfWl9JI6qzK1uEAGe+7yxk+5piNiL4ieGZfEEmjpfyfaklkt95tpRC00a7pIll27GdRyVBz+NU4Pit4QutLjv7LUbi6hlkSGFYLG4aSd3DFVjTZuc4Vs4BxjnFUofhTYxa59r/tS+bTo76fU4NOKp5cVzMpV33bdxA3MQpPBPepU+GdtB4U8MaTZard2174dfzLHUEjRnDbWVtyMCpBDEEfSgC0vxG0Se60ma11KwOkX1ldXpnlMqOqQY3nb5e0BeQwdlYEdDziHwZ8R7Xxb4wvNK0y0uFsIdPhvorq4hkgaUSOwGEdQSuACGGQc+1Zy/BvRfsWn2cl7eyQW9jfWUpYrvnN0d0khIHDZyRgY/KtXwT4Bfw3r02rXWuXeq3T6fDpw8+GOMJFESVxsAyeec5P8gAWp/iP4Yg13+yZL6cXQvRpzt9jm8mO5YArE0uzYGbIxzzWPonxW0ubw3balrUUtrc3N1dwQ2lpDJdSyLbyMruFRSdoADE4wM9ay9O+GF9eeLNcvdc1GWLR5deTWILCAIVuGRE2M7Y3DDLyoODgU+9+CekXOl6ZAb1mutOuLqeGa4tIbiNhcSb3R4pFZWAPQ8EdaAOmf4neD0EO7WF3TwwXECC3lL3CTNtjMShcyEscEKCVP3gKunx14dAcnUfuasuht+4k4vWxiL7v+0Pm+7z1rlrr4TQz3mjXn9uXMV3okaJpZgtoYo7Zt+6RvLRQh342kYAC9Bnmi5+EsMviF7+PxBqMdi+uQ+IG07y4jEbpCpJ3bd+DtAxnA96AOn8KeOdD8VXUkOhy3lwgRnS5aymjt5lVgrGOVlCPhiBwfpkA109edeAPhZZeD/E13rkWoz3N1PAbcotvDbRspbdudYlUO/H3iPXjmvRaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyK8+Mclp4yudIm0BDYQazDohuo78GYySjKuIPLGV9cNke9dG3xV8Krb6lObu78rT5Ggmf7FNtMokEflo23DuWIAVST36c1a0L4eaFpPirWPEP2WK71XUbn7UJ7iCNntjt27Yn27lB+tUp/hdot14O1Hw5dzXclpe6hJqXm5USRTPJ5mV+UrgHsQcjrmgBLf4seGbiO28g6lLdz3E9ollHYSvcedCgd0KAEg7WBz0568HCT/FvwnHp1jfRXN3cwXVo1+fs1pJK0FujlHllAGUVWBU57g+lc7efCbULfXPC8+i67LbpY3F3Pc3sdtawyx+ZbiJRHGkIjPTBLLnBJBzjGlN8GdEXTbSy03UtW09E06TSbl4JI2a8tpJGkkWQujYJdnO5dpG5h06AGlrvxZ8KaJeXNvd3N44tVgkuJ7ezllhgjmGY3eRV2qpyO9ZUvxatpG8QxR2M9k+kalHYNPe283ky7pETO5U4Y7+F9MN05q/qvwo0a/sfFFmtzd29tr1rZWkiRlf3EdqMRhMg9R1zmk1T4WWF/c64x1bUorTV72HUJrVfKKJPGyNuUlN3PlgEEkcn2wAW2+KXhlfEC6OZb7zzqP9kmb7FL5C3XGIjLt27jngZ/TmpvDnxL8N+IteTSdMubh55lka2le3dIroRnEnlORhtp6/mMiqz/AAz01vNze3n7zxIniY/d4nXbiPp9z5R7+9Q+DPhVpPhDWo7zSLu4FrCZGhtHt7c+XvzkeaIhKVGTgFz260AbOseOdI0vXzozLf3d/GiS3C2VnJOLZHOFaUqCFBwffAz05rn9O+LOjf2Lo8968l3f6n9oaG30u1mmLJFK0bMFKhsDbjkcnOMitnU/AyXHim513TNa1TSLq9SGK/S0MRS6WInZnejFSASMqQcGuY1H4I6Pf+F9N0CbVL/7BZCdRugtpGYSytKxVniYxtliAyYOAOtAGhbfFvRv7Z8UWmpWuoafZ6CkUkt5Nay7HDqpAI2fKxLAKp5fquRU8fxd8KG28yee/t5hdiya1ksZTOkpQyKDGqluVBIxnP1qHUPhJo19Lr8c19qX9na3a29vd2fmIVLQKiwyq7KXDKEHUkE8kGk0n4UafYXOmXD6ndTy2F8l9Hi2toFYojoFYRRJnhySTk9OaALFz8WvC1tqQsppNSV1nht5pDp8wit3mVWjWRyuEJ3DgnOc+hrofFHiJdG+z2tpaS6jrF5uFpYw8GTbjc7t0SNdw3OemQBkkA4OrfDPTdT/ALf829vE/tm/ttQm27fkeDZtVeOh2DOfWu7wM5wMjjNAHMeHfDMsGof234iuE1HxA6lVkUEQ2aHrFbqfuj1Y/M3c4wB1FFFAHzb8cvDv9heMV1W2TbZaqNzYHCzD7w/EYb65qv8ACfUFt/EElszYW5T5fdhz/LNe7/EHw1H4r8LXemttWcjzLdz/AASj7p/mD7E18r6Zcz6VqsUjo0dzaTYdG6hlPIP6iuiL542OqD9pDlPpteKnjbNU7KeO8sobiFg0cqB1I7gjNY+rjW7G+Go6Q32+3ChZ9LkKqXA/jhk/hf8A2WJVv9k/NXOcpifHSzNx4LS4UZNrdJIT6Agr/NhXkfh7SLvX7+OysEVpnUtljhVA6kmvcNevrDxX4A1v7BIzlYJFkhkQpLDKo3BJEPKsCBwfqMjBrzX4HzBfFaKf+Wls6j9D/St6crQZ005Wg/I5nW9KutF1KWxvkVZ48Z2nIIIyCDUNqiDMkvCLzXYfGCPb42kJ/jhjb9CP6VxZjmvru30+yUvPPIsSKO7E4Faxd1c2i7pMWO3v/FN3/ZOl2bXbSjHkqMjHqc8Ae5r0K3+F1zoUdpqHjaOfWNOUZuW09ma4th2MoxmZB3ZcOP8AbHI9l8A+ELHwfokdnaKr3TANcXOPmlf/AAHYf/XrpqwnUu9DmnVu/dOe8KaJ4atNNt7nw3Z6f9klUSRXEAD7weh38k/nVnVNKmnujc2cqLIwCukgJVsdDkdDVay8MwaRrF5qOiPJapdIzTWCEC2lmJBEu3HyP1BK4DZyQSM14h8NNa0+OwOoX1/rV98WIUv5Z9LnnuP3sqRylYWhH7sR4C7cAc7cHOBXPVpxqrlnqZxnKLuj2oaJqBJy9gmTkkIzc+vapk0Cd/8Aj51F8dxDEE/U5rwax+LXi7/hD9d1H+1dJu7mG1tJo18tfMtJnuoopI3jXou2Q4DncCO/Wt74meNvG3hTXLTSG1jS4CLE3SajcWi29veTmZ/3Xzs20KgUbVbec7s9qwWCoroaOvN9T2q00WwtmDLAJJP78pLt+vT8K0a+aNA8Z6tYeOtUi0vU4JL7UPE8EcmieT5jywSRR+bIH+8ioMnOABg5znFOi+I3irWbrXdP1a6sLZJLTVIbjSXUR3Fp5cMhjZAPnPCjLN8p3cY4FdEYxirRVjJyctWfStFfMHhvxFrGgaRq2paRulu4fCnh873RpRCrptkmKDltqksfpk8A104+IPiaTREXTtUtLyOXxTaaNZ62bMeXdQSgbmCAgMVY4ypAOOO5qhHvFFfPvhv4geNhrOjx3l7aaslzc6xp32WOyELzSWcbvG+4MfmYqFwAAB2J5rK0X4teMpPDWv35utMv7qDSlu/sqxDzrCbzo0k3RrzsRZGbD/N+77gmgD6Xor5j0jx1daB4p8R6tD4gi1fS5te0e2v9V+zjyzataPvcKvCAMqrkf1rRt/F974s8ceGbqW4D28Ot+ILO2MaGMNbx2h8vcOpODnnmgD6Lor5NPxM1zwr8N/CsGjakLe4h0NL0x3cKGO5PmsCFZsu7YHKrtwOS3YeqWXiDxr4h1Xxumi6jYW6aOFSztWsfMeWR7ZZFBk3gAbz/AHSTnqKAPXqK83+CnjHVvHumajr17EttpbyRW9lbmPDhkjXz2LdwZCwHptNeceLPH+qXXhzxd/autWMGo27XcQ8MS2GWWGMnY7PnccgBt/3DnAwcUAfR9FeDX3xB8QxfFOy8Pw6hClhPLbW8NvY28c8qb4gWaaNyJAoJJ3p8gXGcmuY0H4g+KtJ+HOihtf8AtFxJqdza6le3cYaTTNryFEkeQkAvgYL8KuB6GgD6gorxPwF4y8X+J/FWiaZJqukRQ/2MmpXklva+etyVvZYWEbbl270Rfm+YAk4B4NVvhj468W6pqvgGfXNSs7ux8UWl872sdkIjbtb4wwcMSxbPOcD2oA91ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMjxjqkuieEdc1W2jEs9jYz3UaEZDMkbMB+JFeaHxNq3hTRvh9pcGqWdxc6/BPNdarrUzyokggE27O9cIWOAoIAGAMV6/NFHPDJFMiyROpV0YZDA8EEelcXD8MtAWHw7Bci5vrXQTOLKC8ZZUCSps8tgV+ZVH3c8jA5OKAPN3+NWuz+H7C9itNE0+caHPrM5vTIY7sxTtF5NvhlILbNwJ3cOowetXNf+LHie2k8QX1hpmkx6Toj6WbiC7Ev2l0u0iJUEEKGVpMZI7dK9lutH0y7jtUutOs50tSDAskCsIccDYCPl6DpRPpGm3H2r7Rp9nL9rKNcb4FbzimNhfI+bbgYz0wMUAeE6l428RwN43j1PULSeGw1+3tba3hmkt5442lhAwUZWMeHOc9TkHI4rdk+JniZfELEWejHQ4/Fq+GHXEv2k7tu2QHO0Y3DPHPtXq0+haRcXM1xcaXYS3E23zJXt0Zn2kFdxIycEAjPTAp50jTTnOn2fNwLw/uF5nHSXp9/gfN1460AeTfC74qa94v8TWkV5pmn2+k3v2hVVZVW4tXjJwrgylpCQpziNMe45rb1DxzqjfEXVNBtLnw/ptnpRsxJ/ajOJr3z8E+SQwC4ztGQ2W44rvYdG0yDUpNQh06yjv5M77lIFErZ65cDJ/OnXmk6de3cF1eafaXFzbkGGaWFXeM5z8rEZHPpQB8+Q/F3W9G8F6BdQQ2a200V3PdXF1JJfyx7LuWNQUaZZQhCn58uBjAXA40Jvih4k0O4+It9dT6bqNtpk1uLK0w0bRLL5QWQ5IPlhZMtnndgZUdPa28N6Gy2yto2msLYkwA2sZ8oltxK8fLkknjuc1YbStOa8mu2sLQ3c8fkyzGFS8icfKzYyV4HB44oA8ds/ij4smg061OnaG2p3usLp8Uhl2xPE0LOshWOSQocqRgscjp6h2tfEzxdpupauTZ6C9houp2On3igTebL56x7jGc4GGc4yDx2459atPD+jWaRJZ6Rp8CRSedGsVsiBJMY3jA4bHGetSy6Rps3n+bp9m/nyLLNugU+Y642s3HJGBgnpigDkvDl1d2PxW8TaG13cXeny2dvq0KzStL9ld2kjeNSxJCnywwXoMnAANd3WNovh2z0nVdY1OJ557/VJVkuJp2BO1F2pGuAAEUZwPckkk1s0AFFFFABXzt8ePCx0nX0161X/Q9RbbMAOEmA/wDZgM/UGvomsfxdokPiPw5faXcAYnjIRj/A45VvwOKqEuV3Lpz5ZXPJPg5rZubCbSp2y9v88WT1Qnkfgf516IRhq+dfBOpyeH/FMDXqmJoJWguUbqo+62foefwr6LJDoGBBBHUVVWNncutG0r9zC8Q+HE1Cf+0NOnOn6yqeWLlF3LMn/PKZOPMT24I6qVPNeT/COS1Pjm1iiza3cfmpLZTPkghWyYm48xf/AB5e4x8x90B4r58ttMtLn4n3NhqERMDalJt2sUZCzHaysMFWBIIIOQaIbMVO7TsdF8b49nii2kH8dqv6M1Tfs96Kmo+Kr3VZ03Jp8QEeegkfIz+Chvzqj8Ure5sL6xtfEOoLMvlstpqcihdyg/cucDCsM8Sj5Tn5gnLH0j9n7TXsPCl+1xG0dxLetuDDnaETH1HJIPvV837s05/3R6hnn6UUYorA5gooooAKqavqNrpGlXeo6jMsFnaRNNNI3RUUZJ/IVbrkvi1ol34i+HGvaXpqLJezW+Yo26SMrBwh/wB7bt/GgDTtfEunPodhquoSjSYL1FeJNRdIX+YZAILYBxg4zkZ5weKIvE2mlNQlu50sbeyn+zvPdSJHG5wCCrbuhz3wfauG8QeHdT8V6zoXjDStO064P9mSWj6R4khkhEBkZWL7djEONpUgrgjoec1zes/CHXLy31Hyjo5nm1f+0rYx3UtuIB9nSIbf3Tjqp+Uqwxjkc0AetW/i7QLnxEmh2+q20uqPai8SFGyHiLEBgw+UnIPAOcc4xzVy31zSbmK4lt9UsZYrdxHM8dwjCJicBWIPBzxg15HbfCPWI9UtLi4udEmebw4+i3l5Hb+RNBMTIRcQKqbS2HCZJQ4Ge+KxIPgjro8Katpb/wBix3dzZ2lks6XcxSZYbmOXLJ5QCfKjAffOWxkCgD3a617SLRN91qthCnrJcIo+8V7n+8CPqCKfJrWlxakmnSalZJqDgFbVp1ErZ6YTOT+VeYeL/hDb6rrWrzabp2gwabL4Yl0jT7cwBBbXbSyyCVVVCEXMmdy/NnPFc/qPwh8V3ms6PPLe6NLBYS6bKknmyRPH9nRFkXasX7wkqdru2cYGB2APdb6/s9PjEl/d29qhyQ00gQcDJ5J7DmoYda0ucyiHUrKTyoRcSbJ0OyIjIc88KRznpXMfEDwY3ivX/CVxNFYXGnaXeSz3dvdrvEqtEVUKu0gkMQecdK848O/BjXNE0iyjsbjQbbUU8P3ml3M6RmRZppZQyMwaP502jaSwyPQigD2u217SLnT5r621WwmsYf8AW3EdwjRx/wC8wOB+NNk1nR57BpW1WyNpIGQyrdKq/dycMDwQDng5HWvn+++Fev6Joev316tlctcX2lXiWFr9pvluDbs4kSVViDFG3g/KhxjoAK0PAPw81XXTZ6nrmjWNlYjxPeatJp13CyhoJLdI02xMmfvrkBwpwAcA8UAevaJN4T8JeHdL0/TL/TNP0jYRZK14u11JydrMxL8nOcnrV1vEdnH4ri8PzJPFez2zXdu7qPLnRSA4Rs8su5cggHBB5FeIaj8FvFEnhi30W2utCazjh1CJYDJJEIWmmZ4nV1iLMoBAMfyrkZ+au5g0bUT4y+Hunm2lKeGtOkkvb7y3ELu1uIFijcgbySWcjsFGcEgUAen0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGV4m8Q6X4Y0ptR1u6FvbB1jUhGdndjhURVBZmJ6AAmoNA8U6ZrdrPPbtc23kSeVLFf20lrIjY3crIqnpznpWb8UfDsnijwx/Z0WmafqY89JWt7y5kthhc8xyxgsjg4wcEdQeteP6p4G8U6Tp/ha11KAeIAfEf2mDTLq6kuobSDyHAjkuGiJ257lNoOMdc0Ae+PrVqt9Z2y+ZIl1C86XEa7oQq4zufoM549asrqFmyzst3blYADKRIv7vIyN3PHHrXhcXwg8QQ6PBbrLpokOlazbNDHIwit5bwfu448r/q1PBOB9Knm+EmsadFef8IxBodjJc+GLbTpVaNTHNepMHkd0KFW3ICA7A8kEigD1nVvFekaZHpMktyJotUvk062e3xIpmcMQCQeB8h5rWvL21skV7y5ht1Y7VaWQICfQZ714V4b+E/iDT5bVnj0+2gj8UWmtfZ47oyhIY4HRxkRIC5Zh0UA10Xxr+H+seMNS0y80OGwa5tYJIUlu7hdkbORy8LwSpIuB22t70Aeq/aYMMfOjwpAJ3DgnpWR4a8U6V4jW4/s24BeG4mt2ikwr7on2OQvUrkda8j1r4ZeMHn1uzsm0OfTdTvNOvXnMjwyI1uIw6rGFKgHyyR83AwPo7w/8LfENp4otbxrbRLH7Jq99qi6pFI0lzOJt4jhZdi4UbgWy56cUAe12+p2FysrW97ayrFxIY5VbZ9cHii51KxtSgur22hLnavmSqu4+gyeTXzpYfBjxYtprqzx6NBNf+H30z/R5wI5Z/PjdX2JCiou1WAGGI9Tmuk+JPwl1DVLCy07wxp+hx6WmnTwtC22Bo7p8fvt/lOzLxyoKEkAk0Ae1zXltDcRW81zDHPL/AKuNnAZ/oOp/Csjwn4s0fxTolrqmlXSm3uIjOqSkJIEDFSzLnIGQea848PfDrWtI8SxXt7pmga2twNNLXl7M/wBo0420aK4iHlndkqWUhk5PzZrm7H4I6pYeF9BtrK30i31aLRtW0/U54mKm4kuIisG5guXCk8k9B0zQB9BQ3trMZhDcwyGHHmBJAdmRkbvTiqd1rdnDFYywl7yK8uVto5LQeaqsQfmYjoo2nJ7cV4xe/Ba/NpfWui/2ZpUd74YtdOnMOUWa9jnEjtIFXlXVdpfk4Y8Grtp8Mdc/tC11AW+k6XG3iaz1htKspS0FrDDbtE2w7FBdyQSAoHvQB6hf+K9JsvEulaDLch9T1JpUhijw20xx+Y2/H3flHGetat1fWlo8aXV1BA8pxGJJApc+gz1rxXwb8L9e0Xxt4bvru10ZoNKvtRuLjVI5mN3frcJIEMimMYK7lGN574973xX+G+t+J/Gltq+hx6Yji3itjc3sqyoirIWYNbvC4bg8FHQ5PPrQB66l5bPcCBLiFpyCwjDgtgHBOOvBptpqFneGQWd3b3HlnD+VKr7frg8V4B4B8Ca5fa8mpR6bp+kLp2v6leDUZQ32u53F1SMpsH7v5gc7yCOmKr6L8FvFWzWo7qbS9Mkv9Ak0tprOUbZJ/OjcMY0hjCRlVZcDcQD1OaAPoQapp5tXuhfWptozteYTLsU+hbOAatI6yIrxsGRhlWU5BHqK8M8RfDDW9ZsdMkttB8M6M2n3Qkk0yyn/AHN6vlFN7O0BUOM/LujbAJyc4r0LwR4Tn0j4caf4dmnuNOkgDfNaXfmvEplZwglaNc/KQp+QY6DoDQB2dU9R1TT9Mj36lfWtonXdcTLGP1I9DXPHwBos2Dfy6xqDf9PmrXMin/gHmbB+C1d07wX4X02TzLDw7pEEuc+YlnGHJ9S2MmgD57+Lknh+fxlJqmha5pNzbXaBpvs9wsuJhwQAmc5G0/XOa9O+Geq/2r4Utw7Zmtv3D/8AAeh/LFbHxr0Eax4BufIjBnsGW5iAGMBeGH/fJb8q87+C8ktvc3dpICFmRZF+o4P8/wBK1+KHobt81P0PVAOcV4d46jOkfFgXOMLI0FyPwwD+qmvehbsSCBXm3xY8Ny32uaZexKSfJaI4/wBlsj/0I0qbsyaTtLUq/He3MlrpE+MgGRD+IU/0NO+C6eINK8Gm/wBDd9T0+K5kim0aVgGVQAd1s54Vuf8AVt8p7FT167x9oTa14as1C5dJEf8A8dI/rWj8J9Hk0PRLu1kBAa4Moz7qB/7LQ2uSw206djo/Duvaf4hsTdaZMXVGMcsTqUlgkHVJEPzIw7gitSuZ8ReFjd3/APbOhXR0rxAihBcqm6O4UdI54+PMT0PDL/CRznzb4oa/4w0v4uacnhUXF/HbaG15NpMZOy5LT+Tu256qZFbPohrMxPb6K+ZPDXxF8V+HvBcFte339oalceI7zTJdUvSjpCIkUhQJJYk+Y5wGkUDnGTgVe8V/FDxFf+E2s7m80LQbmfw3e389ykwnFzMkkkAgtZEl2h/l3ZDOVLAYODQB9G0V89XPxjvvDXhXWbe4m0r+0dN0XSbjS0vC3mXzzRAzFvnBk29flwRznNJZavqTeKoo21C8MZ+Itza7TO2PJFqCI8Z+4Dzt6UAfQ1FeIfDX4r6p4m+INrpck1hd6RqFvczQNHAsE0JicAZUTSNg8j94qMcZAHSrPjr4nazofjLV7G0/stINLl0+KLTp42N1qouWAdoW3jGzOOFblWz2FAHs1FfPng7xzrOneM7rTl1Oy1GG+8Z3+nvpsm57yGHLETK2/wCWJNoG3Zjk8+mV4W+JWu6P8N/C0S6jp9tIdDvNVe/1kPN9skimKrbId6neQeuWOMYFAH0xRXg/iX4peL47bWb3SrTSLODSdGsNXmtr2CV5mM4y8O4OAMYIzt7fiH3Hxa1o+LUt4ptDtrdvEdpoY0qeN3vHhk2FrkMJFwPm+X5CPX3APdaK+erP4t6/q/iW50zTbrTZbS9ttSNpJ9mEc1s9urFSUWdnIOCPnWMnGQMVSHxa1/TPh14Ymj13R7zWLiwmvJWkt1YMI0jIjkd7hAJMs24LuY5XCDuAfSVFY/g3VpNf8IaHrE0aRS6hYQXbxocqhkjViBnsM1sUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA10WRGR1DIwIIPII9K5TR/B1vpl+J4DhVY7R/sntXW0U07DTaIxCg7Cop7OCfb5qBtvIzVmjFIRH5UewJtG0dqeqhfugClxRQAVF9nh+0i48qP7Rs8vzdo3bc52564zzipaKAKp06yNvLbmztjBKxeSPyl2ux6kjGCfemy6Xp8sMUMtjavFCCsaNCpVARggDHAI44q5RQBTm0vT5wonsbSQLH5Q3wqcJ/d5HT2p4sLMPvFpbh/NM+7y1z5hGC/T72OM9as0UAVIdNsYLg3ENlbRzksxkSJQxLfeOQM5OBn1qWW0tpbmK4lt4XniyI5GQFkz1weoqaigCpBptjBdvdQWVtHcvndMkSq7ZOTlgMnJ5oOmWBt4YDZWvkQtuij8pdqH1UYwD9Kt0UAV5rG0mMxmtYJDMoSUtGD5ijoG9R9a5i9+Hmh33iuHX777dcXUEyXEMMl05gikQAIyx5xxjIHQEk4rr6KAKkem2MV0bmKytkuNzN5qxKHy33jnGcnv60w6PphiSI6dZ+WjF1TyFwGPUgY6mr1FADYY0hiSKFFjiRQqoowFA6ADsKdRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The superior cistern (located dorsal to the midbrain) together with the subarachnoid space at the sides of the midbrain are referred to clinically as the cisterna ambiens. The superior cistern is important because it contains internal cerebral veins which join caudally to form the great cerebral vein (of Galen). It also contains the posterior cerebral and superior cerebellar arteries. The choroid plexuxes in the roof of the third and fourth ventricles are shown in red.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_9_39063=[""].join("\n");
var outline_f38_9_39063=null;
var title_f38_9_39064="Langerhans histiocytosis skin 1";
var content_f38_9_39064=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57722%7EDERM%2F69504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57722%7EDERM%2F69504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Yellow-brown and erythematous papules, erosions, and crusts are present on this infant with Langerhans cell histiocytosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Yellow-pink papules with scale are present in the diaper area of this infant with Langerhans cell histiocytosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_9_39064=[""].join("\n");
var outline_f38_9_39064=null;
var title_f38_9_39065="Multifetal pregnancy reduction and selective termination";
var content_f38_9_39065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Multifetal pregnancy reduction and selective termination",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/9/39065/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/9/39065/contributors\">",
"     Meredith Rochon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/9/39065/contributors\">",
"     Joanne Stone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/9/39065/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/9/39065/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/9/39065/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/9/39065/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/9/39065/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/9/39065/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of high order multifetal gestation (ie, triplets or more) increased dramatically over the past three decades, primarily due to widespread use of assisted reproductive technology (ART) (eg, in vitro fertilization, ovulation induction), but has fallen significantly in the past few years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/1\">",
"     1",
"    </a>",
"    ]. The increase in high order multifetal gestation is important because these pregnancies are at higher risk of maternal, fetal, and neonatal complications than singleton pregnancies. The two most serious risks are (1) complete pregnancy loss and (2) preterm birth, with its potential sequelae including perinatal mortality, respiratory and gastrointestinal complications, infection, and long-term neurologic impairment. The risks of prematurity are discussed in detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14520?source=see_link\">",
"       \"Incidence and mortality of the premature infant\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/15/31992?source=see_link\">",
"       \"Short-term complications of the premature infant\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22713?source=see_link\">",
"       \"Late preterm infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13814?source=see_link\">",
"       \"Long-term complications of the premature infant\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When matched for gestational age at birth, the neonatal outcome of multifetal gestations is similar to that of singleton gestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]; however, the unadjusted risk of adverse neonatal outcome is not equivalent because the incidence of preterm birth is much higher in multifetal gestations than in singleton gestations (",
"    <a class=\"graphic graphic_table graphicRef75320 graphicRef60676 \" href=\"mobipreview.htm?16/25/16797\">",
"     table 1A-B",
"    </a>",
"    ). In 2009, the average length of gestation for singletons, twins, triplets, quadruplets, and quintuplets or higher in the United States was 38.7, 35.3, 31.9, 29.5, and 26.6 weeks of gestation, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/4\">",
"     4",
"    </a>",
"    ]. In 2010, more than 50 percent of twins and 90 percent of triplets were delivered preterm, compared with about 10 percent of singletons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ideally, multifetal pregnancy is prevented by limiting the number of embryos transferred in ART or cancelling",
"    <span class=\"nowrap\">",
"     cycles/intrauterine",
"    </span>",
"    insemination when ovarian response suggests a high risk of multifetal pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/6\">",
"     6",
"    </a>",
"    ]. When multifetal pregnancy occurs, multifetal pregnancy reduction (MPR) and selective termination (ST) are two procedures specifically developed to mitigate risks and address problems unique to multifetal gestations. The goal of MPR is to reduce the risk of adverse outcomes in survivors of higher order pregnancies by decreasing the number of fetuses in the gestation, since the risk of complications is proportional to the number of fetuses in utero. By comparison, the goal of ST is to prevent the survival of a specific anomalous fetus of a multifetal pregnancy in which the fetuses are discordant for anomalies.",
"   </p>",
"   <p>",
"    This topic will discuss MPR and ST. Prevention of multifetal pregnancy and other aspects of management of multifetal gestation are reviewed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/27/43449?source=see_link\">",
"       \"Strategies to control the rate of high order multiple gestation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40682?source=see_link\">",
"       \"Twin pregnancy: Prenatal issues\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/11/5306?source=see_link\">",
"       \"Twin pregnancy: Labor and delivery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/28/11718?source=see_link\">",
"       \"Triplet pregnancy: Early pregnancy management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/34/12842?source=see_link\">",
"       \"Triplet pregnancy: Mid and late pregnancy complications and management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5510?source=see_link\">",
"       \"Delayed-interval delivery in multifetal pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MULTIFETAL PREGNANCY REDUCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information on the natural history and outcome of multifetal pregnancies is limited by several factors, including insufficient ascertainment of early losses, analysis of data derived from either small series or birth certificates, and inadequate long-term follow-up. Despite these limitations, it is clear that the morbidity and mortality of multifetal gestation increase with increasing numbers of fetuses, and that adverse outcomes are primarily the consequence of preterm birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/7-21\">",
"     7-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increasing risk of perinatal mortality with increasing numbers of fetuses was illustrated by data from the United States National Center for Health Statistics for 1995 to 1997, which included 304,466 twins, 16,068 triplets, 1448 quadruplets, and 180 quintuplets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/15\">",
"     15",
"    </a>",
"    ]. Early mortality (death from 20 weeks of gestation through the first year of life) was 4.8 percent for twins, 8.6 percent for triplets, 10.8 percent for quadruplets, and 28.9 percent for quintuplets. The authors estimated that by limiting multifetal gestations to twins, approximately 58 percent of early triplet mortality and 70 percent of early quadruplet mortality could be prevented.",
"   </p>",
"   <p>",
"    The increased risk of long-term neurodevelopmental morbidity is of particular concern: the prevalence of cerebral palsy ranges from 1.6 to 2.3 per 1000 surviving infants in singletons, 7 to 12 per 1000 surviving infants in twins, and 28 to 45 per 1000 surviving infants in triplets (",
"    <a class=\"graphic graphic_table graphicRef78659 \" href=\"mobipreview.htm?4/4/4172\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. While one study reported that the risk of CP in survivors of triplet gestation may not be reduced by MFR to twins, there was insufficient statistical power to reach such a conclusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multifetal pregnancy also increases the mother's risk of developing pregnancy complications, including preeclampsia, postpartum hemorrhage, and gestational diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/16,23-25\">",
"     16,23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medical outcomes are not the only consideration. The economic and psychological impacts of multiple birth on families are also important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. First-time parents rarely appreciate the intensity of care that infants require. The emotional stress and complexity of caring for singleton newborns are magnified with multiples, especially those with medical or developmental issues. Over 25 percent of multiple birth parents experience depression or anxiety disorders in the perinatal period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/28\">",
"     28",
"    </a>",
"    ]. Most also experience difficulties in caring for twins or higher order multiples, but obtaining assistance from additional caregivers may be affected by socioeconomic, geographic, or cultural factors. Thus, economic and psychological issues can be additional indications for MPR.",
"   </p>",
"   <p>",
"    Ideally, higher order multifetal gestations should be prevented by better control of ovulation induction and embryo transfer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/27/43449?source=see_link\">",
"     \"Strategies to control the rate of high order multiple gestation\"",
"    </a>",
"    .) In the absence of successful preventive interventions, reducing the number of fetuses lowers the risk of complications in survivors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Reduction of high order multifetal pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;MPR should be considered for any pregnancy with three or more fetuses, as there is good evidence that it improves pregnancy outcome for survivors (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Pregnancy outcome'",
"    </a>",
"    below). In fact, an International Federation of Gynecologists and Obstetricians (FIGO) Committee Report stated that, \"Multiple pregnancy of an order of magnitude higher than twins involves great danger for the woman's health and also for her fetuses, which are likely to be delivered prematurely with a high risk of either dying or suffering damage\" and \"where such pregnancies arise, it may be considered ethically preferable to reduce the number of fetuses rather than to do nothing\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Reduction of twin pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;MPR can also be considered for a twin pregnancy, although this is more controversial in the absence of a medical or obstetrical indication (eg, maternal cardiac disease, history of preterm singleton delivery, cervical insufficiency with history of pregnancy loss) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/6,30-33\">",
"     6,30-33",
"    </a>",
"    ]. Reduction to a singleton has become more common over the years. One center reported an increase in frequency from 11.8 percent of their first 1000 MPRs to 31.8 percent of their last 1000 MPRs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the increased risk associated with a twin pregnancy, MPR in this setting is still medically indicated. Some patients choose to reduce twins to a singleton based on evidence that the perinatal morbidity and mortality of twins, although relatively low, is still at least twice that of singletons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/35\">",
"     35",
"    </a>",
"    ]. Others feel that they can meet the needs of one additional child, but not multiple additional children. Patients considering such a decision should be given objective information, and not be influenced by the ethical or moral values of the consulting physician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Preprocedure considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to be familiar with local laws. In some states, patients may need to be consented for an abortion, which may require a specific waiting period.",
"   </p>",
"   <p>",
"    MPR is usually performed between 10 and 13 weeks of gestation for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Technical issues (eg, the fetuses have to be large enough for adequate visualization by transabdominal ultrasound)",
"     </li>",
"     <li>",
"      Most spontaneous fetal losses will have occurred by 10 weeks",
"     </li>",
"     <li>",
"      Chorionic villus sampling (CVS) can be performed and some fetal abnormalities can be identified, thus potentially converting MPR to ST. In those patients not opting for CVS, nuchal translucency screening should be performed between 10",
"      <sup>",
"       5",
"      </sup>",
"      to 13",
"      <sup>",
"       5",
"      </sup>",
"      weeks.",
"     </li>",
"     <li>",
"      Early reduction allows parents to undergo the procedure while the pregnancy is relatively private",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Knowledge of chorionicity is crucial before performing MPR or ST. Chorionicity is best established by ultrasound examination in the first trimester. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40682?source=see_link&amp;anchor=H7#H7\">",
"     \"Twin pregnancy: Prenatal issues\", section on 'Amnionicity and chorionicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The traditional technique of injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    assumes multichorionic placentation, which does not contain interfetal placental vascular anastomoses. If two fetuses have a shared circulation and one is reduced by injection of a toxin, there is a very high likelihood that the toxin will also get into the cotwin's circulation and cause fetal death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, acute adverse hemodynamic changes in the survivor could occur due to blood loss into the vascular system of the dead fetuses. MPR by potassium chloride injection should not be performed in monochorionic fetuses, and alternative techniques should be employed (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Monochorionic fetuses'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immediately prior to any invasive procedures, an ultrasound examination is performed to establish the relationship of the gestational sacs to each other, to determine which of the fetuses are most accessible to needle insertion, and to survey the fetal anatomy for structural anomalies and markers of aneuploidy, such as increased nuchal translucency or absent nasal bone. Although MPR is usually performed at the end of the first trimester, which is before a comprehensive anatomical survey is likely to reveal most anomalies, a limited structural survey can be performed in this gestational age range. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22170?source=see_link\">",
"     \"Sonographic findings associated with fetal aneuploidy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Chorionic villus sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chorionic villus sampling (CVS) can be performed on one or more of the fetuses prior to MPR. In general, CVS is performed on the fetuses that are not intended to be reduced. The obvious advantage of performing CVS before MPR is to ensure that the chromosomally normal fetuses are not reduced. Women with multifetal gestations are at increased risk of carrying aneuploid fetuses because (1) many of these women are of advanced maternal age, (2) the risk of aneuploidy is cumulative (risk multiplied by the number of fetuses), and (3) reproductive endocrine techniques may affect embryonic genes and chromosomes.",
"   </p>",
"   <p>",
"    At our center, 44 percent of MPRs after 2002 were preceded by CVS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/34\">",
"     34",
"    </a>",
"    ]. The vast majority of patients have the MPR performed after the full culture results are known, which takes about seven to nine days. Some patients who are geographically located distant from our center have the procedure after FISH, analysis for chromosomes 13, 18, 21, X and Y. Although 30 percent of chromosomal anomalies identified on a full karyotype analysis would not be detected by FISH using these probes, the absolute risk that a clinically significant abnormality would be missed is small. Given both a normal FISH and normal ultrasound (including nuchal translucency), the residual risk of abnormal karyotype has been calculated to be about",
"    <span class=\"nowrap\">",
"     1/400",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     1/500",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/40\">",
"     40",
"    </a>",
"    ]. However, even at that relatively small risk, many women prefer to wait for the additional information available on the full karyotype result. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28169?source=see_link\">",
"     \"Chorionic villus sampling: Risks, complications, and techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Performing CVS before MPR does not increase the post-procedural pregnancy loss rate above that of MPR alone, and may decrease losses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. The largest series reported on the outcome of 758 patients who underwent MPR, of whom 58 percent also had CVS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/44\">",
"     44",
"    </a>",
"    ]. The overall loss rates in the CVS and non-CVS groups were not significantly different (CVS 4 percent and non-CVS 7 percent). When the groups were stratified by finishing number, there was a significantly lower loss rate in the singleton CVS group than in the singleton non-CVS group (2 versus 9 percent). It is unclear why the CVS group had lower loss rates, but it may be that leaving a chromosomally normal fetus is somehow protective. We did not have information on the incidence of chromosomal abnormalities among those patients who underwent pregnancy loss and did not have a CVS.",
"   </p>",
"   <p>",
"    An accurate description, as well as a diagram of the relative positions of the gestational sacs and placentas, must be carefully recorded so that if an abnormal karyotype is identified, it can be correctly matched to the affected fetus. Attention should also be paid to the relative fullness of the maternal bladder, as filling and emptying the bladder can change the appearance of the",
"    <span class=\"nowrap\">",
"     sacs/placentas.",
"    </span>",
"    Nevertheless, diagnostic error due to incorrect matching of results and fetus has been reported in up to 1.5 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Technique for MPR",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a multichorionic pregnancy, the fetus(es) reduced are those that are most easily accessible, usually those closest to the anterior uterine wall",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the fundus. The fetus above the cervix is avoided whenever possible because of a hypothetical increased risk for infection or uterine irritability if that fetus were reduced. However, if a fetus has a lagging crown rump length, a significantly smaller sac, markers of aneuploidy, or an obvious anomaly, then that fetus is preferentially reduced since these findings are associated with adverse pregnancy outcome (miscarriage, fetal aneuploidy, etc).",
"   </p>",
"   <p>",
"    The most common technique uses a transabdominal (TA) approach. A transcervical (TC) or a transvaginal (TV) approach can be used, but have been associated with increased post-procedural pregnancy loss rates when compared with the TA approach; therefore, these approaches are usually reserved for situations in which the TA approach is not technically feasible (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Pregnancy outcome'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The procedure is performed by injection of approximately 2 to 3 mL of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    (concentration 2 mEq",
"    <span class=\"nowrap\">",
"     KCl/mL)",
"    </span>",
"    into the fetal thorax using a 22 gauge spinal needle under ultrasound guidance. Asystole is usually seen within one minute of injection of potassium chloride, and total procedural time is typically less than five minutes. Additional fetuses can be reduced with the same needle puncture or, more commonly, with a separate needle stick.",
"   </p>",
"   <p>",
"    While prophylactic antibiotics were used at our center in the early years of MPR, over the last 10 years, antibiotics have not been given. Since they are not used for CVS or amniocentesis, there was no plausible rationale for their use with MPR.",
"   </p>",
"   <p>",
"    The patient is asked to wait in the waiting area, and an ultrasound is performed one hour after the procedure to again confirm asystole in the reduced fetus(es) and cardiac activity in the nonreduced fetus(es). The reduced embryo(s) or fetus(es) are left in situ and typically become desiccated and compressed to become part of the fetal",
"    <span class=\"nowrap\">",
"     membranes/placenta.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Postprocedure considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data available on the optimal follow-up protocol after reduction. Repeat ultrasound examination to confirm fetal well-being is usually performed one to two weeks after the procedure. We also perform monthly ultrasounds for fetal growth in the third trimester.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pregnancy outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy outcome is improved when higher order multifetal gestations are reduced. The range of pregnancy outcomes with and without MPR is illustrated by the following examples. No randomized trials have been performed, as randomization in this setting would not be acceptable to most couples.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of studies of pregnancy outcome of triplet pregnancies reduced to twins (n = 2240) and conservatively managed triplet pregnancies (n= 604) reported the following results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/9\">",
"       9",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Miscarriage before 24 weeks of gestation: 5.1 versus 11.5 percent with conservative management. (Odds of miscarriage in reduced versus unreduced: odds ratio [OR] 0.45, 95% confidence interval [CI] 0.3 to 0.6)",
"     </li>",
"     <li>",
"      Delivery before 28 weeks of gestation: 2.9 versus 8.4 percent with conservative management. (Odds of delivery &lt;28 weeks in reduced versus unreduced: OR 0.35, 95% CI 0.2 to 0.6)",
"     </li>",
"     <li>",
"      Delivery before 32 weeks of gestation: 10.1 versus 20.3 percent with conservative management. (Odds of delivery &lt;32 weeks in reduced versus unreduced: OR 0.5, 95% CI 0.37 to 0.66)",
"     </li>",
"     <li>",
"      Perinatal mortality rate per pregnancy:",
"      <span class=\"nowrap\">",
"       26.6/1000",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       92/1000",
"      </span>",
"      with conservative management (Odds of perinatal death in reduced versus unreduced: OR 0.3, 95% CI 0.2 to 0.5)",
"     </li>",
"     <li>",
"      Take home baby rate per pregnancy: 93 versus 79 percent with conservative management. &nbsp;(Odds of pregnancy loss or neonatal death in reduced versus unreduced: OR 0.3, 95% CI 0.2 to 0.7)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest collaborative series on pregnancy outcome after MPR reviewed 3513 cases from 11 centers in five countries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/33\">",
"       33",
"      </a>",
"      ]. The overall unintended pregnancy loss rate (ie, unintended loss of the entire pregnancy before 24 weeks) was 9.6 percent.",
"     </li>",
"     <li>",
"      The largest single center series of 1000 patients undergoing MPR reported an unintended pregnancy loss rate of 5.4 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/46\">",
"       46",
"      </a>",
"      ]. The loss rate varied with both starting and finishing number:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The loss rate was lowest when twins were reduced to singletons (2.5 percent), remained stable (about 5 percent) when the starting number was three, four, and five fetuses, but increased to 12.9 percent when the starting number was six or more fetuses (",
"      <a class=\"graphic graphic_table graphicRef67444 \" href=\"mobipreview.htm?8/43/8891\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The loss rate was similar when the finishing number was one or two (3.5 and 5.5 percent, respectively), but was higher for a finishing number of three (16.7 percent) (",
"      <a class=\"graphic graphic_table graphicRef55719 \" href=\"mobipreview.htm?2/56/2955\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This same group subsequently published their data on the outcomes of the next 1000 patients who underwent MPR (",
"      <a class=\"graphic graphic_table graphicRef64933 \" href=\"mobipreview.htm?13/24/13707\">",
"       table 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/35\">",
"       35",
"      </a>",
"      ]. In this series, the overall loss rate was 4.7 percent, which was not significantly different from their prior report.",
"      <br/>",
"      <br/>",
"      The pregnancy loss rate of about 5 percent after reduction of triplets to twins is comparable to that of nonreduced twins (6 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/11\">",
"       11",
"      </a>",
"      ]), thus it is unlikely to get any lower with changes in technique [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/47\">",
"       47",
"      </a>",
"      ]. The 5 percent loss rate seen in this single center series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/35,46\">",
"       35,46",
"      </a>",
"      ], as compared with the 10 percent rate in the collaborative series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/33\">",
"       33",
"      </a>",
"      ], is likely due to the inherent differences of a multicenter experience versus that of a single center with a small number of operators and a well-established protocol. Furthermore, the collaborative series included some TV and TC procedures, which are associated with higher loss rates than the TA approach, while the single center series only used the TA approach.",
"     </li>",
"     <li>",
"      In contrast to most other analyses, a systematic review including 893 trichorionic triplet pregnancies managed expectantly or reduced to twins reported MPR was associated with a significantly higher miscarriage rate (delivery &lt;24 weeks) (8.1 versus 4.4 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/48\">",
"       48",
"      </a>",
"      ]. However, MPR also resulted in significantly fewer early preterm births (delivery at 24 to 31 weeks) (10.4 versus 26.7 percent). Seven (95% CI 5&ndash;9) reductions would need to be performed to prevent one early preterm delivery, while the number of reductions that would cause one miscarriage was 26 (95% CI 14&ndash;193). Of note, few data were provided about baseline maternal characteristics that may have affected loss rates, and all of the data were from observational studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Ending number",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most higher order multifetal pregnancies are reduced to twins. Many couples desire a twin birth after their years of infertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. However, as noted above, reduction to a singleton is becoming more common. Reduction to a singleton appears to be a relatively safe procedure, with pregnancy loss rates of 2 to 4 percent versus 4 to 6 percent with reduction to twins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reduction to a singleton also results in fewer preterm deliveries than reduction to twins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/35,46,53\">",
"     35,46,53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rate of delivery at 24 to 27.9 weeks is 1.1 percent for reduction to singletons versus 2.9 percent for reduction to twins",
"     </li>",
"     <li>",
"      Rate of delivery at 28 to 31.9 weeks is 2.9 percent for reduction to singletons versus 8.1 percent for reduction to twins",
"     </li>",
"     <li>",
"      Rate of delivery at 32 to 35.9 weeks is about 10 percent for reduction to singletons versus about 40 percent for reduction to twins",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Larger studies are needed to determine whether reduction to a singleton significantly improves pregnancy outcome over a reduction to twins, who typically have good pregnancy outcomes compared to higher order multifetal gestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Operator experience",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy outcomes after MPR, including total pregnancy loss and prematurity rates, improve significantly with increased operator experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/33,46\">",
"     33,46",
"    </a>",
"    ]. In the collaborative series, loss rates decreased from 13.2 percent in procedures done before 1990 to 6.4 percent in procedures performed from 1995 to 1998 and each center noted decreased loss rates with increased experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Psychological outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to undergo MPR, usually after many anxious years of infertility, is a difficult one for most patients. A prospective study compared patients undergoing MPR over a two-year period with those who did not reduce their triplet pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/54\">",
"     54",
"    </a>",
"    ]. Although many in the MPR group expressed sadness and guilt one year after birth of the remaining fetuses, the majority overcame the pain associated with the reduction at two years. Furthermore, when compared with mothers of nonreduced triplets, mothers who had undergone MPR had less anxiety and depression and a more satisfactory relationship with their children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27594?source=see_link&amp;anchor=H40#H40\">",
"     \"Neonatal outcome, complications, and management of multiple births\", section on 'Impact on family'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Being selective when sharing information about fertility and infertility treatments, pregnancy, and MPR with family, friends, and acquaintances can help reduce stress associated with these issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/40,55\">",
"     40,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LEGAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear legally whether or not MPR should be, or is, considered a form of abortion. Since MPR is not really a \"termination of pregnancy,\" but a procedure developed to \"increase the prospects of pregnancy continuation,\" we do not consider it a type of abortion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/56\">",
"     56",
"    </a>",
"    ]. However, since laws may vary from state to state, it is important to know the law in the state in which the MPR is performed, and be aware of any special legal considerations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SELECTIVE TERMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective termination (ST) refers to a procedure in which one or more anomalous fetus(es) in a multifetal pregnancy are terminated. The affected fetus usually has a chromosomal, structural, or genetic abnormality that has been identified by ultrasound examination or by an invasive prenatal diagnostic test, such as amniocentesis or chorionic villus sampling. In contrast to multifetal pregnancy reduction (MPR), the selectively terminated fetus(es) is chosen based upon a fetal abnormality rather than randomly or based upon its position in the uterus.",
"   </p>",
"   <p>",
"    ST was initially developed for fetuses with major anomalies that could result in the survival of a severely impaired fetus. ST is also offered for lethal anomalies because, for some parents, it is emotionally preferable to undergo ST than to continue to carry a fetus that will die after birth. In addition, it is theorized that in some cases, termination of the anomalous twin may optimize the outcome of the normal fetus. As an example, anencephaly is often complicated by polyhydramnios due to impaired fetal swallowing, which increases the risk of preterm labor. Termination of the anencephalic fetus, and subsequent resolution of the polyhydramnios, theoretically may decrease the risk of preterm labor. In addition, ST has been reported to reverse preeclampsia when occurring in the setting of a hydropic fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Preprocedure considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step is to identify which fetus is to be terminated. Previously diagnosed fetal abnormalities, particularly genetic disorders in which the fetus may appear sonographically normal, are not always obvious at the time of ST. Correct identification of the affected fetus can be made by ultrasound detection of a structural abnormality (if present), by gender (if discordant), or by previously documented fetal, sac",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    placental position. Use of dye at the time of invasive testing is typically not useful even when sequential samples are obtained hours or days apart, as it may not remain in the amniotic fluid long enough. Thus, precise in utero mapping of fetal and placental positioning at the time of prenatal diagnosis is critical. If there is any doubt as to the correct identification of the affected fetus, rapid determination of fetal karyotype by fluorescent in situ hybridization (FISH) can be performed before the procedure. Results of FISH are usually available within 48 hours. As with MPR, accurate determination of chorionicity is crucial before performing ST, as conventional termination techniques can only be performed on a dichorionic fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/45\">",
"     45",
"    </a>",
"    ]. Monochorionic fetuses require a different reduction procedure (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Monochorionic fetuses'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dichorionic fetuses",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Technique for selective termination",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34711?source=see_link\">",
"     Potassium chloride",
"    </a>",
"    is injected into the thorax (ideally intracardiac) of the affected fetus under ultrasound guidance until asystole is confirmed, similar to the technique used for MPR (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Multifetal pregnancy reduction'",
"    </a>",
"    above). The fetus is then left in situ for the duration of the pregnancy. Usually performed at a more advanced gestational age than MPR and with a larger fetus, the terminated fetus is generally not resorbed. Over a period of weeks to months, however, the amniotic fluid around the fetus will disappear, and the fetal tissue will become significantly condensed. The reduced fetus is usually delivered along with the placenta, and the patient is not aware of its presence. It can be sent to pathology, but usually is too macerated for any meaningful evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Pregnancy outcome after selective termination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In continuing pregnancies, outcome after ST is generally favorable, with low rates of prematurity and few maternal complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In two large series, the median gestational age at delivery after ST, for continuing pregnancies, was 35.7 and 37.1 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall pregnancy loss rate before 24 weeks of gestation after ST was 4.0 percent in the largest single center series of 200 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/58\">",
"     58",
"    </a>",
"    ] and 7.5 percent in the largest collaborative experience of 402 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/59\">",
"     59",
"    </a>",
"    ]. The effects of starting number, finishing number, and number of fetuses reduced are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef76689 \" href=\"mobipreview.htm?20/28/20939\">",
"     table 6",
"    </a>",
"    ). The lowest loss rate (2.4 percent) after ST is observed with a starting number of two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/58\">",
"     58",
"    </a>",
"    ]. This rate increased significantly to 11.1 percent when starting with three or more fetuses. The most striking increase in post-procedural loss rates was seen when more than one fetus was terminated: 42.9 versus 2.6 percent when only one fetus was terminated. The reason for the higher multifetal loss rate with ST than with MPR (see above) is unclear, but may be an effect of small numbers in these series.",
"   </p>",
"   <p>",
"    The effect of gestational age on post-procedure loss rate has been a source of concern when the fetal abnormality is diagnosed after 20 weeks of gestation. Initial studies reported higher rates of preterm delivery for patients who underwent ST after 20 weeks than those undergoing the procedure at or before this gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. As an example, one series showed a trend towards increasing loss rates with advancing gestational age at the time of the procedure: for procedures performed at 9 to 12 weeks, 13 to 18 weeks, 19 to 24 weeks, and 25 or more weeks, the loss rates were 5.4, 8.7, 6.8, and 9.1 percent, respectively, although these differences did not reach statistical significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/59\">",
"     59",
"    </a>",
"    ]. In contrast, another study found no advantage to performing ST at an earlier gestational age and observed a trend toward a higher rate of pregnancy loss in patients undergoing ST at less than 20 weeks compared with ST performed later (5.9 versus 1.3 percent, p = 0.09) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/58\">",
"     58",
"    </a>",
"    ]. We believe the best interpretation of these data is that, in experienced hands, ST is safe and effective at any gestational age, but should occur soon after the decision is made to proceed with termination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Third trimester termination",
"    </span>",
"    &nbsp;&mdash;&nbsp;ST in the third trimester is legal in some states within the United States and in several countries. One series describes 36 dichorionic pregnancies that underwent ST at greater than or equal to 24 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/61\">",
"     61",
"    </a>",
"    ]. Sixty-four percent of the terminations were performed for structural anomalies and 36 percent for chromosomal abnormalities. The mean gestational age at delivery was 36.9 weeks; 13.8 percent of patients delivered before 34 weeks. This study established late ST in twin pregnancies as a safe procedure with reasonable perinatal outcome. Patients with an anomalous fetus, particularly those who are diagnosed after 24 weeks of gestation, should be made aware that third trimester termination is an option, even though it may not be available in the particular state or country where they reside.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Monochorionic fetuses",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, termination of a fetus of a monochorionic pair is possible, but more complicated because of shared fetoplacental vessels. Alternative techniques must be used to avoid passage of a toxin (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    ) from one fetus to the other or sequelae from hemodynamic changes within the shared circulation.",
"   </p>",
"   <p>",
"    Potential approaches for ST in monochorionic twins include open surgical procedures (via hysterotomy), endoscopic procedures (fetoscopy), and ultrasound guided needle techniques. The most common method of termination has been cord occlusion, which can be performed in a variety of ways, including bipolar, laser, or photo coagulation; radiofrequency ablation, or suture ligation. Radiofrequency ablation has become the preferred procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/62-78\">",
"     62-78",
"    </a>",
"    ]; however, the optimal method has not been established, as most studies consist of single case reports or small case series and technical factors (eg, cord diameter and length) affect the choice of procedure. Complication rates have come down over time as the size of procedure needles and trocars has been reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of studies of umbilical cord occlusion for selective feticide in monochorionic twins included 345 cases performed at 14 and 35 weeks of gestation between 2000 and 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/80\">",
"     80",
"    </a>",
"    ]. Major findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Survival of the cotwin was higher if the procedure was performed after 18 weeks of gestation (89 versus 69 percent).",
"     </li>",
"     <li>",
"      Survival after radiofrequency ablation, bipolar cord coagulation, laser cord coagulation, and cord ligation was 86, 82, 72, and 70 percent, respectively. The majority of cotwin deaths occurred within two weeks of the procedure. The overall rate of neonatal death was 4 percent.",
"     </li>",
"     <li>",
"      Three percent of procedures failed because of technical difficulties or complications, such as bleeding.",
"     </li>",
"     <li>",
"      Premature rupture of membranes complicated 22 percent of the pregnancies and preterm delivery (&le;34 weeks) occurred in 33 percent.",
"     </li>",
"     <li>",
"      Seven percent of survivors experienced neonatal morbidity related to neurologic lesions or secondary to prematurity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to delaying performance of the procedure to &ge;19 weeks of gestation, if possible, use of thinner instruments and minimizing operating time may reduce the rate of preterm birth and pregnancy loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     LABORATORY CHANGES POSTPROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maternal serum alpha-fetoprotein (MSAFP) concentration is typically elevated for several weeks after any fetal reduction procedure and is not necessarily indicative of fetal defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/82\">",
"     82",
"    </a>",
"    ]. The elevation is probably caused by release of tissue or serum from the dead fetus(es); therefore, amniotic fluid alpha-fetoprotein and acetylcholinesterase concentration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal karyotype are not indicated based upon elevated MSAFP levels alone. Since MSAFP is always elevated, it should not be drawn for screening purposes because it has no value. Instead, detailed ultrasonography should be performed to screen for fetal structural defects. Information on the effects of MPR on midtrimester maternal serum levels of human chorionic gonadotropin (hCG) and unconjugated estriol (uE3) are limited, contradictory, and difficult to interpret (as with any multifetal gestation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25145?source=see_link\">",
"     \"Prenatal screening and diagnosis of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, laboratory evidence of coagulopathy has been observed, but no cases of clinically evident disseminated intravascular coagulation have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/85\">",
"     85",
"    </a>",
"    ]. One study has shown that MPR does not affect the validity of fetal fibronectin testing performed later in gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39065/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multifetal pregnancy reduction is a procedure that reduces the number of fetuses in a multifetal pregnancy so that the remaining fetuses have a better chance of survival. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multifetal pregnancy reduction of pregnancies with three or more fetuses to twins results in fewer pregnancy losses before 24 weeks of gestation and fewer preterm births before 32 weeks than unreduced pregnancies. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pregnancy outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reduction to a singleton appears to be a relatively safe procedure, with pregnancy loss rates of 2 to 4 percent versus 4 to 6 percent with reduction to twins, and lower preterm birth rates than reduction to twins. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Ending number'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multifetal pregnancy reduction loss rates reach a nadir at 5.4 percent but depend, in part, upon operator experience, the starting numbers of fetuses (higher risk of loss at six or more fetuses), and the finishing number of fetuses (higher risk of loss with three or more fetuses). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pregnancy outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chorionic villus sampling before multifetal pregnancy reduction does not increase post-procedural loss rates and offers assurance of leaving behind chromosomally normal fetuses. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Chorionic villus sampling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Selective termination has been established as a safe and effective means for termination of one or more abnormal fetuses in a multifetal pregnancy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Selective termination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The unintended pregnancy loss rate after selective termination is 4 to 11 percent, but drops to 2 to 7.5 percent when performed on a twin pregnancy. Loss rates after selective termination do not appear to increase with gestational age; however, losses do increase with increased starting and finishing numbers. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pregnancy outcome after selective termination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Traditional techniques for multifetal pregnancy reduction and selective termination are appropriate for multichorionic pregnancies only; specialized techniques (eg, cord occlusion by coagulation or intrafetal ablation) are needed for monochorionic pregnancies and are associated with higher loss rates. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Monochorionic fetuses'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/1\">",
"      Russell RB, Petrini JR, Damus K, et al. The changing epidemiology of multiple births in the United States. Obstet Gynecol 2003; 101:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/2\">",
"      Jacquemyn Y, Martens G, Ruyssinck G, et al. A matched cohort comparison of the outcome of twin versus singleton pregnancies in Flanders, Belgium. Twin Res 2003; 6:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/3\">",
"      Ballabh P, Kumari J, AlKouatly HB, et al. Neonatal outcome of triplet versus twin and singleton pregnancies: a matched case control study. Eur J Obstet Gynecol Reprod Biol 2003; 107:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/4\">",
"      Martin JA, Hamilton BE, Ventura SJ, et al. Births: final data for 2009. Natl Vital Stat Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/5\">",
"      Births: Final data for 2010. Natl Vital Stat Rep 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/6\">",
"      ACOG Committee opinion no. 553: multifetal pregnancy reduction. Obstet Gynecol 2013; 121:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/7\">",
"      Stone J, Eddleman K. Multifetal pregnancy reduction. Curr Opin Obstet Gynecol 2000; 12:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/8\">",
"      Luke B, Brown MB. Maternal morbidity and infant death in twin vs triplet and quadruplet pregnancies. Am J Obstet Gynecol 2008; 198:401.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/9\">",
"      Wimalasundera RC, Trew G, Fisk NM. Reducing the incidence of twins and triplets. Best Pract Res Clin Obstet Gynaecol 2003; 17:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/10\">",
"      Dodd J, Crowther C. Multifetal pregnancy reduction of triplet and higher-order multiple pregnancies to twins. Fertil Steril 2004; 81:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/11\">",
"      Yaron Y, Bryant-Greenwood PK, Dave N, et al. Multifetal pregnancy reductions of triplets to twins: comparison with nonreduced triplets and twins. Am J Obstet Gynecol 1999; 180:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/12\">",
"      Tummers P, De Sutter P, Dhont M. Risk of spontaneous abortion in singleton and twin pregnancies after IVF/ICSI. Hum Reprod 2003; 18:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/13\">",
"      Glinianaia SV, Rankin J, Wright C, et al. A multiple pregnancy register in the north of England. Twin Res 2002; 5:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/14\">",
"      La Sala GB, Nucera G, Gallinelli A, et al. Lower embryonic loss rates among twin gestations following assisted reproduction. J Assist Reprod Genet 2005; 22:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/15\">",
"      Salihu HM, Aliyu MH, Rouse DJ, et al. Potentially preventable excess mortality among higher-order multiples. Obstet Gynecol 2003; 102:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/16\">",
"      Wen SW, Demissie K, Yang Q, Walker MC. Maternal morbidity and obstetric complications in triplet pregnancies and quadruplet and higher-order multiple pregnancies. Am J Obstet Gynecol 2004; 191:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/17\">",
"      Strauss A, Paek BW, Genzel-Borovicz&eacute;ny O, et al. Multifetal gestation--maternal and perinatal outcome of 112 pregnancies. Fetal Diagn Ther 2002; 17:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/18\">",
"      Pharoah PO, Cooke T. Cerebral palsy and multiple births. Arch Dis Child Fetal Neonatal Ed 1996; 75:F174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/19\">",
"      Petterson B, Nelson KB, Watson L, Stanley F. Twins, triplets, and cerebral palsy in births in Western Australia in the 1980s. BMJ 1993; 307:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/20\">",
"      Yokoyama Y, Shimizu T, Hayakawa K. Prevalence of cerebral palsy in twins, triplets and quadruplets. Int J Epidemiol 1995; 24:943.",
"     </a>",
"    </li>",
"    <li>",
"     Office of National Statistics. Series DH3, No. 33 London: HMSO, 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/22\">",
"      Dimitriou G, Pharoah PO, Nicolaides KH, Greenough A. Cerebral palsy in triplet pregnancies with and without iatrogenic reduction. Eur J Pediatr 2004; 163:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/23\">",
"      Day MC, Barton JR, O'Brien JM, et al. The effect of fetal number on the development of hypertensive conditions of pregnancy. Obstet Gynecol 2005; 106:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/24\">",
"      Walker MC, Murphy KE, Pan S, et al. Adverse maternal outcomes in multifetal pregnancies. BJOG 2004; 111:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/25\">",
"      Conde-Agudelo A, Beliz&aacute;n JM, Lindmark G. Maternal morbidity and mortality associated with multiple gestations. Obstet Gynecol 2000; 95:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/26\">",
"      Ellison MA, Hall JE. Social stigma and compounded losses: quality-of-life issues for multiple-birth families. Fertil Steril 2003; 80:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/27\">",
"      Vilska S, Unkila-Kallio L, Punam&auml;ki RL, et al. Mental health of mothers and fathers of twins conceived via assisted reproduction treatment: a 1-year prospective study. Hum Reprod 2009; 24:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/28\">",
"      Leonard LG. Depression and anxiety disorders during multiple pregnancy and parenthood. J Obstet Gynecol Neonatal Nurs 1998; 27:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/29\">",
"      FIGO Committee for the Ethical Aspects of Human Reproduction and Women's Health. Ethical recommendations on multiple pregnancy and multifetal reduction. FIGO Committee for the Ethical Aspects of Human Reproduction and Women's Health. Int J Gynaecol Obstet 2006; 92:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/30\">",
"      Chervenak FA, McCullough LB, Wapner RJ. Selective termination to a singleton pregnancy is ethically justified. Ultrasound Obstet Gynecol 1992; 2:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/31\">",
"      Evans MI, Krivchenia EL, Gelber SE, Wapner RJ. Selective reduction. Clin Perinatol 2003; 30:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/32\">",
"      Evans MI, Kaufman MI, Urban AJ, et al. Fetal reduction from twins to a singleton: a reasonable consideration? Obstet Gynecol 2004; 104:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/33\">",
"      Evans MI, Berkowitz RL, Wapner RJ, et al. Improvement in outcomes of multifetal pregnancy reduction with increased experience. Am J Obstet Gynecol 2001; 184:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/34\">",
"      Stone J, Belogolovkin V, Matho A, et al. Evolving trends in 2000 cases of multifetal pregnancy reduction: a single-center experience. Am J Obstet Gynecol 2007; 197:394.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/35\">",
"      Stone J, Ferrara L, Kamrath J, et al. Contemporary outcomes with the latest 1000 cases of multifetal pregnancy reduction (MPR). Am J Obstet Gynecol 2008; 199:406.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/36\">",
"      Benson CB, Doubilet PM, Acker D, Heffner LJ. Multifetal pregnancy reduction of both fetuses of a monochorionic pair by intrathoracic potassium chloride injection of one fetus. J Ultrasound Med 1998; 17:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/37\">",
"      De Catte L, Camus M, Foulon W. Monochorionic high-order multiple pregnancies and multifetal pregnancy reduction. Obstet Gynecol 2002; 100:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/38\">",
"      Lewi L, Van Schoubroeck D, Gratac&oacute;s E, et al. Monochorionic diamniotic twins: complications and management options. Curr Opin Obstet Gynecol 2003; 15:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/39\">",
"      Alphathanasiadis AP, Zafrakas M, Tarlatzis BC, et al. Multifetal pregnancy reduction in pregnancies with a monochorionic component. Fertil Steril 2005; 83:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/40\">",
"      Evans MI, Britt DW. Fetal reduction 2008. Curr Opin Obstet Gynecol 2008; 20:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/41\">",
"      Brambati B, Tului L, Baldi M, Guercilena S. Genetic analysis prior to selective fetal reduction in multiple pregnancy: technical aspects and clinical outcome. Hum Reprod 1995; 10:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/42\">",
"      Jenkins TM, Wapner RJ. The challenge of prenatal diagnosis in twin pregnancies. Curr Opin Obstet Gynecol 2000; 12:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/43\">",
"      Eddleman KA, Stone JL, Lynch L, Berkowitz RL. Chorionic villus sampling before multifetal pregnancy reduction. Am J Obstet Gynecol 2000; 183:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/44\">",
"      Ferrara L, Gandhi M, Litton C, et al. Chorionic villus sampling and the risk of adverse outcome in patients undergoing multifetal pregnancy reduction. Am J Obstet Gynecol 2008; 199:408.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/45\">",
"      Evans MI, Goldberg JD, Dommergues M, et al. Efficacy of second-trimester selective termination for fetal abnormalities: international collaborative experience among the world's largest centers. Am J Obstet Gynecol 1994; 171:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/46\">",
"      Stone J, Eddleman K, Lynch L, Berkowitz RL. A single center experience with 1000 consecutive cases of multifetal pregnancy reduction. Am J Obstet Gynecol 2002; 187:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/47\">",
"      Rochon M, Stone J. Invasive procedures in multiple gestations. Curr Opin Obstet Gynecol 2003; 15:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/48\">",
"      Papageorghiou AT, Avgidou K, Bakoulas V, et al. Risks of miscarriage and early preterm birth in trichorionic triplet pregnancies with embryo reduction versus expectant management: new data and systematic review. Hum Reprod 2006; 21:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/49\">",
"      Ryan GL, Zhang SH, Dokras A, et al. The desire of infertile patients for multiple births. Fertil Steril 2004; 81:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/50\">",
"      Gleicher N, Campbell DP, Chan CL, et al. The desire for multiple births in couples with infertility problems contradicts present practice patterns. Hum Reprod 1995; 10:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/51\">",
"      Pinborg A, Loft A, Schmidt L, Andersen AN. Attitudes of IVF/ICSI-twin mothers towards twins and single embryo transfer. Hum Reprod 2003; 18:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/52\">",
"      Child TJ, Henderson AM, Tan SL. The desire for multiple pregnancy in male and female infertility patients. Hum Reprod 2004; 19:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/53\">",
"      Brambati B, Tului L, Camurri L, Guercilena S. First-trimester fetal reduction to a singleton infant or twins: outcome in relation to the final number and karyotyping before reduction by transabdominal chorionic villus sampling. Am J Obstet Gynecol 2004; 191:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/54\">",
"      Garel M, Stark C, Blondel B, et al. Psychological reactions after multifetal pregnancy reduction: a 2-year follow-up study. Hum Reprod 1997; 12:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/55\">",
"      Britt DW, Evans MI. Information-sharing among couples considering multifetal pregnancy reduction. Fertil Steril 2007; 87:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/56\">",
"      Dickens BM, Cook RJ. Multiple pregnancy: legal and ethical issues. Int J Gynaecol Obstet 2008; 103:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/57\">",
"      Heyborne KD, Porreco RP. Selective fetocide reverses preeclampsia in discordant twins. Am J Obstet Gynecol 2004; 191:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/58\">",
"      Eddleman KA, Stone JL, Lynch L, Berkowitz RL. Selective termination of anomalous fetuses in multifetal pregnancies: two hundred cases at a single center. Am J Obstet Gynecol 2002; 187:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/59\">",
"      Evans MI, Goldberg JD, Horenstein J, et al. Selective termination for structural, chromosomal, and mendelian anomalies: international experience. Am J Obstet Gynecol 1999; 181:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/60\">",
"      Lynch L, Berkowitz RL, Stone J, et al. Preterm delivery after selective termination in twin pregnancies. Obstet Gynecol 1996; 87:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/61\">",
"      Lipitz S, Shalev E, Meizner I, et al. Late selective termination of fetal abnormalities in twin pregnancies: a multicentre report. Br J Obstet Gynaecol 1996; 103:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/62\">",
"      Ville Y, Hyett JA, Vandenbussche FP, Nicolaides KH. Endoscopic laser coagulation of umbilical cord vessels in twin reversed arterial perfusion sequence. Ultrasound Obstet Gynecol 1994; 4:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/63\">",
"      Deprest JA, Evrard VA, Van Schoubroeck D, Vandenberghe K. Endoscopic cord ligation in selective feticide. Lancet 1996; 348:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/64\">",
"      Quintero RA, Romero R, Reich H, et al. In utero percutaneous umbilical cord ligation in the management of complicated monochorionic multiple gestations. Ultrasound Obstet Gynecol 1996; 8:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/65\">",
"      Dommergues M, Mandelbrot L, Delezoide AL, et al. Twin-to-twin transfusion syndrome: selective feticide by embolization of the hydropic fetus. Fetal Diagn Ther 1995; 10:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/66\">",
"      Rodeck C, Deans A, Jauniaux E. Thermocoagulation for the early treatment of pregnancy with an acardiac twin. N Engl J Med 1998; 339:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/67\">",
"      Denbow ML, Overton TG, Duncan KR, et al. High failure rate of umbilical vessel occlusion by ultrasound-guided injection of absolute alcohol or enbucrilate gel. Prenat Diagn 1999; 19:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/68\">",
"      Deprest JA, Audibert F, Van Schoubroeck D, et al. Bipolar coagulation of the umbilical cord in complicated monochorionic twin pregnancy. Am J Obstet Gynecol 2000; 182:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/69\">",
"      Nicolini U, Poblete A, Boschetto C, et al. Complicated monochorionic twin pregnancies: experience with bipolar cord coagulation. Am J Obstet Gynecol 2001; 185:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/70\">",
"      Taylor MJ, Shalev E, Tanawattanacharoen S, et al. Ultrasound-guided umbilical cord occlusion using bipolar diathermy for Stage III/IV twin-twin transfusion syndrome. Prenat Diagn 2002; 22:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/71\">",
"      Shevell T, Malone FD, Weintraub J, et al. Radiofrequency ablation in a monochorionic twin discordant for fetal anomalies. Am J Obstet Gynecol 2004; 190:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/72\">",
"      Lewi L, Gratacos E, Ortibus E, et al. Pregnancy and infant outcome of 80 consecutive cord coagulations in complicated monochorionic multiple pregnancies. Am J Obstet Gynecol 2006; 194:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/73\">",
"      Rustico MA, Baietti MG, Coviello D, et al. Managing twins discordant for fetal anomaly. Prenat Diagn 2005; 25:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/74\">",
"      Robyr R, Yamamoto M, Ville Y. Selective feticide in complicated monochorionic twin pregnancies using ultrasound-guided bipolar cord coagulation. BJOG 2005; 112:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/75\">",
"      Tsao K, Feldstein VA, Albanese CT, et al. Selective reduction of acardiac twin by radiofrequency ablation. Am J Obstet Gynecol 2002; 187:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/76\">",
"      Moise KJ Jr, Johnson A, Moise KY, Nickeleit V. Radiofrequency ablation for selective reduction in the complicated monochorionic gestation. Am J Obstet Gynecol 2008; 198:198.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/77\">",
"      Paramasivam G, Wimalasundera R, Wiechec M, et al. Radiofrequency ablation for selective reduction in complex monochorionic pregnancies. BJOG 2010; 117:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/78\">",
"      Wimalasundera RC. Selective reduction and termination of multiple pregnancies. Semin Fetal Neonatal Med 2010; 15:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/79\">",
"      Roman A, Papanna R, Johnson A, et al. Selective reduction in complicated monochorionic pregnancies: radiofrequency ablation vs. bipolar cord coagulation. Ultrasound Obstet Gynecol 2010; 36:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/80\">",
"      Rossi AC, D'Addario V. Umbilical cord occlusion for selective feticide in complicated monochorionic twins: a systematic review of literature. Am J Obstet Gynecol 2009; 200:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/81\">",
"      Lanna MM, Rustico MA, Dell'Avanzo M, et al. Bipolar cord coagulation for selective feticide in complicated monochorionic twin pregnancies: 118 consecutive cases at a single center. Ultrasound Obstet Gynecol 2012; 39:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/82\">",
"      Grau P, Robinson L, Tabsh K, Crandall BF. Elevated maternal serum alpha-fetoprotein and amniotic fluid alpha-fetoprotein after multifetal pregnancy reduction. Obstet Gynecol 1990; 76:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/83\">",
"      Rotmensch S, Celentano C, Shalev J, et al. Midtrimester maternal serum screening after multifetal pregnancy reduction in pregnancies conceived by in vitro fertilization. J Assist Reprod Genet 1999; 16:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/84\">",
"      Groutz A, Amit A, Yaron Y, et al. Second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol after early transvaginal multifetal pregnancy reduction. Prenat Diagn 1996; 16:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/85\">",
"      Berkowitz RL, Stone JL, Eddleman KA. One hundred consecutive cases of selective termination of an abnormal fetus in a multifetal gestation. Obstet Gynecol 1997; 90:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39065/abstract/86\">",
"      Roman AS, Rebarber A, Lipkind H, et al. Vaginal fetal fibronectin as a predictor of spontaneous preterm delivery after multifetal pregnancy reduction. Am J Obstet Gynecol 2004; 190:142.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6743 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_9_39065=[""].join("\n");
var outline_f38_9_39065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MULTIFETAL PREGNANCY REDUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rationale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Reduction of high order multifetal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reduction of twin pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Preprocedure considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Chorionic villus sampling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Technique for MPR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Postprocedure considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pregnancy outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Ending number",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Operator experience",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Psychological outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LEGAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SELECTIVE TERMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Preprocedure considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dichorionic fetuses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Technique for selective termination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Pregnancy outcome after selective termination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Third trimester termination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Monochorionic fetuses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      LABORATORY CHANGES POSTPROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6743\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6743|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/53/32603\" title=\"table 1A\">",
"      Mortality per 1000 live births by plurality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/56/23436\" title=\"table 1B\">",
"      GA and BW characteristics of US singleton twin triplet births",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/4/4172\" title=\"table 2\">",
"      Cerebral palsy rate by pleurality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/43/8891\" title=\"table 3\">",
"      Unintended loss rate after MPR by starting number",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/56/2955\" title=\"table 4\">",
"      Unintended loss rate after MPR by finishing number",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/24/13707\" title=\"table 5\">",
"      Loss rate after MPR by starting and ending number",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/28/20939\" title=\"table 6\">",
"      Pregnancy loss rates after selective termination",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28169?source=related_link\">",
"      Chorionic villus sampling: Risks, complications, and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5510?source=related_link\">",
"      Delayed-interval delivery in multifetal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14520?source=related_link\">",
"      Incidence and mortality of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22713?source=related_link\">",
"      Late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13814?source=related_link\">",
"      Long-term complications of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27594?source=related_link\">",
"      Neonatal outcome, complications, and management of multiple births",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25145?source=related_link\">",
"      Prenatal screening and diagnosis of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/15/31992?source=related_link\">",
"      Short-term complications of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22170?source=related_link\">",
"      Sonographic findings associated with fetal aneuploidy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/27/43449?source=related_link\">",
"      Strategies to control the rate of high order multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/28/11718?source=related_link\">",
"      Triplet pregnancy: Early pregnancy management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/34/12842?source=related_link\">",
"      Triplet pregnancy: Mid and late pregnancy complications and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/11/5306?source=related_link\">",
"      Twin pregnancy: Labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40682?source=related_link\">",
"      Twin pregnancy: Prenatal issues",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_9_39066="Cancer pain management: Adjuvant analgesics (coanalgesics)";
var content_f38_9_39066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cancer pain management: Adjuvant analgesics (coanalgesics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/9/39066/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/9/39066/contributors\">",
"     Russell K Portenoy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/9/39066/contributors\">",
"     Ebtesam Ahmed, PharmD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/9/39066/contributors\">",
"     Yair Y Keilson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/9/39066/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/9/39066/contributors\">",
"     Janet Abrahm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/9/39066/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/9/39066/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/9/39066/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid therapy is the first-line approach for moderate or severe pain in populations with active cancer. However, the comprehensive management of pain in patients with cancer also requires expertise in the use of the nonopioid analgesics, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen (paracetamol)",
"    </a>",
"    , non-steroidal antiinflammatory agents (NSAIDs), and a group of drugs referred to as \"adjuvant\" analgesics or coanalgesics. Adjuvant analgesics are drugs that are marketed for indications other than pain, but are potentially useful as analgesics when added to opioid therapy in patients with chronic pain syndromes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4488?source=see_link\">",
"     \"Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A stepwise approach to management of cancer pain that includes both opioid and nonopioid drugs has been codified in the World Health Organization's (WHO) \"analgesic ladder\" approach to cancer pain management (",
"    <a class=\"graphic graphic_figure graphicRef63298 \" href=\"mobipreview.htm?0/45/724\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Step 1, which represents mild to moderate cancer-related pain, suggests the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or an NSAID, possibly combined with an adjuvant drug to provide additional analgesia, treat a side effect, or manage a coexisting symptom.",
"     </li>",
"     <li>",
"      For patients with moderate or severe pain, and those who do not achieve adequate relief with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or an NSAID alone, treatment with a step 2 opioid (conventionally used for moderate pain) or a step 3 opioid (conventionally used for severe pain) is appropriate. On both steps 2 and 3, the use of an acetaminophen or an NSAID should be considered, as well as other drugs (adjuvants) to enhance analgesia or treat side effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The analgesic ladder approach is not an evidence-based guideline, but it provides a framework for the stepwise and systematic approach to managing cancer pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=see_link&amp;anchor=H4#H4\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\", section on 'General principles of pain management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will cover the use of adjuvant analgesics in cancer pain management. Assessment of cancer pain, a review of specific cancer pain syndromes, the clinical use and side effects of opioid analgesics, use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and NSAIDs in patients with cancer pain, and non-pharmacologic methods of cancer pain management are covered elsewhere. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF AN ANALGESIC ADJUVANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"adjuvant analgesic\" was originally coined to refer to a small number of drugs that were marketed for indications other than pain, but were found to be potentially useful as analgesics in patients receiving opioid therapy. Over the past three decades, the number, diversity and uses of these drugs have increased dramatically, and several are now indicated as first-line therapy for certain types of pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/2\">",
"     2",
"    </a>",
"    ]. As a result, the term \"adjuvant analgesic\" has become somewhat of a misnomer, but it is still commonly applied in the context of cancer pain. The term is used interchangeably with the term \"coanalgesic\".",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Integration into cancer pain management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant analgesics are often considered for treatment of chronic cancer pain when a patient is poorly responsive to opioids (ie, inability to titrate the opioid to a dose that maintains a favorable balance between analgesia and side effects). The addition of an adjuvant analgesic is one approach among many that may be considered for such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link&amp;anchor=H27#H27\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Dose titration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=see_link\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a general rule, a trial of a coanalgesic in the setting of poor opioid responsiveness should usually be considered only after efforts have been made to optimize opioid therapy (ie, by adjusting the dose or, if indicated, rotating to a different opioid). Adding a second analgesic only after the opioid has been optimized ensures that the second drug is needed, reduces the risk of additive toxicity by eliminating the need to titrate both drugs simultaneously, and limits confusion in determining the source of an adverse drug effect should one arise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link&amp;anchor=H28#H28\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Using opioid rotation to manage poorly responsive pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Available agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large and growing number of adjuvant analgesics can be categorized on the basis of how they are used in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/2\">",
"     2",
"    </a>",
"    ]. This information is evolving as new trials are conducted, clinical experience expands, and as treatments that were developed for populations with noncancer pain are extrapolated to the cancer population. Based upon conventional practice, the categories of available agents include (",
"    <a class=\"graphic graphic_table graphicRef80423 \" href=\"mobipreview.htm?2/57/2973\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef82318 \" href=\"mobipreview.htm?1/28/1485\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Drugs potentially useful for any type of pain (multipurpose analgesics)",
"     </li>",
"     <li>",
"      Drugs used for treatment of neuropathic pain",
"     </li>",
"     <li>",
"      Drugs used for bone pain",
"     </li>",
"     <li>",
"      Drugs used for pain and other symptoms in the setting of bowel obstruction",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MULTIPURPOSE ANALGESICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some drug classes have been studied in diverse types of chronic pain. The evidence of broad analgesic efficacy supports the view that the specific agents within these classes (including glucocorticoids, antidepressants, alpha-2 adrenergic agonists, cannabinoids, and topical therapies) function as multipurpose analgesics that have potential value for any type of chronic pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;In palliative care, glucocorticoids are often used to alleviate symptoms such as pain, nausea, fatigue, anorexia, and malaise, and improve overall quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. A large body of clinical experience suggests that glucocorticoids may be beneficial for a variety of types of pain, including neuropathic and bone pain, pain associated with capsular expansion or duct obstruction, pain from bowel obstruction, pain caused by lymphedema, and headache caused by increased intracranial pressure. The mechanism of analgesia probably relates to reduction of tumor-related edema, antiinflammatory effects, and direct effects on nociceptive neural systems. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link&amp;anchor=H9#H9\">",
"     \"Assessment of cancer pain\", section on 'Nociceptive pain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39335?source=see_link\">",
"     \"Management of vasogenic edema in patients with primary and metastatic brain tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26970?source=see_link\">",
"     \"Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Choice of agent and dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    is usually preferred for the management of cancer-related pain, presumably because of its long half-life and relatively low mineralocorticoid effects (",
"    <a class=\"graphic graphic_table graphicRef64138 \" href=\"mobipreview.htm?41/61/42972\">",
"     table 3",
"    </a>",
"    ). However, there is no empiric evidence that this drug is either safer or more effective in the cancer population than any other glucocorticoid.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    are acceptable alternatives. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=see_link\">",
"     \"Pharmacologic use of glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A typical regimen for patients with cancer-related pain is 1 to 2 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    orally or parenterally twice daily; this may be preceded by a larger loading dose of 10 to 20 mg. This regimen, or comparable regimens of alternative steroids, is based upon clinical experience and is not evidence-based. Patients may do well with lower or higher doses, or with once-daily rather than twice-daily dosing.",
"   </p>",
"   <p>",
"    Regardless of the regimen that is selected, the intent is usually for ongoing chronic use in the setting of advanced illness. In this situation, the risk of long-term toxicity, which includes myopathy, immunocompromise, psychotomimetic effects, and hypoadrenalism, is attenuated by limited life expectancy and the need to address the multiple sources of suffering. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are some situations for which a brief regimen of high-dose glucocorticoids might be selected. Originally developed for the treatment of emerging epidural spinal cord compression (including cauda equina syndrome), a brief period of high-dose glucocorticoids is appropriate for any \"pain crisis\", which is defined as severe and escalating pain that is not responding sufficiently to an opioid.",
"   </p>",
"   <p>",
"    In such cases, a typical regimen consists of a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    loading dose of 50 to 100 mg intravenously, which may be followed by 12 to 24 mg four times daily; this dose is then tapered over one to three weeks, usually as some other intervention, such as radiotherapy or a pain intervention (eg, neural blockade), is used to treat the pain.",
"   </p>",
"   <p>",
"    Although the high-dose regimen is administered with the expectation that it will provide more rapid and substantial pain relief than a lower dose regimen, the only evidence for this originates from populations with epidural spinal cord compression, and even these data are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/7\">",
"     7",
"    </a>",
"    ]. Both the limited evidence and the potential for dose-related toxicity (which is clearly higher with higher dose regimens) must be recognized in weighing the potential benefits of the high-dose approach. This subject is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26970?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\", section on 'Clinical trials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Analgesic antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressants have been widely studied in populations with chronic pain, and the available data suggest that these drugs act as multipurpose analgesics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/2,8-11\">",
"     2,8-11",
"    </a>",
"    ]. Although very few of these studies have included cancer patients, the utility of these drugs for treatment of cancer pain has been extrapolated from data in other conditions.",
"   </p>",
"   <p>",
"    In opioid-treated populations with advanced medical illness, antidepressants have been predominantly used for neuropathic pain. However, given the range of their potential analgesic efficacy, they could be considered for other types of chronic pain as well. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link&amp;anchor=H10#H10\">",
"     \"Assessment of cancer pain\", section on 'Neuropathic pain'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H18\">",
"     'Drugs used for neuropathic pain'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Mechanism of analgesic effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressants function as primary analgesics. Although pain reduction may be enhanced if there is a positive mood effect, analgesia is not dependent on mood elevation and pain can be improved in euthymic patients. If a patient with chronic cancer pain has depressed mood, a relatively early trial of an analgesic antidepressant is appropriate in the hope of achieving a separate and positive effect on mood.",
"   </p>",
"   <p>",
"    The primary analgesic mode of action is thought to be related to enhanced availability of monoamines at synapses within neural pathways that are part of the descending pain modulating system. Inhibition of norepinephrine reuptake appears to be the most important mode of action, but serotonergic and dopaminergic effects also may play a role in analgesia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/59/16312?source=see_link\">",
"     \"Definition and pathogenesis of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Selection of agent and dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antidepressants comprise several subclasses and numerous drugs (",
"    <a class=\"graphic graphic_table graphicRef80423 \" href=\"mobipreview.htm?2/57/2973\">",
"     table 1",
"    </a>",
"    ). Analgesic efficacy is best established for some of the tricyclic compounds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/8,12-14\">",
"     8,12-14",
"    </a>",
"    ] and the serotonin-norepinephrine reuptake inhibitors (SNRIs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/11,14-17\">",
"     11,14-17",
"    </a>",
"    ]; there is minimal evidence of analgesic efficacy with the serotonin-selective reuptake inhibitors (SSRIs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/8,18,19\">",
"     8,18,19",
"    </a>",
"    ]. Benefit has also been suggested for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    (a dopamine reuptake inhibitor) in patients with neuropathic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tricyclic antidepressants include tertiary amines, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    , and secondary amines, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    . The secondary amines are more selective at noradrenergic reuptake sites, and they have a more favorable side effect profile than does amitriptyline. As a result, when a tricyclic is chosen in a medically ill patient, desipramine or nortriptyline is usually preferred. All of the tricyclic compounds are relatively contraindicated in patients with serious heart disease, severe prostatic hypertrophy, and narrow-angle glaucoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=see_link&amp;anchor=H19#H19\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is strong evidence that at least some of the SNRIs (which include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/33/18967?source=see_link\">",
"     desvenlafaxine",
"    </a>",
"    ) have analgesic effects. Evidence of analgesic efficacy is best described with duloxetine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], but the literature lacks trials in patients with cancer pain, and there are no comparative trials within the SNRI class.",
"   </p>",
"   <p>",
"    Overall, the side effect profile of the SNRIs (which includes nausea, sexual dysfunction, and somnolence or mental clouding) is favorable relative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    . There is a great deal of individual variation, however. Among patients with serious medical illness, such as those with cancer, the first-line analgesic antidepressants to consider should be either a secondary amine tricyclic compound (usually desipramine) or a SNRI (usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    ), and the decision between these drugs usually is based on a case-by-case assessment of risk and cost.",
"   </p>",
"   <p>",
"    Other antidepressants are considered as second-line drugs, typically considered if the initial therapeutic attempt yields side effects or a limited analgesic response. The exception is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    , a dopamine and norepinephrine reuptake inhibitor that is distinguished by its tendency to be activating. Given this latter effect, a trial of bupropion sometimes is considered early if cancer pain is complicated by fatigue or somnolence, even though the evidence of analgesic efficacy is weak. Bupropion should be avoided in patients at risk for seizures.",
"   </p>",
"   <p>",
"    All of the analgesic antidepressants should be started at a relatively low initial dose (",
"    <a class=\"graphic graphic_table graphicRef82318 \" href=\"mobipreview.htm?1/28/1485\">",
"     table 2",
"    </a>",
"    ). The starting dose for a trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    , for example, is 10 to 25 mg at night. The dose should be increased no more quickly than every few days in the absence of satisfactory relief or side effects. If analgesia is going to occur at any given dose, it typically appears within a week (developing more rapidly than the antidepressant effects). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link&amp;anchor=H26#H26\">",
"     \"Initial treatment of depression in adults\", section on 'Timing of response and follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients who experience pain relief with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    respond at a dose between 50 and 150 mg per day. However, the tricyclics may have a drug concentration-response relationship for analgesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/12\">",
"     12",
"    </a>",
"    ], and if neither analgesia nor intolerable side effects occur, continued dose escalation is reasonable. At relatively high doses (ie, above 100 mg per day), the plasma drug concentration and an electrocardiogram (ECG) should be checked. Tricyclic antidepressants can prolong the QTc interval and predispose to cardiac arrhythmias. These drugs should be used cautiously when a patient has known heart disease or is receiving other drugs (including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    ) that can prolong the QT interval (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"mobipreview.htm?2/48/2830\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=see_link&amp;anchor=H7#H7\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\", section on 'Plasma levels and therapeutic response'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=see_link&amp;anchor=H28#H28\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\", section on 'Cardiac evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other antidepressants such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    should similarly be started at a relatively low initial dose (",
"    <a class=\"graphic graphic_table graphicRef82318 \" href=\"mobipreview.htm?1/28/1485\">",
"     table 2",
"    </a>",
"    ), and titrated to conventional maximal doses to determine whether an analgesic or positive mood effect occurs. Unlike the tricyclics, these drugs do not prolong the QTc interval. However, gastrointestinal side effects (including nausea, dry mouth, and constipation) are common with duloxetine, and bupropion causes jitteriness or headache as relatively common initial side effects.",
"   </p>",
"   <p>",
"    If possible, it is preferable to taper these drugs prior to discontinuation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other multipurpose analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are far fewer data supporting the use of the alpha-2 adrenergic agonists, cannabinoids, and topical therapies as multipurpose analgesics for the treatment of cancer pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Alpha-2 adrenergic agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classification of alpha-2 adrenergic agonists such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/35/12855?source=see_link\">",
"     tizanidine",
"    </a>",
"    as multipurpose analgesics is supported by both animal and human studies. Clonidine, which can be administered orally, transdermally, or intraspinally, has been mainly studied in patients with noncancer-related chronic pain. Spinally-administered clonidine has analgesic properties in patients with cancer pain and is more efficacious for neuropathic than nociceptive pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=see_link\">",
"     \"Cancer pain management: Interventional therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is less evidence of analgesic efficacy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/35/12855?source=see_link\">",
"     tizanidine",
"    </a>",
"    , an orally active centrally acting alpha-2 agonist that is approved as an antispasticity agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/23\">",
"     23",
"    </a>",
"    ], or the parenteral alpha-2 agonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. However, this class of drugs can provide analgesia in diverse types of pain. Although the mechanism is unknown, the analgesic effects presumably relate to increased activity in monoamine-dependent, endogenous pain modulating pathways in the spinal cord and brain.",
"   </p>",
"   <p>",
"    The alpha-2 agonists produce somnolence and dry mouth, and may cause hypotension, which is usually orthostatic. This potential, combined with analgesic efficacy that appears to be lower than with other multipurpose drugs, indicates a limited role for these drugs in the medically ill.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/35/12855?source=see_link\">",
"     Tizanidine",
"    </a>",
"    has less hypotensive effect than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    and could be considered for a trial in patients with opioid-refractory neuropathic pain. Patients who are hemodynamically unstable, predisposed to serious hypotension (eg, by autonomic neuropathy, intravascular volume depletion, or concurrent therapy with potent hypotensive agents), or encephalopathic from other causes are not appropriate candidates. Dosing with tizanidine may be initiated just at bedtime in an effort to provide hypnotic effects. If the drug is tolerated, dose escalation using two divided daily doses is typically used when the intent of therapy is analgesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cannabinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cannabinoids are derived from the cannabis (marijuana) plant, which contains over 400 compounds, including more than 60 cannabinoids. The primary psychoactive cannabinoid is delta-9-tetrahydrocannabinol (THC, also known as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/49/30485?source=see_link\">",
"     dronabinol",
"    </a>",
"    ). In vivo, cannabinoid molecules such as THC interact with an endogenous system that includes cannabinoid-like ligands (the endocannabinoids) as well as multiple receptors in both the periphery and central nervous system. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1079?source=see_link\">",
"     \"Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although concern about the abuse potential of cannabinoid drugs has slowed their development, several cannabinoid-type drugs are commercially available, and others are under study. The available data suggest that these compounds may be useful as multipurpose analgesics, although few studies have been conducted in cancer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/26-30\">",
"     26-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An oromucosal spray containing THC plus cannabidiol (and smaller concentrations of other compounds),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/44/15046?source=see_link\">",
"     nabiximols",
"    </a>",
"    (Sativex), is approved in Canada and elsewhere (but not yet in the United States) for treatment of neuropathic pain due to multiple sclerosis and as an adjunctive treatment for pain in patients with advanced cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/31\">",
"     31",
"    </a>",
"    ]. It is rapidly absorbed from the buccal mucosa, and the dose can be self-titrated by the patient.",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/44/15046?source=see_link\">",
"     nabiximols",
"    </a>",
"    for management of cancer pain was shown in a double-blind trial in which 177 cancer patients with inadequate analgesia despite chronic opioid dosing were randomly assigned to nabiximols (n = 60), THC alone (n = 58), or placebo (n = 59) for two weeks; doses were self titrated (with maximum permitted doses) until satisfactory relief or untoward side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/29\">",
"     29",
"    </a>",
"    ]. By the end of the study period, compared to placebo, the adjusted mean reduction in pain score from baseline was significantly higher with nabiximols, but not with THC alone. In addition, there was a nonsignificant trend toward fewer daily doses of all breakthrough medications in the nabiximols group, compared to placebo. However, there were imbalances in the baseline opioid dose that could have biased the results in favor of nabiximols.",
"   </p>",
"   <p>",
"    Until newer cannabinoid preparations such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/44/15046?source=see_link\">",
"     nabiximols",
"    </a>",
"    become available in the US, clinical use of cannabinoids for cancer pain is limited to those agents that are marketed for purposes other than pain, including THC and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/63/6133?source=see_link\">",
"     nabilone",
"    </a>",
"    . A trial of one of these drugs is usually considered only in those patients who are refractory to opioids and other appropriate adjuvant analgesics; most will have neuropathic pain. Nabilone should be started at 0.5 to 1 mg at night and titrated up to 3 mg twice daily, or higher if tolerated.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/49/30485?source=see_link\">",
"     Dronabinol",
"    </a>",
"    usually is started at a dose of 2.5 mg once or twice daily, and titrated.",
"   </p>",
"   <p>",
"    The most common side effects associated with the cannabinoids are dizziness, somnolence, and dry mouth.",
"   </p>",
"   <p>",
"    The use of medical marijuana for refractory cancer pain is very controversial. Medical use of marijuana is legal in several countries, including the Netherlands and Canada. However, despite legalization by several states, marijuana use is still illegal in the United States at the federal level (which considers marijuana a schedule I controlled substance), and individuals prescribing or using marijuana for medical use are at risk for prosecution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although severe or chronic pain accounts for over 90 percent of the qualifying conditions for use of medicinal marijuana among registered users in several states in which it is legal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/33-36\">",
"     33-36",
"    </a>",
"    ], there are no controlled studies demonstrating the efficacy of inhaled marijuana as an adjunct to traditional pain medications for patients with cancer-related pain, and, particularly in view of concerns for higher cancer rates among cannabis smokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/37\">",
"     37",
"    </a>",
"    ], its use cannot be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Topical therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical therapies have the potential to deliver analgesic compounds directly to the site that is presumably responsible, at least in part, for the persistent pain. The relative lack of systemic toxicity offers a therapeutic advantage that may be particularly relevant to the medically ill. Although topical analgesics have been used mostly for neuropathic pain, they have the potential for broader application.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Lidocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely used topical therapies for pain contain local anesthetics.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    5 percent transdermal patches are widely used for the treatment of focal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regional pain of all types. The evidence to support benefit is relatively weak, and consists of small, short-term, open-label nonrandomized studies that were conducted in patients with postherpetic neuralgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/38\">",
"     38",
"    </a>",
"    ], and other noncancer disorders causing chronic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Although the current approved use (based on clinical trials) is a 12 hour per day dosing regimen, some patients find that pain relief does not last 24 hours and continuous application is common in the clinical setting. Multiple patches are often used together. There are limited data that indicate a high level of safety with four patches applied for 24 hours a day for up to 72 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most frequently reported adverse event is mild to moderate skin irritation at the patch application site, which seems to be related to the vehicle rather than to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    . There is only a remote risk of toxicity from systemic absorption of lidocaine. Cost may be prohibitive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other local anesthetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical analgesia also may be possible using creams or gels containing local anesthetics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A commercially available mixture of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/32/6660?source=see_link\">",
"       prilocaine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      , known as eutectic mixture of local anesthetics (EMLA) cream, is capable of penetrating the skin and producing a dense local cutaneous anesthesia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/42\">",
"       42",
"      </a>",
"      ]. This product and others have been approved to prevent the pain of needle puncture or incision. In cancer patients with a peripheral source of pain, application of a thin layer under an occlusive dressing has been used as an adjunct to chronic therapy. The treatment is relatively expensive and difficult to sustain for long periods.",
"     </li>",
"     <li>",
"      Surveys of studies using relatively high concentrations of topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      gel suggest that a compound of this type can produce similar benefits for focal, peripherally-generated pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/43\">",
"       43",
"      </a>",
"      ]. Although there is a remote risk of toxicity from systemic absorption, the safety of the lidocaine patch or compounded creams suggest that a trial should be considered in patients who have pain that is localized to a relatively small area.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14022?source=see_link\">",
"       Capsaicin",
"      </a>",
"      , the naturally occurring constituent of the chili pepper, depletes substance P from the terminals of afferent C-fibers. Topical application of a commercially available capsaicin cream or low-dose transdermal patch (which are available over the counter in the US) or a single application of a high-dose patch (8 percent capsaicin, Qutenza, which requires a prescription) has yielded weak to moderate analgesic effects in controlled trials focusing on patients with various types of neuropathic and joint pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/44-46\">",
"       44-46",
"      </a>",
"      ]. Burning at the application site, which is often transitory, is the major side effect and may be limiting. Application three to four times daily for a period of at least a week is needed to determine benefit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Antiinflammatory and antidepressant drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous anti-inflammatory drugs have been investigated for topical use;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    patch, cream, and gel are commercially available in the US. Like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    , there is some evidence that diverse types of pain may respond favorably. Although data from controlled trials in populations with musculoskeletal pain are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/47,48\">",
"     47,48",
"    </a>",
"    ], there is sufficient evidence of effectiveness and safety to warrant a therapeutic trial in patients with small areas of pain related to neuropathic or nociceptive mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link&amp;anchor=H8#H8\">",
"     \"Assessment of cancer pain\", section on 'Inferred pathophysiology (types of cancer pain)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence for the analgesic efficacy of topical tricyclic antidepressants is conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/49\">",
"     49",
"    </a>",
"    ], but a cream containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    is commercially available and approved for the short-term management of pruritus. Given the safety of this approach, a trial of topical doxepin may be considered for the patient with local or regional pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6058?source=see_link\">",
"     \"Pruritus: Overview of management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other drugs have been used empirically in specially compounded creams for use in patients with pain. The most popular are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , but a variety of others are in use. Supporting data are very meager or absent, but given the relative safety of topical application of these agents, a clinical trial may be reasonable. Cost must be considered when recommending these strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DRUGS USED FOR NEUROPATHIC PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the drugs classified as multipurpose analgesics may be considered for a clinical trial in patients with opioid-refractory neuropathic cancer pain. However, the most important of the multipurpose adjuvant analgesics for treatment of neuropathic pain are the analgesic antidepressants, and anticonvulsants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described previously, the most useful of the analgesic antidepressants are the serotonin-norepinephrine reuptake inhibitors (SNRIs) such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    , and the secondary amine tricyclic compounds (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    ). Evidence of analgesic efficacy for chronic pain has been demonstrated in randomized controlled trials and meta-analyses. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Analgesic antidepressants'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    At least one randomized, double-blind placebo-controlled crossover trial conducted in patients with painful chemotherapy induced peripheral neuropathy supports a benefit for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    in this setting. In this multi-institutional trial, conducted by the Cancer and Leukemia Group B, 231 patients with taxane or platinum-related painful chemotherapy induced peripheral neuropathy (59 percent attributed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ) at least grade 1 sensory neuropathy and an average pain score",
"    <span class=\"nowrap\">",
"     &gt;4/10",
"    </span>",
"    that persisted for three or more months, with stable use of analgesics, were randomly assigned to duloxetine (30 mg daily for one week, then 60 mg daily for four additional weeks) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/50\">",
"     50",
"    </a>",
"    ]. Pain score was measured weekly by the",
"    <a class=\"external\" href=\"file://www.npcrc.org/usr_doc/adhoc/painsymptom/briefpain_short.pdf\">",
"     brief pain inventory, short form",
"    </a>",
"    (",
"    <a class=\"external\" href=\"file://www.npcrc.org/usr_doc/adhoc/painsymptom/briefpain_short.pdf\">",
"     BPI-SF",
"    </a>",
"    ); other end points included QOL as assessed by the FACT-GOG NTX (Functional Assessment of Cancer Therapy-Gynecologic Oncology Group neurotoxicity subscale [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/51\">",
"     51",
"    </a>",
"    ]) and the EORTC (European Organization for Research and Treatment of Cancer) QLQ-C30 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/52\">",
"     52",
"    </a>",
"    ] instruments, as well as non-painful symptoms. After the five weeks, there was a taper and washout period for two weeks, and all patients crossed over to the alternative treatment. Individuals receiving duloxetine during their initial five-week period had a significantly larger average decrease in mean pain score than did those who initially received placebo (mean decrease 1.06 versus 0.34, p = 0.003). Furthermore, patients randomized to duloxetine also had a greater degree of improvement in functional and QOL scores, and more patients reported improved numbness and tingling in the feet (41 versus 23 percent) but not the hands (36 versus 34 percent). Fatigue (7 percent), insomnia, and nausea (5 percent each) were the most common side effects reported with duloxetine while the placebo-treated patients reported somnolence (8 percent), insomnia (7 percent), and fatigue (5 percent) most often.",
"   </p>",
"   <p>",
"    Although trials comparing antidepressants versus other strategies (such as anticonvulsants) for treatment of neuropathic pain are lacking, most experts consider these drugs to represent preferred first-line treatments for neuropathic pain that is associated with significant depressed mood, and appropriate second-line agents (after the alpha-2-delta modulators",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    , see below) for non-depressed patients who have neuropathic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Analgesic antidepressants'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The positive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/50\">",
"     50",
"    </a>",
"    ] for painful chemotherapy-induced neuropathy suggests that in this setting, duloxetine is an appropriate first-line agent, particularly in view of a negative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    trial (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Gabapentin and pregabalin'",
"    </a>",
"    below). However, additional data will be needed to establish the superiority of duloxetine or any other antidepressant over an alpha-2-delta modulator in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Anticonvulsant analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anticonvulsants represent a diverse group of drugs that vary in mechanisms and clinical effects (",
"    <a class=\"graphic graphic_table graphicRef80423 \" href=\"mobipreview.htm?2/57/2973\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef82318 \" href=\"mobipreview.htm?1/28/1485\">",
"     table 2",
"    </a>",
"    ). Analgesic effects are best characterized for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    , two drugs that are now considered the first-line approach for patients without comorbid depression who have neuropathic cancer pain that is refractory to opioid analgesics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Gabapentin and pregabalin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    have been extensively studied in diverse types of neuropathic pain, particularly postherpetic neuralgia and painful diabetic neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/54-61\">",
"     54-61",
"    </a>",
"    ]. In two randomized placebo-controlled trials involving populations of opioid-treated patients with cancer-related neuropathic pain, gabapentin and pregabalin were significantly better than placebo in improving neuropathic pain and dysesthesias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/55,62\">",
"     55,62",
"    </a>",
"    ]; one of these trials directly compared gabapentin and pregabalin, and is discussed in more detail below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/62\">",
"     62",
"    </a>",
"    ]. On the other hand, another randomized trial of gabapentin versus placebo for chemotherapy-induced painful neuropathy failed to show any benefit for gabapentin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    both act by binding to the alpha-2 delta protein modulator of the N-type, voltage-gated calcium channel. Binding to this protein reduces calcium influx into the neuron, and lessens the likelihood of depolarization.",
"   </p>",
"   <p>",
"    Unlike all other anticonvulsants,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    are not metabolized in the liver and they have no known drug-drug interactions. Both drugs are excreted by the kidneys, which necessitates dose reduction in the setting of renal impairment. Their main side effects are mental clouding, dizziness, and somnolence; edema and weight gain are less common.",
"   </p>",
"   <p>",
"    The main difference between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    is pharmacokinetic. Absorption and entry of gabapentin into the central nervous system (CNS) is facilitated by a saturable transporter in the small bowel and CNS. At relatively higher doses (approximately 1800 mg per day, but could be higher or lower in individual cases, (",
"    <a class=\"graphic graphic_table graphicRef82318 \" href=\"mobipreview.htm?1/28/1485\">",
"     table 2",
"    </a>",
"    )), the kinetics become nonlinear and there is less complete absorption with each dose increment. These saturable kinetics mean that gabapentin has a pharmacokinetic \"ceiling\", which coexists with a possible pharmacodynamic \"ceiling\" of the type that is observed with all adjuvant analgesics (ie, at some point, a maximum effect is reached even if the plasma concentration of the drug is further increased).",
"   </p>",
"   <p>",
"    In contrast, absorption of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    is not dependent on a saturable transport mechanism, and this drug only has the unpredictable pharmacodynamic ceiling. This linear pharmacokinetic profile simplifies dosing of pregabalin compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Whether either drug is superior to the other for treatment of neuropathic pain is unclear. A double-blind trial randomly assigned 120 patients with cancer and severe neuropathic pain to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    (900 mg daily for one week followed by 1200 mg daily for one week, then 1800 mg daily),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    (150 mg daily for one week, followed by 300 mg daily for one week, then 600 mg daily),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    (50 mg daily for one week followed by 75 mg per day for one week, then 100 mg daily at bedtime), or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/62\">",
"     62",
"    </a>",
"    ]. The primary outcome measure was global intensity of pain, as measured on a 100 mm Visual Analog Scale (VAS). By week four, the mean VAS score with pregabalin was significantly less than that of the patients receiving gabapentin, and the percentage of patients requiring rescue",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    in the placebo, amitriptyline, gabapentin, and pregabalin groups was significantly different (100, 57, 33, and 17 percent, respectively).",
"   </p>",
"   <p>",
"    This study suggests that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    may have superior efficacy but the limitations of the study (no indication of how randomization or blinding was performed, no power analysis, and the primary endpoint analysis was not an &ldquo;intention to treat&rdquo; analysis) preclude definitive conclusions. In addition, the drugs were tested at doses that may not be fairly compared; the initial dose of pregabalin was relatively high while the top dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    was the minimum dose that is often chosen. For all of these reasons, it cannot be concluded that pregabalin is superior to gabapentin for treatment of neuropathic pain.",
"   </p>",
"   <p>",
"    The starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    is usually 50 to 75 mg per day in two divided doses (a lower dose should be used in the medically frail), and escalation to the usual effective dose of 150 to 300 mg twice daily typically is accomplished in two to three steps over one week. In the medically frail cancer patient,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    is often initiated at a dose of approximately 100 to 300 mg per day (one-half the dose of a non-frail patient). The dose is gradually escalated every few days while monitoring analgesia and side effects. If pain relief does not occur, in the absence of an analgesic ceiling or adverse effects, dose escalation can extend to 3600 mg per day administered in two to three divided doses and sometimes higher.",
"   </p>",
"   <p>",
"    Controlled trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    that have included \"",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    failures\" have shown that patients may respond to pregabalin even if gabapentin was not tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/64\">",
"     64",
"    </a>",
"    ]. Given these data and extensive clinical observations, it is appropriate to consider a trial of the alternate drug if an attempt with the first does not yield benefit.",
"   </p>",
"   <p>",
"    If possible, it is preferable to taper these drugs prior to discontinuation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Other anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous other anticonvulsants have been studied as analgesics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/65\">",
"     65",
"    </a>",
"    ]. Older anticonvulsant such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    are perceived as having potential analgesic effects based on trials performed several decades ago [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/66\">",
"     66",
"    </a>",
"    ]. Carbamazepine remains a preferred drug for trigeminal neuralgia, but in the cancer population, it is seldom used because of the risk of leucopenia and the need for monitoring myelosuppressive effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34873?source=see_link\">",
"     \"Trigeminal neuralgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The data supporting the analgesic efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    are limited. Although these drugs may be considered for trials in patients with intractable neuropathic pain, conventional practice in countries that have access to newer agents relegates them to trials after other anticonvulsants have been demonstrated to be ineffective.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     Lamotrigine",
"    </a>",
"    has been effective in studies of central pain, trigeminal neuralgia and painful HIV polyneuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/57\">",
"     57",
"    </a>",
"    ], but it has not been analgesic in other trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/67\">",
"     67",
"    </a>",
"    ]. Lamotrigine is associated with a small risk of severe cutaneous hypersensitivity, which is relatively higher in younger patients. The drug should not be used in patients under the age of 15, and slow titration of the dose from a low initial dose is necessary to reduce the risk of hypersensitivity.",
"   </p>",
"   <p>",
"    The need for this slow initial titration, which ideally requires more than one month to reach a dose that might be effective, as well as the risk of Stevens-Johnson syndrome, diminishes enthusiasm for an early trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    . Typically, it is considered only after trials of several preferred drugs for neuropathic pain have been ineffective.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     Oxcarbazepine",
"    </a>",
"    is a metabolite of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , which has similar anticonvulsant properties and a safer pharmacologic profile. Although studies have not been uniformly positive, it has been shown to be analgesic in trigeminal neuralgia and several other types of neuropathic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/68\">",
"     68",
"    </a>",
"    ]. Like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    , a trial may be considered after trials of the alpha-2-delta modulators and perhaps one or two of the analgesic antidepressants have proved to be ineffective.",
"   </p>",
"   <p>",
"    Other anticonvulsants may be considered for treatment-refractory cancer-related neuropathic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/2,65\">",
"     2,65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       Topiramate",
"      </a>",
"      , an effective drug for migraine, has been variably effective in studies of neuropathic pain, but anecdotal experience suggests that some patients respond and derive substantial benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are conflicting reports on the analgesic efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"       levetiracetam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"       zonisamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/22/26982?source=see_link\">",
"       tiagabine",
"      </a>",
"      , and in the absence of additional data, these drugs usually are not considered unless others are not available.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"       Clonazepam",
"      </a>",
"      is a benzodiazepine. Very meager data support analgesic efficacy in patients with neuropathic pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/70\">",
"       70",
"      </a>",
"      ]; its anxiolytic effects may be favorable, however, and a trial often is considered in the patient with refractory neuropathic pain associated with anxiety.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/19/35125?source=see_link\">",
"       Lacosamide",
"      </a>",
"      , a relatively new anticonvulsant, is a sodium channel modulator, a unique mechanism of action. Large controlled trials in patients with painful diabetic neuropathy suggest benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/71\">",
"       71",
"      </a>",
"      ], although there are no data in patients with cancer-related pain. This agent could be considered among those that are potentially useful for treatment of refractory neuropathic pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other drugs used for neuropathic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other drug classes play a far less prominent role in the clinical strategy for cancer-related neuropathic pain. Nonetheless, occasional patients with refractory neuropathic pain may be candidates for a trial of one or more of these uncommon treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Other multipurpose analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the drug classes used less often are those previously grouped with the multipurpose analgesics. A trial of an alpha-2 agonist such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/35/12855?source=see_link\">",
"     tizanidine",
"    </a>",
"    , or a trial of a cannabinoid such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/49/30485?source=see_link\">",
"     dronabinol",
"    </a>",
"    , might be considered in refractory cases of neuropathic pain. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Alpha-2 adrenergic agonists'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'Cannabinoids'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Topical analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical agents, usually a local anesthetic, may also be considered for an early trial when neuropathic pain is focal or regional and opioid therapy is not sufficient. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Topical therapies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Sodium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blockade of sodium channels has been recognized as an analgesic mechanism for decades and the potential role of the new sodium channel modulator,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/19/35125?source=see_link\">",
"     lacosamide",
"    </a>",
"    , was mentioned above (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Other anticonvulsants'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Treatment approaches using older sodium channel blockers include oral therapy with antiarrhythmic drugs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    or tocainide, or",
"   </p>",
"   <p>",
"    parenteral therapy, usually with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    . A brief intravenous infusion of lidocaine, typically 2 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    infused over 20 to 30 minutes in a monitored setting, can be extremely useful in the management of severe neuropathic pain, resulting in prompt pain reduction so that other strategies can be implemented more gradually. The analgesic effects and generally favorable safety profile of these drugs are strongly supported by the literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]; the usual side effects are dizziness, nausea, and fatigue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Ketamine and other NMDA receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The N-methyl-D-aspartate (NMDA) receptor is involved in both the sensitization of central neurons and the functioning of the opioid receptor, and there is good evidence that one of the commercially available NMDA receptor antagonists,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    , has analgesic properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/74\">",
"     74",
"    </a>",
"    ]. At subanesthetic doses, ketamine may be used as a brief infusion for treatment of severe refractory pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/75,76\">",
"     75,76",
"    </a>",
"    ], as a more prolonged infusion (typically at the end of life), or as oral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/77\">",
"     77",
"    </a>",
"    ]. The evidence to support benefit of ketamine as an adjuvant to opioid therapy is quite limited. Two small trials suggested enhanced control of cancer pain when ketamine was given with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]; however, a Cochrane review concluded that the evidence was insufficient to assess the benefits and harms of ketamine as an adjunct to opioids for relief of cancer pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/80\">",
"     80",
"    </a>",
"    ]. Two later randomized trials, one conducted in 20 patients with refractory cancer pain, and the other in 185 patients with refractory chronic pain related to cancer or its treatment, failed to demonstrate any benefit from the addition of infusional ketamine to opioids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. In the larger of the two trials, only 39 of the original 93 patients allocated to ketamine received the full five days of planned treatment, with approximately equal numbers discontinuing therapy for lack of efficacy and treatment-related toxicity (somnolence, constipation,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    dizziness, cognitive disturbance) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/82\">",
"     82",
"    </a>",
"    ]. Only 35 of the original 91 patients assigned to placebo received the full five days of planned treatment, but nearly all of the dropouts were for treatment failure.",
"   </p>",
"   <p>",
"    Nevertheless, this approach continues to be used by experienced pain clinicians, particularly in the setting of otherwise refractory neuropathic pain at the end of life, based mainly upon favorable anecdotal experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. The side effect profile of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    , including particularly psychotomimetic effects and delirium, is problematic, however; and as a result, the most common use is short-term therapy in a monitored setting. Based upon anecdotal observations that treatment with a benzodiazepine, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    , or a neuroleptic, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    , reduces the risk of psychotomimetic effects from ketamine, most practitioners co-administer one of these drugs prior to the start of the infusion and repeatedly during longer term treatment; a benzodiazepine usually is preferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other NMDA receptor antagonists, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"     memantine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    , have been studied in neuropathic pain states, with mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/84\">",
"     84",
"    </a>",
"    ]. They are rarely considered for trials in cancer-related neuropathic pain that has not responded to other agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     GABA receptor inhibitors and agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the gamma aminobutyric acid (GABA) receptor inhibitors are the benzodiazepines, which affect the GABAA receptor subtype, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    , which affects the GABAB subtype. As noted previously, the only benzodiazepine that is typically used for neuropathic pain is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Other anticonvulsants'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"     Baclofen",
"    </a>",
"    , a selective GABAB agonist, is an antispasticity drug with established efficacy in trigeminal neuralgia. It has been used anecdotally for neuropathic pain of other types, including cancer pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/85\">",
"     85",
"    </a>",
"    ]. A low starting dose of 5 mg twice daily can be gradually escalated to doses that may exceed 200 mg per day in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Summary and recommendations of expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioids are widely used for treatment of cancer pain because of their safety, ease of titration, reliability, and effectiveness for all types of pain, including neuropathic pain. Although neuropathic pain may be more difficult to treat, a favorable response to opioid-based analgesia is often possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link\">",
"     \"Assessment of cancer pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For this reason, some experts advocate a trial of an adjuvant analgesic for cancer-related neuropathic cancer pain only in the setting of relatively poor opioid responsiveness, ie, after an opioid has been titrated to optimize the balance between analgesia and side effects. This view is somewhat controversial, however, and others advocate early use of adjuvant analgesics, usually in tandem with cautious opioid titration.",
"   </p>",
"   <p>",
"    Experts generally agree that this first-line or concurrent use of an opioid should be considered only in patients with active cancer; patients with no active disease (such as those with posttreatment neuropathic pain like a postmastectomy pain syndrome) are usually similar to patients with neuropathic pain that is not cancer-related. In these situations, opioid therapy is usually perceived to have a more limited role.",
"   </p>",
"   <p>",
"    As an example, guidelines for treatment of neuropathic pain from the International Association for the Study of Pain (IASP) focus on noncancer pain populations and recommend first-line use of selected anticonvulsants (specifically",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ) or an analgesic antidepressant (either a secondary amine tricyclic antidepressant such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    or an SNRI such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/53\">",
"     53",
"    </a>",
"    ]. An analgesic antidepressant should be tried initially if the patient has a depressed mood. The guidelines indicate that opioid analgesics either alone or in combination with an analgesic adjuvant should be considered for patients with neuropathic cancer pain, as well as for episodic exacerbations of severe pain, or when prompt pain relief during titration of an adjuvant analgesic is needed.",
"   </p>",
"   <p>",
"    Guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    and the European Association for Palliative Care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/86\">",
"     86",
"    </a>",
"    ] broadly concur with the IASP guidelines, suggesting that antidepressants or anticonvulsants are preferred first-line coanalgesics for the treatment of cancer-related neuropathic pain in patients whose pain is only partially responsive to opioids.",
"   </p>",
"   <p>",
"    A stepwise approach to assessment and treatment is recommended in the IASP guidelines and is relevant to neuropathic cancer pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/53\">",
"     53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of the pain and establishment of the likely neuropathic etiology. The assessment should also include identification of relevant comorbidities which may be impacted by treatment of neuropathic pain, or require modifications in the initial treatment regimen. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link\">",
"       \"Assessment of cancer pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Initiate antineoplastic therapy for the disease causing the neuropathy, if applicable.",
"     </li>",
"     <li>",
"      Initiate symptom treatment for the painful neuropathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decision to try an opioid or to select specific adjuvant analgesics also may be influenced by the type of neuropathic pain. For example, chemotherapy-induced peripheral neuropathy is relatively refractory to treatment with analgesic antidepressants and anticonvulsants alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/87\">",
"     87",
"    </a>",
"    ]. At least three randomized trials have failed to show benefit from monotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/63,88,89\">",
"     63,88,89",
"    </a>",
"    ]. There is no uniformly accepted approach to these patients, and if the pain is relatively severe, it may be appropriate to consider an opioid early, even in the setting of no active disease, given the higher probability of a poor response to conventional adjuvant analgesics.",
"   </p>",
"   <p>",
"    Given the weight of evidence, we consider analgesic antidepressants such as SNRIs or tricyclics to represent first-line treatments for neuropathic pain that is associated with significant depressed mood, and second-line (after the alpha-2-delta modulators",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ) in non-depressed patients who have neuropathic cancer pain that is refractory to opioid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     ADJUVANT DRUGS USED FOR BONE PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of a patient with new bone pain may suggest the need for radiation therapy or an intervention such as kyphoplasty or surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link\">",
"     \"Assessment of cancer pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with multifocal pain usually are managed with a non-steroidal antiinflammatory agent (NSAID), unless they have a specific contraindication to use of these agents, and an opioid, with or without an adjuvant analgesic used specifically for bone pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4488?source=see_link&amp;anchor=H13#H13\">",
"     \"Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs\", section on 'Indications and contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to a glucocorticoid, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , drugs to consider in this setting include bisphosphonates,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    , and bone-seeking radionuclides (",
"    <a class=\"graphic graphic_table graphicRef80423 \" href=\"mobipreview.htm?2/57/2973\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Osteoclast inhibitors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1154723\">",
"    <span class=\"h3\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with metastatic bone disease, bisphosphonates prevent skeletal-related events, including fracture, and they may also improve pain and quality of life. Bisphosphonates act by directly inhibiting osteoclast activity, stimulating osteoblasts to produce osteoclast-inhibiting factor, and causing osteoclast apoptosis.",
"   </p>",
"   <p>",
"    There are substantial data supporting the analgesic potential of all of the parenteral bisphosphonates, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    (not available in the US), as well as oral ibandronate and clodronate. Comparative data are very limited, and the specific drug is chosen on the basis of experience, cost and convenience. This subject is addressed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=see_link\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although generally well tolerated, the bisphosphonates are associated with some side effects (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=see_link\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These drugs can impair renal function, but this is usually a transitory problem. Renal function should be checked prior to treatment, and if impaired, the starting dose should be lowered and the patient carefully monitored. Severe renal insufficiency is a relative contraindication to therapy.",
"     </li>",
"     <li>",
"      A temporary flu-like syndrome with fever and body aches commonly follows treatment initiation. Treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      may be helpful.",
"     </li>",
"     <li>",
"      Hypocalcemia is possible when these drugs are administered even to normocalcemic patients. These patients usually are subsequently found to be vitamin D deficient. The calcium level should therefore be monitored during therapy.",
"     </li>",
"     <li>",
"      An unusual complication, osteonecrosis of the jaw, is characterized by painful erosions, ulcers, and sinus tracts in the mandible, and occasionally, the maxilla. This complication usually occurs after months of treatment and may be relatively more common during therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      than with other bisphosphonates; it is rare during oral therapy. Given the evidence that oral trauma and dental infections increase the risk of this complication, patients with bone pain and very poor dentition, jaw infection, or recent substantial dental procedures should be considered for an alternative pharmacologic strategy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=see_link&amp;anchor=H1928329#H1928329\">",
"       \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Osteonecrosis of the jaw'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1154730\">",
"    <span class=\"h3\">",
"     Denosumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoclast inhibition can also be achieved by targeting receptor activator of nuclear factor kappa B ligand (RANKL), a key component in the pathway for osteoclast formation and activation.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    , a monoclonal antibody targeting RANKL, has been compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    in patients with metastatic bone disease from a variety of solid tumors; all have concluded that there is a slight benefit to denosumab in terms of preventing skeletal-related events, but only one of the trials has reported endpoints related to bone pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/90\">",
"     90",
"    </a>",
"    ]. In this trial comparing zoledronic acid versus denosumab in 2046 patients with advanced breast cancer and bone metastases, 43 percent of patients reported moderate to severe pain at baseline, although only approximately 16 percent were using strong opioids. Compared with the zoledronic acid group, fewer patients receiving denosumab who had no or mild pain at baseline progressed to moderate or severe pain (although the absolute difference was only 5 percent), there was an almost four month longer delay in the median time to pain worsening to moderate or severe, and fewer shifted from no or low analgesic use to strong analgesic use. However, palliation of pain severity as measured by the proportion of patients with meaningful improvement in pain (defined as a decrease of &ge;2 points in the worst pain score), median time to meaningful improvement in worst pain score, and the time to decreased pain interference, was similar for both treatment groups. Thus, the analgesic superiority of denosumab relative to that of bisphosphonates for patients with painful bone metastases is not yet established. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=see_link\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/36999?source=see_link\">",
"     \"Management of bone metastases in advanced prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8042?source=see_link\">",
"     \"Osteoclast inhibition in the management of bone metastases from breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The modest benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    for patients with skeletal metastases comes at a higher cost (the cost of denosumab is approximately $1650 monthly based upon wholesale acquisition costs, while the cost for zoledronic acid&nbsp;(4 mg monthly) is approximately $450 per dose). Two major advantages of denosumab are that it is administered subcutaneously rather than intravenously, and it is not associated with renal toxicity. In addition, it is not associated with the temporary flu-like syndrome with fever and body aches that commonly follows treatment initiation with bisphosphonates. Patients who have found that reaction problematic may find denosumab more tolerable. On the other hand, hypocalcemia is more frequent with denosumab than with zoledronic acid, while the risk of jaw osteonecrosis appears to be similar. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=see_link\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Calcitonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small controlled trials have yielded conflicting information about the potential for subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    to reduce metastatic bone pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/91\">",
"     91",
"    </a>",
"    ]. Given the lack of consistent evidence, this treatment generally is not recommended, although an empirical trial could be considered when other treatments are unavailable or ineffective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Bone-targeted radioisotopes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone-seeking radioisotopes, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26851?source=see_link\">",
"     strontium-89",
"    </a>",
"    and samarium-153, link a short-lived radiation source to a bisphosphonate molecule. Once injected, the drug is taken up at the site of bone metastases, and delivers radiation focally.",
"   </p>",
"   <p>",
"    Although bone-targeted radioisotopes can be a useful treatment for multifocal bone pain, myelosuppression is a significant concern (although less with samarium than with strontium), and treatment requires special skills and facilities. If available, this approach is typically considered for the patient with refractory multifocal bone pain, whose blood counts are not very low, and who is not expected to require myelosuppressive chemotherapy in the near future.",
"   </p>",
"   <p>",
"    These agents have been used most often for men with metastatic prostate cancer; their use is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/36999?source=see_link&amp;anchor=H261305508#H261305508\">",
"     \"Management of bone metastases in advanced prostate cancer\", section on 'Bone-targeted radiopharmaceuticals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     DRUGS USED FOR THE PAIN OF BOWEL OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bowel obstruction is a well-recognized complication in patients with advanced intraabdominal or pelvic tumors. Most of these patients are inoperable, and their survival is generally short. Some cases may be amenable to placement of a self-expanding metal stent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/92\">",
"     92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/34/5673?source=see_link\">",
"     \"Enteral stents for the management of malignant colorectal obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with inoperable intestinal obstruction who are not appropriate for a stent, management with IV fluids and placement of a nasogastric tube for decompression has been the conventional approach historically. Decompression of gastric contents can also be achieved by placement of a percutaneous gastrostomy tube. However, these procedures provide only incomplete relief of distressing symptoms, and the ongoing presence of these tubes can be uncomfortable and distressing for the patient and his or her family.",
"   </p>",
"   <p>",
"    More recently, medical management of inoperable patients has focused on adequate control of pain, distention, and vomiting using hydration, opioids, and adjuvant analgesics that may reduce symptoms by lessening peritumoral edema (glucocorticoids) and diminishing intraluminal secretions and peristaltic movements (anticholinergic agents and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    ). Anticholinergic drugs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/20/11591?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    ) and octreotide both reduce propulsive as well as nonpropulsive gut motility, and they decrease intraluminal secretions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Anticholinergics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     Scopolamine",
"    </a>",
"    can be administered by a transdermal patch, a convenient route for those with limited GI absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. In many countries, however, this drug is available only as the hydrobromide salt (hyoscine hydrobromide), which crosses the blood-brain barrier and may produce central nervous system side effects such as somnolence and confusion.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/20/11591?source=see_link\">",
"     Glycopyrrolate",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef82318 \" href=\"mobipreview.htm?1/28/1485\">",
"     table 2",
"    </a>",
"    ) has a pharmacologic profile that is similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    , but there is minimal penetration of the blood-brain barrier. When an anticholinergic is chosen, it is preferred in patients who are predisposed to somnolence and mental confusion. Although this drug has never been systematically evaluated as a treatment for the symptoms of bowel obstruction, anecdotal evidence supports benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Somatostatin analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin analogs like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    have been increasingly used to relieve distressing GI symptoms in patients with advanced cancer and malignant bowel obstruction. Somatostatin analogs inhibit gastric, pancreatic, and intestinal secretions, reduce motility, and may relieve pain and other symptoms in bowel obstruction. At least three small randomized trials concluded that octreotide is superior to an anticholinergic agent alone (typically",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    ) for symptomatic management of malignant bowel obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/93,94,96\">",
"     93,94,96",
"    </a>",
"    ]. A systematic review of these trials and other uncontrolled reports from the literature concluded that therapeutic success (control of vomiting) is reported in over 60 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usual starting dose is 0.1 mg (100 micrograms) twice daily given subcutaneously (",
"    <a class=\"graphic graphic_table graphicRef82318 \" href=\"mobipreview.htm?1/28/1485\">",
"     table 2",
"    </a>",
"    ). Rapid dose titration may be needed and doses several times the starting dose, and sometimes significantly higher are needed by some patients. Most patients will have at least some symptom improvement with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , often within the first four hours; however, the full benefit may not be seen for several days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. Side effects are rarely a problem, although cost may be a significant issue.",
"   </p>",
"   <p>",
"    Patients who respond can be given a depot injection of long-acting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (Sandostatin LAR) monthly for maintenance therapy. Drug levels are reliably therapeutic within two weeks.",
"   </p>",
"   <p>",
"    Another option is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    , a long-acting somatostatin analog that can be administered once monthly; modest benefit in patients with inoperable bowel obstruction due to peritoneal carcinomatosis was shown in a small randomized double-blind placebo-controlled trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/100\">",
"     100",
"    </a>",
"    ]. However, there is far more experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , and this agent is preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Benefit of glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the use of glucocorticoids for malignant bowel obstruction is rational, there are few data to support efficacy. The benefit of glucocorticoids is supported by one small randomized trial in which patients with malignant bowel obstruction were randomly assigned to placebo or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    at one of two daily doses (40 or 240 mg daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/101\">",
"     101",
"    </a>",
"    ]. Patients receiving either dose of the glucocorticoid were significantly more likely to have symptom resolution compared to the placebo group (68 versus 33 percent).",
"   </p>",
"   <p>",
"    A systematic review of this trial and a second randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/102\">",
"     102",
"    </a>",
"    ] plus one prospective and six retrospective reports concluded that there was a trend towards resolution of malignant bowel obstruction in patients treated with glucocorticoids, but it was not statistically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=see_link\">",
"       \"Patient information: Managing pain when you have cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant analgesics (coanalgesics) are drugs that were originally marketed for indications other than pain but are potentially useful as analgesics. Many of these drugs are useful for treatment of chronic cancer pain, and in those with active disease, usually are considered when a patient is poorly responsive to opioids. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition of an analgesic adjuvant'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The available agents are categorized on the basis of how they are used in clinical practice (",
"    <a class=\"graphic graphic_table graphicRef80423 \" href=\"mobipreview.htm?2/57/2973\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Available agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     For all types of pain",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids may be beneficial for a variety of types of pain, including neuropathic and bone pain, pain associated with capsular expansion or duct obstruction, pain from bowel obstruction, pain caused by lymphedema, and headache caused by increased intracranial pressure. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In the setting of chronic pain, a typical regimen is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      1 to 2 mg twice daily; this may be preceded by a larger loading dose of 10 to 20 mg. A brief period of high-dose glucocorticoids (eg, dexamethasone 50 to 100 mg IV, followed by 12 to 24 mg four times daily, tapered over one to three weeks) is appropriate for \"pain crisis\" (severe and escalating pain that is not responding sufficiently to an opioid). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Choice of agent and dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For a patient with chronic cancer pain that is poorly responsive to opioid therapy who also has a depressed mood, we suggest an early trial of an analgesic antidepressant (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Options include a serotonin-norepinephrine reuptake inhibitor (SNRI) such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      or a secondary tricyclic drug such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"       desipramine",
"      </a>",
"      ;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      may be considered if cancer pain is complicated by fatigue or somnolence. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Analgesic antidepressants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A trial of a transdermal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      patch could be considered in patients who have focal, peripherally-generated pain. Other topical treatments that may be useful in these patients are creams containing a local anesthetic, a NSAID, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Topical therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Where available, use of an oromucosal spray containing THC plus cannabidiol (and smaller concentrations of other compounds,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/44/15046?source=see_link\">",
"       nabiximols",
"      </a>",
"      [Sativex]) may be useful as an adjunctive treatment for refractory pain in patients with advanced cancer. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cannabinoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Neuropathic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any of the drugs classified as multipurpose adjuvant analgesics could be considered for a clinical trial in patients with opioid-refractory neuropathic cancer pain. The following reflects our general approach to these patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If neuropathic pain refractory to an opioid is associated with significant depressed mood, we suggest first-line therapy with an antidepressant (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Options include a serotonin-norepinephrine reuptake inhibitor (SNRI) such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      , a secondary tricyclic drug such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"       desipramine",
"      </a>",
"      , or possibly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      , if the pain is complicated by fatigue or somnolence. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Analgesic antidepressants'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients with neuropathic pain that is not associated with a depressed mood, we suggest first line therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We generally prefer pregabalin because of simplified dosing. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Gabapentin and pregabalin'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The positive placebo-controlled trial of duloxetine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/9/39066/abstract/50\">",
"       50",
"      </a>",
"      ] for painful chemotherapy-induced neuropathy suggests that in this setting, duloxetine is an appropriate first-line agent. However, additional data will be needed to establish the superiority of duloxetine or any other antidepressant over an alpha-2-delta modulator in these patients. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Antidepressants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For refractory cases, we suggest second-line therapy with the alternative agent, an antidepressant or an anticonvulsant, depending on which drug was used initially.",
"     </li>",
"     <li>",
"      A trial of another anticonvulsant, a cannabinoid (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/49/30485?source=see_link\">",
"       dronabinol",
"      </a>",
"      ), or an alpha-2 adrenergic agonist (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/35/12855?source=see_link\">",
"       tizanidine",
"      </a>",
"      ) could be considered in patients with neuropathic pain that is refractory to opioids and other appropriate adjuvant analgesics. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Alpha-2 adrenergic agonists'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Cannabinoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Other anticonvulsants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A trial of a transdermal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      patch could be considered in patients who have focal, peripherally-generated pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Bone pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multifocal bone pain are usually managed with a non-steroidal antiinflammatory agent (NSAID), unless they have a specific contraindication to use of these agents, and an opioid, with or without an adjuvant analgesic used specifically for bone pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4488?source=see_link&amp;anchor=H13#H13\">",
"     \"Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs\", section on 'Indications and contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend the use of bisphosphonates in patients with symptomatic bone metastases from a variety of cancers (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Bisphosphonates prevent skeletal-related events; they may also improve pain. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Osteoclast inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoids may be useful in patients with opioid-refractory bone pain, especially in patients with advanced illness or a \"pain crisis\", which is defined as severe and escalating pain that is not responding sufficiently to an opioid. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Choice of agent and dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of bone-targeted radioisotopes is typically reserved for the patient with multifocal bone pain that is refractory to other treatment, whose blood counts are not very low, and who is not expected to require myelosuppressive chemotherapy in the near future. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Bone-targeted radioisotopes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Bowel obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical management of patients with malignant bowel obstruction is focused on control of pain, distention, and vomiting using hydration, opioids, and adjuvant analgesics that may reduce symptoms by lessening peritumoral edema or diminishing intraluminal secretions and peristaltic movements.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      for the management of GI symptoms in patients with symptomatic inoperable bowel obstruction (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Somatostatin analogs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases, we use combination therapy rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      alone. This includes an opioid, an anticholinergic drug such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/20/11591?source=see_link\">",
"       glycopyrrolate",
"      </a>",
"      , and a low-dose glucocorticoid such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (1 to 2 mg once or twice daily) (see",
"      <a class=\"local\" href=\"#H37\">",
"       'Benefit of glucocorticoids'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization. Cancer pain relief, 2nd, World Health Organization, Geneva 1996.",
"    </li>",
"    <li>",
"     Portenoy RK. Adjuvant analgesics in pain management. In: Textbook of Palliative Medicine, 4th, Hanks G, Cherny NI, Christakis N, Fallon M, Kaasa S, Portenoy RK (Eds), Oxford University Press, Oxford 2010. p.361.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/3\">",
"      Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness. J Pain Symptom Manage 2001; 21:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/4\">",
"      Della Cuna GR, Pellegrini A, Piazzi M. Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 1989; 25:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/5\">",
"      Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 7:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/6\">",
"      Mercadante SL, Berchovich M, Casuccio A, et al. A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care 2007; 24:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/7\">",
"      George R, Jeba J, Ramkumar G, et al. Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev 2008; :CD006716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/8\">",
"      Verdu B, Decosterd I, Buclin T, et al. Antidepressants for the treatment of chronic pain. Drugs 2008; 68:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/9\">",
"      Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 1992; 49:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/10\">",
"      Collins SL, Moore RA, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 2000; 20:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/11\">",
"      Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007; :CD005454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/12\">",
"      Sindrup SH, Gram LF, Skjold T, et al. Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms. Clin Pharmacol Ther 1990; 47:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/13\">",
"      Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/14\">",
"      Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003; 60:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/15\">",
"      Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 110:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/16\">",
"      Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/17\">",
"      Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/18\">",
"      Sindrup SH, Gram LF, Br&oslash;sen K, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990; 42:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/19\">",
"      Sindrup SH, Bjerre U, Dejgaard A, et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992; 52:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/20\">",
"      Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 2001; 57:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/21\">",
"      Semenchuk MR, Davis B. Efficacy of sustained-release bupropion in neuropathic pain: an open-label study. Clin J Pain 2000; 16:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/22\">",
"      Eisenach JC, DuPen S, Dubois M, et al. Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain 1995; 61:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/23\">",
"      Malanga GA, Gwynn MW, Smith R, Miller D. Tizanidine is effective in the treatment of myofascial pain syndrome. Pain Physician 2002; 5:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/24\">",
"      Arain SR, Ruehlow RM, Uhrich TD, Ebert TJ. The efficacy of dexmedetomidine versus morphine for postoperative analgesia after major inpatient surgery. Anesth Analg 2004; 98:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/25\">",
"      Prommer E. Review article: dexmedetomidine: does it have potential in palliative medicine? Am J Hosp Palliat Care 2011; 28:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/26\">",
"      Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008; 9:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/27\">",
"      Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/28\">",
"      Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/29\">",
"      Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010; 39:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/30\">",
"      Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003; 290:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/31\">",
"      Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers 2007; 4:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/32\">",
"      Furlow B. States and US Government spar over medical marijuana. Lancet Oncol 2012; 13:450.",
"     </a>",
"    </li>",
"    <li>",
"     Montana Department of Health and Human Services. Montana Medical Marijuana Program. Data available online at file://www.dphhs.mt.gov/marijuanaprogram/ (Accessed on January 17, 2013).",
"    </li>",
"    <li>",
"     Colorado Department of Public Health and Environment. The ColoradoMedical Marijuana Registry. Data available online at file://www.cdphe.state.co.us.hs/medicalmarijuana/ (Accessed on January 17, 2013).",
"    </li>",
"    <li>",
"     Oregon Department of Human Services . The Oregon Medical Marijuana Program. Data available online at file://public.health.oregon.gov/diseasesconditions/chronicdisease/medicalmarijuanaprogram/Pages/index.aspx (Accessed on January 17, 2013).",
"    </li>",
"    <li>",
"     Nevada Department of Health and Human Services. Medical Marijuana Program. Data available online at file://health.nv.gov/BudgetDocuments/2012-2013/MMPWHITEPAPR_FY11.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/37\">",
"      Bowles DW, O'Bryant CL, Camidge DR, Jimeno A. The intersection between cannabis and cancer in the United States. Crit Rev Oncol Hematol 2012; 83:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/38\">",
"      Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999; 80:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/39\">",
"      Barbano RL, Herrmann DN, Hart-Gouleau S, et al. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004; 61:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/40\">",
"      Gammaitoni AR, Galer BS, Onawola R, et al. Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale. Curr Med Res Opin 2004; 20 Suppl 2:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/41\">",
"      Gammaitoni AR, Alvarez NA, Galer BS. Pharmacokinetics and safety of continuously applied lidocaine patches 5%. Am J Health Syst Pharm 2002; 59:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/42\">",
"      Stow PJ, Glynn CJ, Minor B. EMLA cream in the treatment of post-herpetic neuralgia. Efficacy and pharmacokinetic profile. Pain 1989; 39:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/43\">",
"      Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol 1995; 37:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/44\">",
"      Knotkova H, Pappagallo M, Szallasi A. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival? Clin J Pain 2008; 24:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/45\">",
"      Jones VM, Moore KA, Peterson DM. Capsaicin 8% topical patch (Qutenza)--a review of the evidence. J Pain Palliat Care Pharmacother 2011; 25:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/46\">",
"      Derry S, Lloyd R, Moore RA, McQuay HJ. Topical capsaicin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2009; :CD007393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/47\">",
"      Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ 2004; 329:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/48\">",
"      Hsieh LF, Hong CZ, Chern SH, Chen CC. Efficacy and side effects of diclofenac patch in treatment of patients with myofascial pain syndrome of the upper trapezius. J Pain Symptom Manage 2010; 39:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/49\">",
"      Ho KY, Huh BK, White WD, et al. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clin J Pain 2008; 24:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/50\">",
"      Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013; 309:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/51\">",
"      Calhoun EA, Welshman EE, Chang CH, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003; 13:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/52\">",
"      Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/53\">",
"      Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/54\">",
"      Serpell MG, Neuropathic pain study group. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain 2002; 99:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/55\">",
"      Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 2004; 22:2909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/56\">",
"      Frampton JE, Foster RH. Pregabalin: in the treatment of postherpetic neuralgia. Drugs 2005; 65:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/57\">",
"      Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003; 60:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/58\">",
"      Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004; 110:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/59\">",
"      Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 2005; :CD005452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/60\">",
"      Vondracek P, Oslejskova H, Kepak T, et al. Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. Eur J Paediatr Neurol 2009; 13:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/61\">",
"      Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009; :CD007076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/62\">",
"      Mishra S, Bhatnagar S, Goyal GN, et al. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care 2012; 29:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/63\">",
"      Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 2007; 110:2110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/64\">",
"      Toth C. Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. Pain Med 2010; 11:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/65\">",
"      Eisenberg E, River Y, Shifrin A, Krivoy N. Antiepileptic drugs in the treatment of neuropathic pain. Drugs 2007; 67:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/66\">",
"      Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. Cochrane Database Syst Rev 2005; :CD005451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/67\">",
"      Wiffen PJ, Rees J. Lamotrigine for acute and chronic pain. Cochrane Database Syst Rev 2007; :CD006044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/68\">",
"      Nasreddine W, Beydoun A. Oxcarbazepine in neuropathic pain. Expert Opin Investig Drugs 2007; 16:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/69\">",
"      Bendaly EA, Jordan CA, Staehler SS, Rushing DA. Topiramate in the treatment of neuropathic pain in patients with cancer. Support Cancer Ther 2007; 4:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/70\">",
"      Hugel H, Ellershaw JE, Dickman A. Clonazepam as an adjuvant analgesic in patients with cancer-related neuropathic pain. J Pain Symptom Manage 2003; 26:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/71\">",
"      Wymer JP, Simpson J, Sen D, et al. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain 2009; 25:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/72\">",
"      Tremont-Lukats IW, Challapalli V, McNicol ED, et al. Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. Anesth Analg 2005; 101:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/73\">",
"      Challapalli V, Tremont-Lukats IW, McNicol ED, et al. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev 2005; :CD003345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/74\">",
"      Ben-Ari A, Lewis MC, Davidson E. Chronic administration of ketamine for analgesia. J Pain Palliat Care Pharmacother 2007; 21:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/75\">",
"      Jackson K, Ashby M, Howell D, et al. The effectiveness and adverse effects profile of \"burst\" ketamine in refractory cancer pain: The VCOG PM 1-00 study. J Palliat Care 2010; 26:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/76\">",
"      Jackson K, Ashby M, Martin P, et al. \"Burst\" ketamine for refractory cancer pain: an open-label audit of 39 patients. J Pain Symptom Manage 2001; 22:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/77\">",
"      Prommer EE. Ketamine for pain: an update of uses in palliative care. J Palliat Med 2012; 15:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/78\">",
"      Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000; 20:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/79\">",
"      Lauretti GR, Lima IC, Reis MP, et al. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology 1999; 90:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/80\">",
"      Bell R, Eccleston C, Kalso E. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 2003; :CD003351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/81\">",
"      Salas S, Frasca M, Planchet-Barraud B, et al. Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: considerations about the clinical research in palliative care. J Palliat Med 2012; 15:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/82\">",
"      Hardy J, Quinn S, Fazekas B, et al. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol 2012; 30:3611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/83\">",
"      Jackson K, Franco M, William L, et al. Ketamine and cancer pain: the reports of my death have been greatly exaggerated. J Clin Oncol 2013; 31:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/84\">",
"      Chizh BA, Headley PM. NMDA antagonists and neuropathic pain--multiple drug targets and multiple uses. Curr Pharm Des 2005; 11:2977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/85\">",
"      Yomiya K, Matsuo N, Tomiyasu S, et al. Baclofen as an adjuvant analgesic for cancer pain. Am J Hosp Palliat Care 2009; 26:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/86\">",
"      Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13:e58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/87\">",
"      Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/88\">",
"      Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 2002; 98:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/89\">",
"      Kautio AL, Haanp&auml;&auml; M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 2008; 35:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/90\">",
"      Cleeland CS, Body JJ, Stopeck A, et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 2013; 119:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/91\">",
"      Martinez-Zapata MJ, Roque i Figuls M, Alonso-Coello P. Calcitonin for metastatic bone pain. Cochrane Database Syst Rev 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/92\">",
"      Frech EJ, Adler DG. Endoscopic therapy for malignant bowel obstruction. J Support Oncol 2007; 5:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/93\">",
"      Ripamonti C, Mercadante S, Groff L, et al. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage 2000; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/94\">",
"      Mercadante S, Ripamonti C, Casuccio A, et al. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 2000; 8:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/95\">",
"      Davis MP, Furste A. Glycopyrrolate: a useful drug in the palliation of mechanical bowel obstruction. J Pain Symptom Manage 1999; 18:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/96\">",
"      Mystakidou K, Tsilika E, Kalaidopoulou O, et al. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial. Anticancer Res 2002; 22:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/97\">",
"      Mercadante S, Porzio G. Octreotide for malignant bowel obstruction: twenty years after. Crit Rev Oncol Hematol 2012; 83:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/98\">",
"      Dean A. The palliative effects of octreotide in cancer patients. Chemotherapy 2001; 47 Suppl 2:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/99\">",
"      Khoo D, Hall E, Motson R, et al. Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer 1994; 30A:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/100\">",
"      Mariani P, Blumberg J, Landau A, et al. Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2012; 30:4337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/101\">",
"      Laval G, Girardier J, Lassauni&egrave;re JM, et al. The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: do they remove the obstruction? Palliat Med 2000; 14:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/102\">",
"      Hardy J, Ling J, Mansi J, et al. Pitfalls in placebo-controlled trials in palliative care: dexamethasone for the palliation of malignant bowel obstruction. Palliat Med 1998; 12:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/9/39066/abstract/103\">",
"      Feuer DJ, Broadley KE. Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers. Systematic Review Steering Committee. Ann Oncol 1999; 10:1035.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2815 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-3A7D25EF8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_9_39066=[""].join("\n");
var outline_f38_9_39066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF AN ANALGESIC ADJUVANT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Integration into cancer pain management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Available agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MULTIPURPOSE ANALGESICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Choice of agent and dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Analgesic antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Mechanism of analgesic effect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Selection of agent and dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other multipurpose analgesics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Alpha-2 adrenergic agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cannabinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Topical therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Lidocaine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Antiinflammatory and antidepressant drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DRUGS USED FOR NEUROPATHIC PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Anticonvulsant analgesics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Gabapentin and pregabalin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Other anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other drugs used for neuropathic pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Other multipurpose analgesics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Topical analgesics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Sodium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Ketamine and other NMDA receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - GABA receptor inhibitors and agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Summary and recommendations of expert groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      ADJUVANT DRUGS USED FOR BONE PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Osteoclast inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1154723\">",
"      - Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1154730\">",
"      - Denosumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Calcitonin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Bone-targeted radioisotopes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      DRUGS USED FOR THE PAIN OF BOWEL OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Anticholinergics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Somatostatin analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Benefit of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      For all types of pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Neuropathic pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Bone pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Bowel obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/2815\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2815|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/45/724\" title=\"figure 1\">",
"      WHO analgesic ladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2815|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/57/2973\" title=\"table 1\">",
"      Adj analgesics cancer pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/28/1485\" title=\"table 2\">",
"      Dose ranges adj analgesics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/61/42972\" title=\"table 3\">",
"      Relative potency glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/48/2830\" title=\"table 4\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=related_link\">",
"      Assessment of cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=related_link\">",
"      Cancer pain management: General principles and risk management for patients receiving opioids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=related_link\">",
"      Cancer pain management: Interventional therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4488?source=related_link\">",
"      Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1079?source=related_link\">",
"      Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/59/16312?source=related_link\">",
"      Definition and pathogenesis of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/34/5673?source=related_link\">",
"      Enteral stents for the management of malignant colorectal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/36999?source=related_link\">",
"      Management of bone metastases in advanced prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39335?source=related_link\">",
"      Management of vasogenic edema in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8042?source=related_link\">",
"      Osteoclast inhibition in the management of bone metastases from breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=related_link\">",
"      Pharmacologic use of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6058?source=related_link\">",
"      Pruritus: Overview of management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26970?source=related_link\">",
"      Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34873?source=related_link\">",
"      Trigeminal neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_9_39067="Dysphagia child";
var content_f38_9_39067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of dysphagia in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Life-threatening",
"       </td>",
"       <td>",
"        <p>",
"         Esophageal foreign body",
"        </p>",
"        <p>",
"         Stevens-Johnson syndrome",
"        </p>",
"        <p>",
"         Caustic ingestion",
"        </p>",
"        <p>",
"         Retropharyngeal abscess",
"        </p>",
"        <p>",
"         Epiglottitis",
"        </p>",
"        <p>",
"         Central nervous system infection (eg, meningitis, encephalitis, cerebral abscess)",
"        </p>",
"        <p>",
"         Impairment of swallowing (eg, cerebral palsy, myasthenia gravis, botulism, Miller Fisher syndrome)",
"        </p>",
"        <p>",
"         Tetanus",
"        </p>",
"        <p>",
"         Diphtheria",
"        </p>",
"        <p>",
"         Poliomyelitis",
"        </p>",
"        <p>",
"         Central nervous system tumor",
"        </p>",
"        <p>",
"         Esophageal perforation",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Common",
"       </td>",
"       <td>",
"        <p>",
"         Stomatitis",
"        </p>",
"        <p>",
"         Infectious pharyngitis",
"        </p>",
"        <p>",
"         Peritonsillar abscess",
"        </p>",
"        <p>",
"         Esophagitis",
"        </p>",
"        <p>",
"         Dystonic reaction",
"        </p>",
"        <p>",
"         Oropharyngeal trauma",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Other",
"       </td>",
"       <td>",
"        <p>",
"         Achalasia",
"        </p>",
"        <p>",
"         Rheumatic disease (eg, juvenile systemic sclerosis, dermatomyositis)",
"        </p>",
"        <p>",
"         Myasthenia gravis",
"        </p>",
"        <p>",
"         Crohn's disease",
"        </p>",
"        <p>",
"         Thyroid enlargement (eg, acute suppurative thyroiditis)",
"        </p>",
"        <p>",
"         Esophageal tumor",
"        </p>",
"        <p>",
"         Vascular ring",
"        </p>",
"        <p>",
"         Globus sensation",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_9_39067=[""].join("\n");
var outline_f38_9_39067=null;
var title_f38_9_39068="Doses IV antimicrobials";
var content_f38_9_39068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73801%7EID%2F62200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73801%7EID%2F62200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intravenous antimicrobials for pneumococcal pneumonia in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Antimicrobial",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose",
"      </td>",
"      <td class=\"subtitle1\">",
"       Interval",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Penicillin G",
"      </td>",
"      <td>",
"       2 to 3 million units",
"      </td>",
"      <td>",
"       Every 4 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ampicillin",
"      </td>",
"      <td>",
"       2 grams",
"      </td>",
"      <td>",
"       Every 6 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ampicillin/sulbactam",
"      </td>",
"      <td>",
"       2 grams ampicillin plus 1 gram sulbactam",
"      </td>",
"      <td>",
"       Every 6 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Amoxicillin/clavulanate",
"      </td>",
"      <td>",
"       1 gram amoxicillin plus 0.125 grams clavulanate",
"      </td>",
"      <td>",
"       Every 6 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cefotaxime",
"      </td>",
"      <td>",
"       2 grams",
"      </td>",
"      <td>",
"       Every 6 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ceftriaxone",
"      </td>",
"      <td>",
"       1 gram",
"      </td>",
"      <td>",
"       Every 12 hours",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oral antimicrobials for pneumococcal pneumonia in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antimicrobial",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penicillin V",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        Four times daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amoxicillin/clavulanate",
"       </td>",
"       <td>",
"        875/125 mg",
"       </td>",
"       <td>",
"        Twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amoxicillin",
"       </td>",
"       <td>",
"        1 gram",
"       </td>",
"       <td>",
"        Three times daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Clarithromycin",
"       </td>",
"       <td>",
"        250 mg",
"       </td>",
"       <td>",
"        Twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1000 mg (two 500 mg extended release tablets)",
"       </td>",
"       <td>",
"        Once&nbsp;daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Azithromycin",
"       </td>",
"       <td>",
"        500 mg on day one",
"       </td>",
"       <td>",
"        250 mg thereafter once daily for 4 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        Once daily for three days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 grams",
"       </td>",
"       <td>",
"        As a single dose microsphere regimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythromycin",
"       </td>",
"       <td>",
"        333 mg",
"       </td>",
"       <td>",
"        Twice daily",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_9_39068=[""].join("\n");
var outline_f38_9_39068=null;
var title_f38_9_39069="Ornipressin on GFR in cirrhosis";
var content_f38_9_39069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ornipressin improves renal function in advanced hepatic cirrhosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 215px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of infusion of ornipressin, an analog of antidiuretic hormone that causes preferential splanchnic vasoconstriction, in patients with advanced hepatic cirrhosis and functional renal failure (the hepatorenal syndrome). Ornipressin raised the glomerular filtration rate (GFR) from 18 to 29 mL/min, lowered the plasma renin activity from 28 to 14 (normal equals less than 3 ng/mL per hour on a regular salt intake), and raised the fraction of the cardiac output delivered to the kidneys from 2 to 5 percent (normal equals 20 percent). Each of these abnormalities was only partially corrected, although it is not known if a greater response would be seen with less severe disease or with a higher dose.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Lenz, K, Hortnagl, H, Druml, W, et al, Gastroenterology 1991; 101:1060.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_9_39069=[""].join("\n");
var outline_f38_9_39069=null;
var title_f38_9_39070="Enlarged esophagus Chagas";
var content_f38_9_39070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal dilation in Chagas disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 271px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest x-ray obtained immediately (left panel) and five minutes after (right panel) a barium swallow in a patient with chronic Chagas disease shows modest esophageal dilatation and full retention of the contrast at five minutes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_9_39070=[""].join("\n");
var outline_f38_9_39070=null;
var title_f38_9_39071="Asympt hematuria proteinuria";
var content_f38_9_39071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Diagnostic algorithm for asymptomatic microscopic hematuria with proteinuria in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 532px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For children between 6 and 24 months, the threshold value is 0.5 mg protein to mg creatinine.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Diven, SC, Travis, LB. A practical primary care approach to hematuria in children. Pediatr Nephrol 2000; 14:65.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_9_39071=[""].join("\n");
var outline_f38_9_39071=null;
